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1.1 Neisseria meningitidis 
Neisseria meningitidis is a gram negative bacterium that colonizes and infects 
only human, and has never been isolated from other animals.1 N. meningitidis is the 
main cause of bacterial meningitis in children and young adults.2 Children younger 
than 5 years are at greatest risk, followed by teenagers of high school age. The World 
Health Organization estimates that there are 1.2 million cases of meningococcal 
meningitis worldwide and 135,000 related deaths annually.3 Especially, the 
Sub-Sahara African has been plagued by large epidemics of meningococcal 
meningitis for over a century.4 Attack rates of 100-800 cases per 100,000 are 
encountered in this area. The meningococcal disease often progresses very rapidly and 
is difficult to diagnose and treat. 
Without treatment, meningococcal meningitis is almost fatal. Persons with N. 
meningitidis infection should be hospitalized immediately for treatment with 
antibiotics.5 However, antibiotic treatment has many important limitations, including 
drug side effects6, and the potential for emergence of resistant organisms. Moreover, 
permanent sequelae such as hearing impairment, mental retardation, or limb loss are 
common in survivors.7 Therefore, the prevention of meningococcal meningitis is 
important. 
To prevent the meningococcal disease, especially to stop an outbreak of 
meningococcal disease, a dose of meningitis vaccine is recommended. The discovery 
that serum bactericidal antibodies to meningococcal capsular polysaccharides protect 
against meningococcal disease is the basis for development of meningococcal 
vaccines.8 The capsular polysaccharides of N. meningitidis are important virulence 
factors that inhibit host cell protection mechanisms. According to the immunology 
specificity of capsular polysaccharides, N. meningitidis is classified into 13 clinically 
significant serogroups. Six most important serogroups, A, B, C, Y, W-135, and X, are 
associated with disease in human. Serogroup A has been the most prevalent in Africa 
and Asia, but is rare practically absent in North America.9 In the United States and 
Europe, serogroup B is the predominant cause of disease and mortality, followed by 
serogroup C.   
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Several effective vaccines using bacterial capsular polysaccharides as target to 
generate bactericidal antibodies against serogroup A, C, Y and W-135 have been 
developed and used.10 However, vaccine against serotype B disease is difficult to 
produce. The capsular polysaccharide on the serotype B bacterium is composed of 
polysialic acid repeating units that are same with the structures found on human 
neuronal cells.11 Antibodies generated against serogroup B capsular polysaccharide 
are cross-reactive with the polysialic acid moieties expressed on human neural cell 
adhesion molecules. As a result, serogroup B capsular polysaccharides are poorly 
immunogenic due to self-tolerance mechanisms. To dissolve this problem, efforts to 
develop serogroup B vaccine have largely focused on other membrane antigens of N. 
meningitides. One attempted solution is focused on the lipooligosaccharides (LOSs) 
of N. meningitides.   
Lipopolysaccharides (LPSs) and lipooligosaccharides (LOSs) are the major 
component of the outer membrane of gram-negative bacteria.12 LPS/LOS contributes 
essentially to the integrity and stability of the outer membrane, and is also the first 
line of defense for bacteria against a range of environmental factors, including 
detergents and antimicrobial agents.13 As a potent virulence factor, LPS/LOS also 
serves as a surface pathogen-associated antigen for recognition by the host immune 
system.14 Therefore, LPS/LOS has attracted much interest for the development of 
diagnostic tools, therapeutic reagents and vaccine candidates.  
 
1.2 Lipopolysaccharide and lipooligosaccharide 
As shown in Figure 1.112c, an LPS consists of three domains: a lipophilic 
moiety termed lipid A, a core oligosaccharide (core OS), and a hydrophilic glycan 
called O-specific polysaccharide (O-antigen), whereas LOS which is limited to 10 
saccharide units lacks an O-antigen polysaccharide. The lipid A moiety, which has a 
-(1-6)-linked D-glucosamine disaccharide backbone, is essential for bacterial 
viability and carries the endotoxic properties of the LPSs/LOSs.15 The O-antigen 
polysaccharide is the most variable portion of the LPS and provides serological 
specificity, which is response for bacterial serotyping.16 In addition, the core 
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oligosaccharide (OS) provides useful information for vaccine development that a core 
oligosaccharide (OS) derived from LOS of pathogenic bacteria strains was reported to 
be recognized by the human antibody.17 So core OS is a focused target for vaccine 
development.  
 
 
Figure 1.1 The structure of LPS and LOS  
 
1.3 Branched inner core OS 
The core OS can be further separated into two regions, one proximal to lipid A 
(inner-core OS) and the other is distal from lipid A but proximal to the O-antigen 
(outer-core OS).12 The inner-core OS is highly conserved in bacterial species. This 
inner-core OS consists of mostly the unusual higher carbon sugars 
3-deoxy-D-manno-2-octulosonic acid (Kdo) and L-glycero-D-manno-heptopyranose 
(Hep). Kdo is the unique compound of the inner core OS and rarely found in other 
glycans. Recent studies employing LOS of Nesseria gonorrhoeae strain 15,253 as 
affinity ligand indicated that human antibodies recognized several epitopes including 
the Kdo region but also the branched heptosyl epitopes.17 Therefore, the inner-core 
OS containing these epitopes draws more attention for vaccine research.  
Furthermore, the general inner-core OS of LPS/LOS is composed of a 
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4,5-branched Kdo structure. In Figure 1.2 for example, the inner-core OS of 
LPSs/LOSs from many gram-negative bacteria, such as Neisserial,18 Salmonella,19 
and haemophilus20 and so on, contains a 4,5-branched 
Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo tetrasaccharide as the common structure. 
Moreover, the Hep I moiety could be substituted by other saccharides (such as Man, 
GalNAc) in some other bacteria, such as Francisella tularensis21 and Pseudomonas 
cichorii22. 
 
 
Figure 1.2 The inner-core OS structure of general gram-negative bacteria, Francisella tularensis 
and Pseudomonas cichorii. 
 
1.4 The extraction of inner-core OS 
Inner-core OS fragments can be extracted from the bacteria strains. For the 
fragmental extraction, the target bacteria strains are isolated, identified, and grown in 
tryptic soy broth medium. The LPS/LOS fragments are released from whole 
bacterial cells by some mild treatments such as strong saline washes23, the use of 
chelating agents24, or aqueous organic solvents.25 The most general and widely used 
procedure is the treatment of the whole bacterial cells with hot aqueous phenol, 
followed by cooling to produce a two-phase system.26 LPS/LOS in crude, 
aqueous-phenol extracts are collected and purified. The presence of LPS/LOS in the 
resulting extract is confirmed by the SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) analysis.27 
To obtain released inner-core OS fragments, the collected LPS/LOS is further 
hydrolyzed under mild acid conditions.28 After further purification by gel permeation 
chromatography and high performance liquid chromatography (HPLC), a set of inner 
core OS fragments with the different lengths could be collected. These fragments are 
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usually used for structure study.   
However, isolation of these oligosaccharides from highly pathogenic bacteria, 
such as N. meningitides, is undesirable. The purification method of extraction and 
nonselectivity hydrolysis of LPS/LOS also limits the output and purity of these 
oligosaccharides. Moreover, the vaccine development needs the well defined 
oligosaccharides to conjugate with carrier proteins for immunizations. It is difficult 
to conjugate the extracted oligosaccharides to carrier proteins without destroying 
vital immunological domains.29   
Fortunately, chemical synthesis can address these issues. Chemical synthesis 
offers a much more attractive approach to produce multigram amount of highly pure 
oligosaccharides and makes it possible to incorporate an artiﬁcial linker for 
controlled conjugation to proteins.  
 
1.5 Chemical synthesis of branched inner core OS 
Chemical synthetic approaches towards components of the inner-core OS 
region have to deal with the elaboration of efficient protocols to prepare multigram 
amounts of the higher carbon aldoses 3-deoxy-D-manno-2-octulosonic acid (Kdo) and 
L-glycero-D-manno-heptopyranose (Hep) followed by transformation into suitable 
glycosyl donor and acceptor derivatives. In the past several decades, the synthetic 
efforts have covered the basic structural units (Kdo30, Hep31) and truncated forms of 
inner-core OS32. However, the chemical synthesis of inner-core OS is still challenging 
due to its highly branched nature, which complicates the installation of the various 
glycosidic linkages.   
 
1.6 Recent research of Kdo synthesis in our laboratory  
 Recently, we reported a useful Kdo intermediate, methyl 
(7,8-di-O-benzoyl-4,5-O-isopropylidene-D-manno-2-octulopyranosid)onate, for the 
preparation of 2-4 and 2-8 linked Kdo disaccharides.33 This Kdo intermediate was 
prepared from the D-mannose via 8 steps in 53% yield (Figure 1.3). For the synthesis 
of 2-4 linked Kdo disaccharide, the Kdo intermediate could be converted to the 
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corresponding glycosyl fluoride donor and the 4,5-diol acceptor with ease. And the 
glycosylation gave the Kdo(2-4)Kdo disaccharide in a good yield (72%, /=5/1). 
 
 
Figure 1.3 The synthesis of Kdo(2-4)Kdo disaccharide.  
 
1.7 Aim of the study 
Although many chemical syntheses of linear inner-core OS structures have been 
described34, there are few reports for the synthesis of branched inner-core OS. Only 
Paulsen group reported a synthesis of the 4,5-branched Hep(1-5)Kdo(2-4)Kdo 
trisaccharide (Figure 1.4).35 In their synthesis, the 4-OH group of Kdo I was firstly 
protected by a p-methoxybenzyl group, and sequentially a Hep donor was coupled 
with Kdo I to form a Hep(1-5)Kdo disaccharide. Then the p-methoxybenzyl group 
of Kdo I was deprotected, and a Kdo donor was installed to the formed 
Hep(1-5)Kdo disaccharide to gave the desired Hep(1-5)[Kdo(2-4)]Kdo 
trisaccharide. However, the yield of this approach appears to be low (4 steps: only 
22%).   
In the study of this thesis, it is aimed to develop a new chemical synthetic 
approach for the 4,5-branched inner-core OSs and to extend the utility of our previous 
synthetic Kdo(2-4)Kdo disaccharide. In this research, the 4,5-branched Kdo 
structures would be synthesized by glycosylation of the 5-OH group of the 2-4 linked 
Kdo disaccharide. This thesis contains three parts, 
1) The observation of the limitation of (2-4)-linked Kdo glycosylation 
2) The new route to synthesize 4,5-branched inner-core trisaccharides 
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3) The convergent synthesis of 4,5-branched inner-core OSs 
 
 
Figure 1.4 Paulsen’s method and our plan to synthesize 4,5-branched Kdo trisaccharide. 
 
In Chapter 2, to optimize the reaction condition of Kdo(2-4)Kdo, the 
glycosidation using several types of Kdo donors and Lewis acid are discussed.  
These Kdo donors are prepared from a Kdo intermediate, which is designed in our 
previous research.  
In Chapter 3, we focus on the discussion of the glycosylation using the 
synthetic Kdo(2-4)Kdo in Chapter 2 as the acceptor, to synthesize 4,5-branched 
inner-core trisaccharides. The reaction conditions of this new route to prepare a 
Hep(1-5)[Kdo(2-4)]Kdo trisaccharide are discussed and the result is compared 
with Paulsen’s method. Moreover, the first synthesis of Man(1-5)[Kdo(2-4)]Kdo 
and GalNAc(1-5)[Kdo(2-4)]Kdo by this new approach is also discussed. 
In Chapter 4, to further observe the utility of the newly synthetic route 
discussed in Chapter 3, a convergent synthesis route using the same Kdo(2-4)Kdo 
disaccharide as the acceptor to produce more complex inner core OS is discussed. To 
test the glycosylation conditions and necessary protecting strategy, a lactose donor is 
chosen as a model compound. Based on the model glycosylation, the corresponding 
Hep units constructed from the Hep building blocks are coupled with the Kdo moiety 
to obtain the desired branched inner-core OS. 
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2.1 Introduction 
The inner-core OS of gram-negative bacteria consists of at least one of the 
higher carbon sugar, 3-deoxy-D-manno-2-octulosonic acid (Kdo). Kdo is rarely found 
in other glycans and thus can be considered as a mark for the presence of LPS/LOS.12 
The incorporation of Kdo appears to be a vital step in LPS biosynthesis and in 
growth of the gram-negative bacteria. Furthermore, the inner core OS of many 
LPSs/LOSs is composed of a 4,5-branched Kdo structure which contains a 
Kdo(2-4)Kdo disaccharide at the reducing end. According to the newly hypothetical 
route to synthesize the 4,5-branched Kdo structure, the 2-4 linked Kdo disaccharide 
would be prepared at first. 
 Although many chemical syntheses of Kdo(2-4)Kdo disaccharide have been 
reported,36 there is still no generally accepted high-yielding procedure for the 
stereoselective preparation of Kdo(2-4)Kdo disaccharide. In recent, for the synthesis 
of Kdo(2-4)Kdo disaccharide, our laboratory reported a useful Kdo intermediate 
from the D-mannose in 8 steps.33 This Kdo intermediate could be easily converted to 
the corresponding glycosyl fluoride donor and 4,5-diol acceptor. And the 
glycosidation of the fluoride donor with the 4,5-diol acceptor gave the Kdo(2-4)Kdo 
in 72% yield (/=5/1). However, the limitation of this glycosidation was not 
investigated. Therefore in this Chapter, to optimize the glycosidation conditions of the 
synthesis of Kdo(2-4)Kdo, several types of Kdo donors and Lewis acid are examined. 
 
2.2 Result and discussion 
2.2.1 Preparation of Kdo donors 
Three types of Kdo donors 2, 3, 4 were synthesized from common Kdo 
intermediate 1 in Scheme 2.1. Treatment of compound 1 with N,N-diethylaminosulfur 
trifluoride at 0 °C gave the fluoride 2 as a mixture of anomers in a good yield (81%).33 
The anomeric ratio of 2 was 3/1, and the major isomer was easily isolated by 
crystallization from ethyl acetate and hexane. The anomeric conﬁguration of the 
major product was presumed to be  based on a compare with the NMR data of 
corresponding Kdo derivatives reported by Imoto.37 The N-phenyl 
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trifluoroacetimidate 3 was prepared in quantitative yield from compound 1 with 
2,2,2-trifluoro-N-phenylacetimidoyl chloride in the presence of potassium 
carbonate.38 However, the reaction needed 1 week to reach completion. The reaction 
for preparing the Kdo trichloroacetimidate donor also demanded a week. This showed 
that the reactivity of the anomeric hydroxyl group of the Kdo derivatives was lower 
than that of aldose because of steric hindrance and low nucleophilicity. Two isomers 
could be separated and the major product was presumed to be. Dibenzyl phosphite 4 
was synthesized in moderate yield (56%) from compound 1 with 1H-tetrazole, 
dibenzyl N,N-diisopropylphosphoramidite (DDP).39 Also, two isomers were separated 
and the major product was presumed to be 
 
 
Scheme 2.1 Conditions: (a) DAST, 0 °C, 0.5 h, 81%,= 3/1; (b) N-phenyl trifluoroacetimidoyl 
chloride, K2CO3, CH2Cl2, rt, 7 days, quant, = 3/2; (c) 1H-tetrazole, DDP, CH2Cl2, 0 °C→ rt, 3 
h, 56%, = 23/1.  
 
2.2.2 The glycosylation of the 4,5-diol acceptor with Kdo donors 
Glycosylation of the 4,5-diol acceptor 533, which was also prepared from the 
Kdo intermediate 1 (Figure 1.4 in Chapter 1), with these Kdo donors 2, 3, 4 was 
examined (Scheme 2.2). The results are summarized in Table 2.1. In entry 1, the 
glycosidation of Kdo fluoride 2in the presence of BF3·OEt2 gave the Kdo(2-4)Kdo 
6 in 72% yield (=5/1). When the activator was changed to a combined promoter 
Cp2HfCl2-AgOTf
40, ﬂuoride 2 was readily converted to glycal 7 (90%, entry 2). 
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Scheme 2.2 The glycosylation of the 4,5-diol acceptor with Kdo donors 
Table 2.1 Glycosylation of Kdo donors 2-4 with the 4,5-diol acceptor 5. 
Entry Donor Lewis acid 
(equiv) 
Temp Time  
(h) 
Yield  
(%) 
 7(%)a 5 (%) 
1 2 BF3·OEt2 (6.0) -20 °C 1.5  72 5:1 - - 
2 2 Cp2Hf(OTf)2(2.2) -20 °C 1.5 16 3.5:1 90  
3 2 BF3·OEt2 (6.0) -20 °C to rt 10 41 2.5:1 73  
4 2 TMSOTf (0.1) -20 °C to rt 10 - - 35b  
5 3 TMSOTf (0.1)  -78 °C  2.0 48 2.4:1   
6 3 TMSOTf (0.1) -78 °C  2.0 61 2.6:1   
7 4 TMSOTf (0.1) -20 °C  2.5 35 3.8:1 61 50 
8 4 BF3·OEt2 (1.0) -20 °C  2.0  30 2.1:1 83 63 
a The yield was based on the donor. 
b Twenty four percent of the donor was recovered. 
 
Using -ﬂuoride 2 with BF3·OEt2 as an activator gave a moderate yield (41%, 
entry 3), whereas using TMSOTf as a promoter gave a poor yield (entry 4). The 
longer reaction time and higher reaction temperature also suggest that the reactivity of 
-ﬂuoride was lower than that of -ﬂuoride. The lower reactivity of -ﬂuoride might 
be due to the effect of 4,5-O-isopropylidene group. As shown in Figure 2.1, in the 
glycosidation of fluoride 2, the C-F bond is firstly cleaved by BF3·OEt2 to give an 
oxocarbenium ion intermediate.41 With the steric hindrance of isopropylidene group 
on the top face, the acceptor prefers to attack the oxocarbenium ion intermediate from 
the bottom side to give -selective glycoside. However, in the glycosidation of the 
fluoride 2, it seems to be difficult to directly form the oxocarbenium ion 
intermediate. Due to the large electronegativity of the fluorine atom, C-F bond is very 
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short and stable. In addition, the covalent radius of the fluorine atom is also very small. 
Therefore, with the steric hindrance of 4,5-O-isopropylidene group, the boron atom 
(Lewis acid) seems to be difficult to attack the fluorine atom to cleave the C-F bond 
from the top face. The fluoride 2 might transfer to 2 to give the glycoside. 
 
 
Figure 2.1 The mechanism of the glycosidation of -and -ﬂuoride. 
 
  The use of N-phenyl triﬂuoroacetimidate 3, 3 (entries 5 and 6) with 
TMSOTf as an activator gave a good yield, although the stereoselectivity was modest.  
The use of glycosyl phosphite (entries 7 and 8) with BF3·OEt2 or TMSOTf gave a 
poor yield and low selectivity. These donors gave glycal 7 as the major product.  
Comparing the glycosylation results above, Kdo ﬂuoride 2 (entry 1) with BF3·OEt2 
as the activator provided the best yield and -selectivity. Thus, the reaction of 
glycosyl ﬂuoride 2 in the presence of BF3·OEt2 was the most effective for this 
reaction. 
 
2.3 Conclusion 
The change of leaving groups in Kdo donors was not effective on the 
improvement in the yield for the glycosidation of Kdo(2-4)Kdo dimer. As shown in 
Figure 2.1, the glycosidation of the Kdo donors with a 4,5-O-isopropylidene 
protecting group tends to proceed in a SN-1 reaction.41 The leaving groups would be 
cleaved to form an oxocarbenium ion intermediate. The glycosidation results indicate 
that the cleaved leaving groups contribute nothing to avoiding the formation of the 
glycal from the oxocarbenium ion intermediate. The formation of the glycal would 
decrease the yield of the glycosidation. Moreover, the stereoselectivity was also not 
 20 
influenced by the type of leaving group. Due to the effect of the 4,5-O-isopropylidene 
group (Figure 2.1), all donors produced the -glycoside as the main product. These 
results are consistent with the results reported by Yoshizaki et al. that glycosidation 
with a 4,5-O-isopropylidinene-protected Kdo fluoride donor has a high 
-selectivity.42 
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3.1 Introduction 
In Chapter 2, the effect of leaving groups and Lewis acid on the yield and 
stereoselectivity for the glycosylation of 2-4 linked Kdo dimer has been discussed. 
The result suggests that the reaction of -ﬂuoride in the presence of BF3·OEt2 is 
the most effective. In this Chapter, we focus on the construction of 4,5-branched 
Kdo structures using the Kdo2-4) Kdo dimer, which was prepared in Chapter 2, 
as common acceptor.  
Although many chemical syntheses of linear core LPS/LOS have been 
reported,34 only Paulsen et al. described the synthesis of the 4,5-branched Kdo 
structure.35 As shown in Figure 1.4 of Chapter 1, they installed the 
L-glycero-D-manno-heptopyranosyl donor (Hep) on the 5-OH of the Kdo acceptor to 
form a Hep(1-5)Kdo disaccharide and then linked a Kdo donor to the 4-OH of the 
Kdo moiety to form Hep(1-5)[Kdo(2-4)]Kdo trisaccharide. However, some defects 
limited the application of this approach. Pre-protection and deprotection of 4-OH of 
the Kdo moiety complicated the reaction. Moreover, due to the steric hindrance of 
heptose in 5-position and fail of the stereo control, the second glycosidation of 
Hep(1-5)Kdo disaccharide with Kdo gave a low yield (37%).   
To solve these problems, a new synthetic strategy different from Paulsen’s 
method was proposed. We prepared this 4,5-branched Kdo trisaccharides by 
glycosylation of the 5-OH group of the 2-4 linked Kdo disaccharide, which was 
constructed in Chapter 2. Three types of 4,5-branched Kdo trisaccharides were 
synthesized through this new route. 
 
3.2 Result and discussion  
3.2.1 The glycosylation to synthesize 4,5-branched Kdo trisaccharides 
Glycosylation of Kdo(2-4)Kdo acceptor 6 with L-glycero-D-manno-heptosyl, 
mannosyl, and 2-azido-2-deoxy-galactosyl imidates 8–10 was examined (Scheme 3.1), 
and the results are presented in Table 3.1.  
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Scheme 3.1 Glycosylation of the dimeric acceptor 6 with donors 8–10. 
Table 3.1 Glycosylation of the dimeric acceptor 6with donors 8–10. 
Entry Donor Temp 
(°C) 
TMSOTf  
(equiv) 
Time (h) Product (%) 12 (%) 6
(%) 
1 8 () 0 0.04  4 10 35 44 
2 8 () r.t. 0.04  2 28 28 19 
3 8 () r.t. 0.06  2 87 3 9 
4 9 () 0 0.04  2 91 - - 
5 10 
(=1:3) 
0 0.04  2 56 - 40 
 
3.2.1.1 The glycosidation of Hep donor with Kdo(2-4)Kdo 
The reaction of heptosyl trichloroacetimidate 843 with acceptor 6 in the 
presence of 0.04 equiv of TMSOTf at 0 °C gave the corresponding 4,5-branched 
trisaccharide, Hep(1-5)[Kdo(2-4)]Kdo (11), in only 10% yield, and orthoester 12 
was the major product (35%). To reduce the formation of 12, the reaction temperature 
was raised to room temperature (entry 2). Correspondingly, the yield of orthoester 12 
reduced to 28%, and that of the target Hep(1-5)[Kdo(2-4)]Kdo (11) increased to 
28%. To suppress the formation of orthoester 12 further, more TMSOTf should be 
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used, because the orthoester could be transferred to 2-O-acyl glycosides in acid.44 
Increasing the amount of TMSOTf (entry 3) afforded trisaccharide 11 in good yield 
(87%) and only a small amount of orthoester 12 was detected (3%).   
The 4,5-branched structure of 11 was determined by 2D NMR analysis (COSY, 
HMQC, and HMBC). From the COSY and HMBC spectra, we were able to identify 
the cyclic proton and carbon atoms of each residue of 11. The newly formed 1-5 
linkage was identified by HMBC analysis. Figure 3.1 shows part of the HMBC 
spectrum. The cross-relay peaks in the HMBC spectrum (Kdo H-5I/Hep C-1III, Hep 
H-1III/Kdo C-5I) confirmed that heptosyl donor 8 is linked to the 5-position of 
acceptor 6. Moreover, the anomeric configuration was determined from the 1JC-1,H-1 
value. The coupling constant between H-1III and C-1III (1JH-1
III
,C-1
III= 178 Hz) of the 
Hep residue suggested that the newly formed glycosidic bond was an -linkage.45 
Thus, the trisaccharide, Hep(1-5)[Kdo(2-4)]Kdo, was successfully synthesized 
from the Kdo disaccharide with a heptosyl donor. 
 
 
Figure 3.1 Partial HMBC spectra of compound 11 in CDCl3 at 25 °C.  
 
In conjunction with the synthesis of Kdo disaccharide 6 in Chapter 2, the 
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preparation of Hep(1-5)[Kdo(2-4)Kdo] by our new route was supposed to be more 
effective than Paulsen’s method. Due to a new reaction sequence, the absence of 
4-OH protection shortened the reaction steps (from four steps to two steps). Without 
the disturbance of Hep at the 5-position, the Kdo(2-4)Kdo linkage could be smoothly 
formed in good yield (72%). Correspondingly, the total yield of 
Hep(1-5)[Kdo(2-4)]Kdo synthesis was improved to 63% (Paulsen: 22%).    
 
3.2.1.2 The glycosidationof Man donor with Kdo(2-4)Kdo 
Following the synthesis of Hep(1-5)[Kdo(2-4)]Kdo (11), other 4,5-branched 
Kdo trisaccharides were also synthesized by the same route with 6 as an acceptor. 
By coupling 6 with mannosyl trichloroacetimidate 946, branched trisaccharide 13 
was also obtained in good yield (91%) (entry 4). The effect of the participating group 
(Ac) at the C-2 position meant that only -isomer, which was identified by the 
1JH-1
III
,C-1
III value of the Man residue (175 Hz), was isolated.45 In contrast, for the 
heptose derivative, mannosylation proceeded smoothly at 0 °C with 0.04 equiv 
TMSOTf, and no orthoester was detected. These results suggest that mannosyl donor 
9 was more active than heptosyl donor 8.   
 
3.2.1.3 The glycosidation of GalN3 donor with Kdo(2-4)Kdo 
Glycosylation of Kdo dimer 6 with GalN3 trichloroacetimidate 1047 was 
accomplished to give GalN3 containing branched trisaccharide 14 as a single isomer in 
moderate yield (56%) (entry 5). The coupling constant between H-1III and H-2III (JH-1, 
H-2= 3.4 Hz) of GalN3 residue indicated that an -glycosidic linkage was formed.45 
The position of azide group meant this glycosylation exploited the anomeric effect to 
give the -isomer. In addition, the presence of acetyl groups at the 3- and 4-position 
was also favorable for -isomer formation.48 As observing from the Thin layer 
chromatography (TLC), only -anomeric donor was consumed during the 
glycosidation. After the reaction, -anomeric donor was almost recovered. These 
suggested that for GalN3 donor, the -isomer is more active than the -isomer.   
Therefore, these glycosylation results indicate that it is available to synthesize 
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the 4,5-branched Kdo trisaccharides by our new approach using Kdo(2-4)Kdo 6 as 
common acceptor. Moreover, due to the steric hindrance in the Kdo(2-4)Kdo 
acceptor, the Man type donors (Hep 8 and Man 9) appear to be easier to couple with 
the Kdo acceptor than then GalN3 donor.  
Next the transformation of the azide group to the original acetamide group in 
trisaccharide 14 was carried out. The azide group could not be converted directly to 
the acetamide group by thioacetic acid (data not shown).49 Hence, a stepwise 
conversion was used (Scheme 3.2). Firstly, the azide group of GalN3 14 was reduced 
to the amine group under Staudinger conditions.50 Then the amine group of 15 was 
acetylated with anhydrous acetic acid in the presence of N,N-dimethylaminopyridine 
(DMAP). Finally, GalNAc trisaccharide 16 was obtained in moderate yield (64%). 
 
 
Scheme 3.2 Conditions: (a) Ph3P, THF/H2O= 19/1, rt, 16 h; (b) Ac2O, DMAP, pyridine, rt, 17 h, 
two steps: 64%.  
 
3.2.2 Full deprotection of 4,5-branched Kdo trisaccharides 
In Final, the deprotection of all synthetic Kdo trisaccharide 11, 13, and 16 was 
carried out. Acid hydrolysis of the isopropylidene group of Kdo trisaccharide (11, 13, 
and 16) with aqueous trifluoroacetic acid and subsequent hydrolysis in 0.1 M sodium 
hydroxide to remove the ester groups afforded fully deprotected 4,5-branched Kdo 
trisaccharides 17–19 as a disodium salt in good yield (Hep 17: 87%, Man 18: 93%, 
GalNAc 19: quantitative) (Scheme 3.3).  
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Scheme 3.3 Conditions: (a) 80% TFA, CH2Cl2, rt; (b) 0.1 M NaOH, MeOH, two steps: Hep 17 
(87%), Man 18 (93%), GalNAc 19 (quant),.  
 
3.3 Conclusion  
A new synthetic strategy using Kdo (2-4)Kdo 6 as an acceptor was developed 
for the synthesis of 4,5-branched Kdo trisaccharides. Glycosylation at the 4-OH 
position of the Kdo acceptor followed by a second glycosylation at 5-OH position 
produced the heptosyl Kdo dimer, Hep(1-5)[Kdo(2-4)]Kdo (11). We also achieved 
the first synthesis of the 4,5-branched partial inner-core trisaccharides 
Man(1-5)[Kdo(2-4)]Kdo (13) from Francisella tularensis21 and 
GalN3(1-5)[Kdo(2-4)]Kdo (14) from Pseudomonas cichorii22 in good yield and 
high -selectivity. This new route might provide another choice for the synthesis of 
the inner-core oligosaccharides of LPS/LOS with the Paulsen’s method.   
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Chapter 4 
The convergent synthesis of 4,5-branched  
inner-core OSs 
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4.1 Introduction 
The highly conserved inner-core OS consists of mostly the higher carbon sugars 
3-deoxy-D-manno-2-octulosonic acid (Kdo) and L-glycero-D-manno-heptopyranose 
(Hep). For example in Figure 4.1, the inner core OS of LPSs/LOSs from many 
gram-negative bacteria contains a 4,5-branched Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo 
tetrasaccharide as the common structure.51 An R (R = Lac, Glc, P) residue is usually 
substituted at the 4-O position of Hep I.52 
 
 
Figure 4.1 General inner-core structure of LPS/LOS. 
 
  In Chapter 3, a new synthetic method to prepare 4,5-branched inner-core 
trisaccharides by coupling monosaccharides (Hep, Man, GalN3) with a common Kdo 
acceptor 6 was introduced. To extend the utility of this approach, in this Chapter we 
prepared more complex 4,5-banched inner core OS structures by using the same Kdo 
disaccharide 6 as the acceptor. A lactose donor was initially chosen as a model 
compound to optimize the glycosylation conditions. Based on the model glycosylation, 
the corresponding Hep units constructed from the Hep building blocks were coupled 
with the Kdo moiety to obtain the desired branched inner-core OS. 
 
4.2 Result and discussion 
4.2.1 Synthesis of Hep units 
To install the Kdo moiety, the Hep units, Gal(1-4)Glc(1-4)Hep trisaccharide 
and Hep(1-3)Hep disaccharide, were prepared. All the Hep building blocks (21, 22, 
25) required for the Hep units were obtained from known methyl 
6,7-di-O-acetyl-2-O-benzyl-L-glycero-D-manno-heptopyranoside 2053 (Scheme 4.1).   
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4.2.1.1 Synthesis of Hep building blocks 
Treatment of 3,4-diol 20 with t-butyldimethylsilyl chloride (TBDMSCl) and 
1H-imidazole in N,N-dimethylformamide (DMF) at room temperature gave 
3-O-TBDMS ether 21 in 94% yield. The acetylation of 21 in acetic anhydride 
(Ac2O)/pyridine and subsequent de-O-silylation of TBDMS group in aqueous 
trifluoroacetic acid gave 3-OH product 22 in 88% yield. L-Glycero-D-manno-heptosyl 
trichloroacetimidate 25 was also prepared from 3,4-diol 20 in a 69% yield over four 
steps as follows: sequential acetylation of 3,4-diol 20, acetolysis of 23, selective 
anomeric deacetylation, and treatment of hemiacetal 24 with trichloroacetonitrile in 
the presence of potassium carbonate. 
 
 
Scheme 4.1 Conditions: (a) TBDMSCl, 1H-imidazole, DMF, rt, 4 h, 92%; (b) (i) Ac2O, DMAP, 
pyridine, 0 °C→ rt, 17 h, 95%; (ii) 90% TFA aq., rt, 1 h, 93%; (c) Ac2O, DMAP, pyridine, 0 °C→ 
rt, 2 h, 94%; (d) (i) H2SO4, Ac2O, AcOH, rt, 2 h, 95%; (ii) hydrazine acetate, 0 °C→ rt, DMF, 2 h, 
80%; (e) Cl3CCN, K2CO3, CH2Cl2, rt, 22 h, 96%.  
 
4.2.1.2 Synthesis of Lac(1-4)Hep unit 
Glycosylation of 4-OH Hep building block 21 with hepta-O-acetyl--lactosyl 
trichloroacetimidate 2654 using TMSOTf as the catalyst in CH2Cl2 proceeded 
smoothly to afford (1-4)-linked Gal(1-4)Glc(1-4)Hep trisaccharide 2755 as a Hep 
unit in 79% yield (Scheme 4.2). The glucosyl-(1-4)-heptose linkage in trisaccharide 
27 was assigned as  based on the coupling constant between H-1 and H-2 of the 
glucose residue (3JH1,H2= 8.0 Hz). Cleavage of the TBDMS group in 
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Gal(1-4)Glc(1-4)Hep trisaccharide 27 with aqueous trifluoroacetic acid produced 
the free 3-OH 28 in 97% yield. To characterize the effect of the protecting group of 
donor moiety on the glycosidation, two types of Gal(1-4)Glc(1-4)Hep donors (31 
and 35) with the different protecting groups at C-2 of the Hep residue were prepared 
from 28, respectively, as follows. Immediate acetylation of 28 with acetic anhydride 
in pyridine gave 29 in 73% yield. Acetolysis of 29 in H2SO4/Ac2O/AcOH and 
subsequent selective anomeric deacetylation afforded hemiacetal 30. 
Gal(1-4)Glc(1-4)Hep hemiacetal 30 was transformed in quantitative yield to the 
corresponding trichloroacetimidate 31. In addition, to obtain a per-O-acetylated 
Gal(1-4)Glc(1-4)Hep donor, the benzyl group at C-2 of the Hep residue in 28 was 
removed by hydrogenolysis (10% Pd/C in EtOAc) to give 2,3-diol 3255 in 97% yield. 
Acetylation of 32 with acetic anhydride in pyridine, followed by acetolysis produced 
33 in 67% yield. Selective anomeric deacetylation of 33 with hydrazine acetate in 
DMF at 0 °C gave hemiacetal 34 in 90% yield. Treatment of 34 with 
trichloroacetonitrile in the presence of K2CO3 gave per-O-acetylated 
Gal(1-4)Glc(1-4)Hep trichloroacetimidate 35 in 92% yield. 
Gal(1-4)Glc(1-4)Hep trichloroacetimidates 31 and 35 were expected to undergo 
[3+2] coupling with the Kdo moiety. 
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Scheme 4.2 Conditions: (a) TMSOTf, CH2Cl2, MS AW 300 molecular sieves, 0 °C, 3 h, 79%; (b) 
TFA/H2O, 9:1, rt, 5 min, 97%; (c) Ac2O, DMAP, pyridine, rt, 2 h, 73%; (d) (i) H2SO4, Ac2O, 
AcOH, rt, 3 h, 64%; (ii) hydrazine acetate, DMF, 0 °C, 8 h, 77%; (e) Cl3CCN, K2CO3, CH2Cl2, rt, 
13 h, quant; (f) 10% Pd/C, H2, ethyl acetate, rt, 3.5 h, 97%; (g) (i) Ac2O, pyridine, rt, 24 h; (ii) 
H2SO4, Ac2O, AcOH, rt, 15 h, two steps: 67%; (h) hydrazine acetate, DMF, 0 °C, 8 h, 90%; (i) 
Cl3CCN, K2CO3, CH2Cl2, rt, 24 h, 92%. 
 
4.2.1.2 Synthesis of Hep(1-3)Hep unit 
The (1-3)-linked heptobiose unit 36 was prepared in 50% yield by glycosidation 
of imidate 25 with Hep building block 22 by using TMSOTf as a promoter in CH2Cl2 
(Scheme 4.3). The coupling constant between C-1 and H-1 (1JC,H= 174 Hz) of 
reducing heptose residue suggested the (1-3) linkage was an -linkage. No -isomer 
was detected. Acetolysis of the methyl ether in 36, followed by selective cleavage of 
the anomeric acetyl group with hydrazine acetate in DMF at 0 °C produced 
disaccharide hemiacetal 37 in 78% yield over two steps. Treatment of 37 with 
trichloroacetonitrile in the presence of K2CO3 gave Hep(1-3)Hep trichloroacetimidate 
38, which was expected to undergo [2+2] coupling with the Kdo moiety. 
 
 
Scheme 4.3 Conditions: (a) TMSOTf, CH2Cl2, 4Å molecular sieves, -78 °C→ rt, 2 h, 50%; (b) (i) 
H2SO4, Ac2O, AcOH, rt, 2 h, (ii) hydrazine acetate, DMF, 0 °C, 7 h, two steps: 78%; (c) Cl3CCN, 
K2CO3, CH2Cl2, rt, 21 h, 80%, /=6:1. 
 
4.2.2 Convergent synthesis of 4,5-branched inner-core OS structures 
Next, we focused on the glycosidation of the Hep units with the Kdo moiety 
(Scheme 4.4 and Table 4.1). A model glycosylation using a lactose derivative as a 
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donor was performed to test this convergent approach.   
 
 
Scheme 4.4 The convergent synthesis of 4,5-branched inner-core OSs. 
Table 4.1 Glycosylation to synthesize 4,5-branched inner-core OSs. 
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4.2.2.1 Model glycosylation of lactose donor with Kdo disaccharide  
Because the glycosylation of per-O-acetylated Hep imidate 8 could provide 
Hep(1-5)[Kdo(2-4)]Kdo trisaccharide 11 in good yield (Chapter 3: Table 3.1), 
per-O-acetylated lactosyl imidate 39 was used for coupling with Kdo(2-4)Kdo 
acceptor 6 (Scheme 4.4 and Table 4.1). However, no Lac-Kdo tetrasaccharide was 
formed. The reactivity of the per-O-acetylated lactose donor was too low to form the 
linkage. Therefore, a more reactive donor, hepta-O-benzyl--lactosyl 
trichloroacetimidate 4056, was examined. To increase the -selectivity in the 
lactosylation, the reaction was carried out in CH2Cl2/Et2O
57 and gave branched 
Gal(1-4)Glc(1-5)[Kdo(2-4)]Kdo tetrasaccharide 41 in only 20% yield as only a 
single isomer. The coupling constant between H-1 and H-2 of the glucose residue 
(3JH1,H2= 3.4 Hz) indicated that the (1-5) linkage was an -linkage. The high 
stereoselectivity was due to the anomeric effect58 and the solvent effect59. The 
introduction of benzyl ethers meant that imidate 40 was more effective in providing 
desired tetrasaccharide 41, despite the high steric hindrance.  
 
4.2.2.2 The convergent glycosylation of Lac(1-4)Hep unit with Kdo disaccharide  
Following the model glycosylation, the [3+2] coupling of the Lac(1-4)Hep 
unit with the Kdo moiety was examined. According to the glycosidation results of 
both Hep donor 8 and 25 giving products in high -selectivity in CH2Cl2, CH2Cl2 was 
used as a solvent for the following heptosylation. The synthesis of 
Lac(1-4)Hep(1-5)[Kdo(2-4)]Kdo pentasaccharide by coupling of 
per-O-acetylated Gal(1-4)Glc(1-4)Hep trichloroacetimidate 35 with Kdo acceptor 
6 failed. No branched pentasaccharide was found and mainly imidate 35 was 
recovered, even though the reaction time was extended to 15 h. In addition, the 
decomposition of the acceptor 6 to lactone 42 was observed. The donor was changed 
to Gal(1-4)Glc(1-4)Hep imidate 31, which contained a benzyl group at C-2 of the 
Hep residue, and desired Gal(1-4)Glc(1-4)Hep(1-5)[Kdo(2-4)]Kdo 
pentasaccharide 43 was obtained in a 26% yield as only the -anomer. The anomeric 
configuration of the Hep residue in pentasaccharide 43 was confirmed by the coupling 
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constants between C-1 and H-1 of the heptose residue (1JC,H= 174 Hz). This was 
consistent with the results of the model glycosylation, which indicated that the 
reactivity of the donor is important for this convergent approach. The introduction of 
an benzyl ether at C-2 of the Hep residue increased the reactivity of the 
Gal(1-4)Glc(1-4)Hep donor to provide the branched pentasaccharide. To increase 
the pentasaccharide yield further, the strategy of benzylating the 3-OH of the heptose 
residue was considered. Therefore, in our convergent approach, the sterically crowded 
heptose unit can be added to the Kdo moiety to produce the desired 4,5-branched core 
OS structures. This approach was also expected to provide the common inner-core OS 
structure containing the heptobiose unit. 
 
4.2.2.3 The convergent glycosylation of Hep(1-3)Hep unit with Kdo dimer 
Dibenzyl Hep(1-3)Hep trichloroacetimidate 38 was coupled with 
Kdo(2-4)Kdo acceptor 6 by using 0.06 equiv of TMSOTf as the activator. As 
expected, the introduction of the dibenzyl group substantially increased the reactivity 
of the Hep(1-3)Hep unit to provide Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo 
tetrasaccharide 44 in moderate yield (57%) as the -anomer. The configuration of 
tetrasaccharide 44 was confirmed by the coupling constants between C-1 and H-1 of 
the corresponding heptoses (1JC, H= 172, 174 Hz). 
Furthermore, all branched structures we synthesized were characterized by 
analyzing the corresponding 2D NMR spectra (COSY, HMQC, and HMBC). For 
example, the existence of the (1-5) linkage in Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo 
tetrasaccharide 44 was supported by the HMBC analysis. The cross-relay peaks, Kdo 
H-5I/Hep C-1III, Hep H-1III/Kdo C-5I, in the HMBC spectrum (Figure 4.2) confirmed 
that the Hep unit is linked to the 5-position of the Kdo moiety. 
These results suggest that it is possible to obtain complex 4,5-branched inner 
core OSs of LPS/LOS using common Kdo dimmer 6 as an acceptor via a convergent 
approach. The Lac-Hep imidate 31 with a benzyl group at C-2 of the reducing residue, 
other than the Lac-Hep peracetate 35, giving the desired product of glycoside 
indicates that the effective improvement of the reactivity is supported by the benzyl 
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group. Meanwhile, the glycosidation of perbenzylated Lac imidate 40 giving less 
product might indicate that the perbenzylated donor should be too active to obtain the 
glycoside in good yield. These results suggest that the introduction of appropriate 
number of benzyl protecting groups appears to be important for the yield of this 
convergent glycosylation.  
 
 
Figure 4.2 Partial HMBC spectrum of tetrasaccharide 44 in CDCl3 at 25 °C. 
 
4.2.3 Full deprotection of 4,5-branched Kdo tetra- and pentasaccharide 
Finally, the deprotection of all synthetic Kdo trisaccharide 41, 43, and 44 was 
carried out. As shown in Scheme 4.5, deprotection of 
Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo tetrasaccharide 44 was performed over three 
steps. Pd(OH)2/C-promoted hydrolysis of the benzyl groups, acid hydrolysis of the 
isopropylidene group with aqueous trifluoroacetic acid, and hydrolysis of the ester 
group in 0.1 M NaOH produced the target 4,5-branched tetrasaccharide 45 in 90% 
yield as the disodium salt. 
Gal(1-4)Glc(1-4)Hep(1-5)[Kdo(2-4)]Kdo pentasaccharide 43 and 
Gal(1-4)Glc(1-5)[Kdo(2-4)]Kdo tetrasaccharide 41 were subjected to similar 
deprotection to afford the corresponding deprotected compounds, 46 (53%) and 47 
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(60%)  
 
 
Scheme 4.5 Conditions: (a) Pd(OH)2/C, H2, MeOH, rt; (b) 80% TFA aq., CH2Cl2, rt; (c) 0.1 M 
NaOH, MeOH, three steps: 41 (90%), 42 (53%), 43 (60%).  
 
4.3 Conclusion 
The convergent synthetic strategy using Kdo(2-4)Kdo as a common acceptor 
was used to prepare more complex 4,5-branched inner core OS structures. Model 
glycosylation using a lactose derivative as a test compound suggested that the 
reactivity of the donor was important for this convergent synthesis, and this was 
supported by the subsequent glycosylation. Based on the convergent approach, the 
first synthesis of 4,5-branched inner-core OSs, namely, 
Gal(1-4)Glc(1-4)Hep(1-5)[Kdo(2-4)]Kdo pentasaccharide and a common 
inner-core Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo tetrasaccharide, was accomplished 
by coupling the corresponding Hep units with Kdo(2-4)Kdo. These results suggested 
that it is a available to synthesize complex 4,5-branced inner-core OS structures by 
our new approach and Kdo(2-4)Kdo 6 is a useful intermediate for these synthesis.  
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Conclusion 
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In this study, a new synthetic approach using a common Kdo(2-4)Kdo 
disaccharide as acceptor to synthesize the 4,5-branched inner-core OS structures was 
described. Using this new approach, several types of 4,5-branced Kdo trisaccharides, 
tetrasaccharides, and pentasaccharides were successfully synthesized in good yield 
and high -selectivity.   
In the Chapter 2, to optimize the condition of glycosylation, several types of 
glycosyl donors with different leaving group and stereoselectivity were prepared from 
common Kdo intermediate and were glycosylated with 4,5-diol acceptor. The results 
showed that all donors produced the -glycoside as the main product and the 
stereoselectivity was not influenced by the type of leaving group. Moreover, the 
-fluoride donor with BF3·OEt2 as the activator provided the best yield and 
-selectivity of product. 
In the Chapter 3, using the constructed Kdo(2-4)Kdo disaccharide as the 
common acceptor, three types of 4,5-branched Kdo trisaccharides were successfully 
synthesized in good yield and high -selectivity. The glycosylation condition of 
Hep(1-5)[Kdo(2-4)]Kdo was discussed and the result seemed to be better than that 
of the Paulsen’s method in the yield and stereoselectivity. The first synthesis of the 
4,5-branched partial inner-core trisaccharides, Man(1-5)[Kdo(2-4)]Kdo (13) from 
Francisella tularensis and GalN3(1-5)[Kdo(2-4)]Kdo (14) from Pseudomonas 
cichorii, were also achieved. These results suggest that it is available to synthesize the 
4,5-branched Kdo structures by the new reaction sequence of glycosylation at the 
4-OH position of the Kdo acceptor followed by a second glycosylation at 5-OH 
position. This new route should be more effective for the synthesis of the inner-core 
oligosaccharides of LPS/LOS than Paulsen’s method.   
In the Chapter 4, to extend the utility of the new synthetic strategy, more 
complex 4,5-branched inner-core OS structures were synthesized. With the same 
Kdo(2-4)Kdo disaccharide as acceptor, three types of 4,5-branched Kdo tetra- and 
pentasaccharides were synthesized in high -selectivity. Model glycosylation using a 
lactose derivative as a test compound suggested that the reactivity of the donor was 
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important for this convergent synthesis, and this was supported by the subsequent 
glycosylation. The first synthesis of 4,5-branched inner-core OSs, namely, 
Gal(1-4)Glc(1-4)Hep(1-5)[Kdo(2-4)]Kdo pentasaccharide and a common 
inner-core Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo tetrasaccharide, was accomplished 
by coupling the corresponding Hep units with Kdo(2-4)Kdo.   
In all, the new synthetic approach using Kdo(2-4)Kdo as an intermediate is 
useful for the synthesis of 4,5-branched inner-core OS structures including Kdo 
trisaccharides, Kdo tetrasaccharides and Kdo pentasaccharide. It would provide 
another synthetic choice to obtain 4,5-branced inner-core OSs, with Paulsen’s method.  
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6.1 General procedures  
Optical rotation was measured with a Horiba SEPA500 polarimeter in CHCl3 
and melting point (uncorrected) was measured with a Yanagimoto micro melting 
point apparatus. All NMR spectra were recorded at 25 °C in CDCl3 or D2O on a 600 
MHz NMR spectrometer (Avance II, Bruker). All NMR chemical shifts () were 
recorded in parts per million (ppm), and coupling constants (J) were reported in hertz 
(Hz). Mass spectrometry (MS) was performed by positive- and negative-mode 
electrospray ionization on a Waters LCT Premier spectrometer. For high-precision 
measurements, the spectra were obtained by scanning the voltage over a narrow mass 
range at a resolution of 10,000. MALDI-TOF spectra were recorded on a Bruker 
Daltonics instrument, using 3,5-dihydroxybenzoic acid as the matrix. Elemental 
analysis was carried out on a performed on Vario ELCUBE and Vario EL III, 
Elementar. Infrared spectra were determined on a JASCO FT/IR-4100 Spectrometer.  
Analytical TLC was performed on Merck silica gel 60 F254 glass plates. The TLC 
plates were visualized with UV light and by staining with Hannessian solution (ceric 
sulfate and ammonium molybdate in aqueous sulfuric acid), and then heating at 
200 °C for 3 min. Column chromatography was performed on silica gel 60 (flash 
column: 0.040–0.063 mm; open column: 0.063–0.200 mm).  
 
6.2 Methyl (7,8-di-O-benzoyl-4,5-O-isopropylidene-3-deoxy-D-manno-2-octulopy
-ranosyl N-phenyl trifluoroacetimidate)onate (3)   
Compound 1 (250.0 mg, 0.5 mmol) was dissolved in dry dichloromethane (5.0 
mL) under argon. N-phenyl trifluoroacetimidoyl chloride60 (716.0 L, 5.0 mmol) and 
potassium carbonate (113.0 mg, 5.0 mmol) was added into the reaction. After stirring 
for 1 week, the mixture was filtered through Celite. The solution was concentrated 
and purified by silica gel column chromatography (ethyl acetate/toluene, 1:5) to give 
3 in quantitative yield (343.0 mg, =3:2). -isomer: []25D = +75.6 (c 1.0, CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.24 (s, 3H, Me), 1.50 (s, 3H, Me), 2.33 (1 H, 
J3a,3e=15.6 Hz, J3a,4=3.4 Hz, H-3a), 2.78 (dd, 1H, J3a, 3e=15.6 Hz, J3e,4=4.0 Hz, H-3e), 
3.78 (s, 3H, OMe), 4.37 (dd, 1H, J5, 6=2.0 Hz, J6,7=8.6 Hz, H-6), 4.41 (dd, 1H, J4,5=7.6 
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Hz, J5,6=2.0 Hz, H-5), 4.62 (ddd, 1H, J3a,4=3.4 Hz, J3e,4=4.0 Hz, J4,5=7.6 Hz, H-4), 
4.72 (dd, 1H, J7,8a=4.0 Hz, J8a,8b=12.4 Hz, H-8a), 5.00 (dd, 1H, J7,8b=2.4 Hz, 
J8a,8b=12.4 Hz, H-8b), 5.75 (ddd, 1H, J6,7=8.6 Hz, J7,8a=4.0 Hz, J7,8b=2.4 Hz, H-7), 
6.74-6.75 (m, 2H, NPh-Ar), 7.05 (m, 1H, NPh-Ar), 7.24–7.25 (ddd, 2H, NPh-Ar), 
7.37-7.44 (m, 4H, Ar), 7.51–7.57 (m, 2H, Ar), 7.98–8.03 (m, 4H, Ar). 13C NMR (150 
MHz, CDCl3):  24.8, 25.6 (CH3), 33.0 (C-3), 52.8 (OCH3), 62.6 (C-8), 69.5 (C-4), 
70.1 (C-7), 70.2 (C-6), 70.8 (C-5), 99.0 (C-2), 110.1 (Cisop), 116.5 (CF3), 119.1 
(NPh-Ar), 124.3 (NPh-Ar), 128.4, 128.5, 128.7, 129.4, 129.6, 129.7, 129.8, 133.1, 
133.3 (14 C, NPh-Ar), 143.2 (C=N), 165.1, 166.2 (C=O), 168.1 (C-1). IR: 1736, 1727, 
1229, 1215, 1202 cm-1. ESI-HRMS for C34H32F3NO10: 694.1876 [M+Na]
+. Found 
694.1873. -isomer: []25D = +6.6 (c 1.0, CHCl3), 1H-NMR (600 MHz, CDCl3):  
1.29 (s, 3H, Me), 1.54 (s, 3H, Me), 2.34 (dd, 1H, J3a,3e=16.2 Hz, J3a,4=3.4 Hz, H-3a), 
2.78 (dd, 1H, J3a, 3e=16.2 Hz, J3e,4=3.0 Hz, H-3e), 3.66 (s, 3H, OMe), 4.26 (dd, 1H, J5, 
6=1.8 Hz, J6,7=8.0 Hz, H-6), 4.44 (dd, 1H, J4,5=8.2 Hz, J5,6=1.8 Hz, H-5), 4.68 (ddd, 
1H, J3a,4=3.4 Hz, J3e,4=3.0 Hz, J4,5=8.2 Hz, H-4), 4.70 (dd, 1H, J7,8a=5.2 Hz, 
J8a,8b=12.4 Hz, H-8a), 4.97 (dd, 1H, J7,8b=2.4 Hz, J8a,8b=12.4 Hz, H-8b), 5.68-5.71 
(ddd, 1H, J6,7=8.6 Hz, J7,8a=5.2 Hz, J7,8b=2.4 Hz, H-7), 6.74–6.75 (dd, 2H, NPh-Ar), 
7.09 (m, 1H, NPh-Ar), 7.27–7.28 (ddd, 2H, NPh-Ar), 7.39–7.44 (m, 4H, Ar), 
7.51–7.57 (m, 2H, Ar), 7.98–8.03 (m, 4H, Ar). 13C NMR (150 MHz, CDCl3):  25.6, 
25.8 (CH3), 29.7 (C-3), 52.8 (OCH3), 62.9 (C-8), 69.2 (C-4), 70.5 (C-7), 70.9 (C-5), 
71.5 (C-6), 99.3 (C-2), 110.0 (Cisop), 114.6 (CF3), 119.3 (NPh-Ar), 124.3 (NPh-Ar), 
128.4, 128.5, 128.6, 128.8, 129.6, 129.7, 129.8, 129.83, 130.0, 134.0, 133.2 (14 C, 
NPh-Cmeta and Ar), 143.2 (C=N), 165.2, 166.1 (C=O), 167.9 (C-1). IR: 1736, 1725, 
1230, 1214, 1205 cm-1. ESI-HRMS for C34H32F3NO10: 694.1876 [M+Na]
+. Found 
694.1855. 
6.3 Methyl (dibenzyl-7,8-di-O-benzoyl-4,5-O-isopropylidene-3-deoxy-D-manno-2
-octulopyranosyl phosphite)onate (4)   
1H-tetrazole (112.0 mg, 1.6 mmol) was added to a solution of 1 (200.0 mg, 0.4 
mmol) in dry dichloromethane (13.0 mL) under argon. Then the reaction mixture was 
cooled to 0 ˚C and treated with dibenzyl N,N-diisopropylphosphoramidite (DDP, 322 
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L/0.96 mmol). After stirring for 3 h, the solution was quenched with triethylamine 
(Et3N) and concentrated. The residue was purified by silica gel column 
chromatography (ethyl acetate/ hexane, 2:3+1% Et3N) to give a mixture of anomers 4 
in 56% yield (167.0 mg, =23:1). -isomer: []25D = +33.8 (c 1.1, CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.20, 1.43 (s, 2H, CH3), 2.06 (dd, 1H, J3a,3e=15.0 Hz, 
J3a,4=3.4 Hz, H-3a), 2.82 (dd, 1H, J3a,3e=15.0 Hz, J3e,4=5.2 Hz, H-3e), 3.70 (s, 3H, 
OMe), 4.25 (dd, 1H, J4,5=7.0 Hz, J5,6=2.0 Hz, H-5), 4.34 (dd, 1H, J5,6=2.0 Hz, J6,7=7.4 
Hz, H-6), 4.47 (ddd, 1H, J3a,4=3.4 Hz, J3e,4=5.2 Hz, J4,5=7.0 Hz, H-4), 4.66 (dd, 1H, 
J7,8a=6.0 Hz, J8a,8b=12.4 Hz, H-8a), 4.77 (dd, 1H, J =12.4 and 7.8 Hz, OCH2Ph), 4.81 
(d, 2H, J=7.8 Hz, OCH2Ph), 4.83 (dd, 1H, J=12.2 and 8.4 Hz, OCH2Ph), 5.00 (dd, 1H, 
J7,8b=2.4 Hz, J8a,8b=12.4 Hz, H-8b), 5.74 (ddd, 1H, J6,7=7.4 Hz, J7,8a=6.0 Hz, J7,8b=2.4 
Hz, H-7), 7.18–7.54 (m, 16H, Ar), 7.97–8.03 (m, 4H, Ar). 13C NMR (150 MHz, 
CDCl3):  25.0, 26.0 (CH3), 33.7 (C-3), 52.7 (OCH3), 63.3 (C-8), 64.2, 64.20, 64.6, 
64.7 (2C, OCH2), 69.8 (C-4), 70.6 (C-7), 70.7 (C-6), 71.4 (C-5), 97.3, 97.33 (C-2), 
109.7 (Cisop), 127.6, 127.7, 127.72, 128.1, 128.3, 128.37, 128.4, 128.7, 129.8, 129.9, 
130.1, 132.9 133.1, 137.9, 138.0, 138.0 (Ar), 165.3, 166.2 (C=O), 168.7 (C-1). IR: 
1749, 1713, 1282, 1252, 1213, 973 cm-1. ESI-HRMS for C40H41O12P: 767.2233 
[M+Na]+. Found 767.2222. -isomer: []25D = +23.4 (c 1.0, CHCl3), 1H-NMR (600 
MHz, CDCl3):  1.21, 1.42 (s, 2H, CH3), 2.40 (dd, 1H, J3a,3e=15.2 Hz, J3a,4=3.0 Hz, 
H-3a), 2.94 (dd, 1H, J3a,3e=15.2 Hz, J3e,4=5.6 Hz, H-3e), 3.73 (s, 3H, OMe), 4.35 (dd, 
1H, J4,5=7.6 Hz, J5,6=2.0 Hz, H-5), 4.52 (ddd, IH, J3a,4=3.0 Hz, J3e,4=5.6 Hz, J4,5=7.6 
Hz, H-4), 4.65 (dd, 1H, J5,6=2.0 Hz, J6,7=7.4 Hz, H-6), 4.66 (dd, 1H, J7,8a=7.0 Hz, 
J8a,8b=12.4 Hz, H-8a), 4.95–5.02 (m, 4H, OCH2), 5.02 (dd, 1H, J7,8b=2.4 Hz, 
J8a,8b=12.4 Hz), 5.78 (ddd, 1H, J6,7=7.4 Hz, J7,8a=7.0 Hz, J7,8b=2.4 Hz, H-7), 7.25–7.53 
(m, 16H, Ar), 7.98–8.03 (m, 4H, Ar). 13C NMR (150 MHz, CDCl3):  24.6, 25.4 
(CH3), 32.2 (C-3), 53.0 (OCH3), 63.5 (C-8), 69.5 (C-4), 69.55, 69.6, 69.62, 69.7 (2C, 
OCH2), 70.3 (C-7), 71.3 (C-5), 72.1 (C-6), 100.0 (C-2), 109.8 (Cisop), 128.1, 128.2, 
128.3, 128.4 128.42, 128.46, 128.48, 128.5, 129.7, 129.75, 129.8, 130.1, 132.8, 133.1, 
135.6 (Ar), 165.3, 166.2 (C=O), 167.2 (C-1). IR: 1748, 1717, 1253, 1213, 954 cm-1. 
ESI-HRMS for C40H41O12P: 767.2233 [M+Na]
+. Found 767.2223. 
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6.4 (2,3,4,6,7-Penta-O-acetyl-L-glycero--D-manno-heptopyranosyl)-(1-5)-[methy
-l O-[methyl (7,8-di-O-benzoyl-4,5-O-isopropylidene-3-deoxy--D-manno-2-octu
-lopyranosyl)onate]]-(2-4)-(allyl 7,8-di-O-benzoyl-3-deoxy--D-manno-2-octulop-
yranosid)onate (11)   
A mixture of 6 (32.0 mg, 32.6 mol), imidate 8 (55.0 mg, 98.7 mol), and 
MS-AW 300 (40.0 mg) was suspended in dichloromethane (1.0 mL). The reaction 
mixture was stirred for 1 h under argon, and then 0.01 M TMSOTf (196.0 L, 1.96 
mol) in dichloromethane was added dropwise to the reaction mixture. After stirring 
for 2 h, the reaction was neutralized by the addition of a few drops of triethylamine 
and aqueous saturated sodium hydrogen carbonate. The reaction mixture was diluted 
with dichloromethane and was filtered through Celite. The filtrate was extracted twice 
with dichloromethane. The combined organic phase was dried over anhydrous sodium 
sulfate, filtrated, and concentrated. The residue was purified by BioRad S-X3 
(toluene/ethyl acetate, 1:1) to give compound 11 (39 mg, 87%) as colorless syrup. Mp 
88.2 ˚C, []25D = +19.7 (c 1.5, CHCl3), 1H-NMR (600 MHz, CDCl3):  1.20 (s, 3H, 
Me), 1.38 (s, 3H, Me), 1.93, 2.02, 2.03, 2.14 (s, 3H x 5, Ac), 2.05 (dd, 1H, J3a,3e=12.6 
Hz, J3a,4=12.0 Hz, H-3a
I), 2.12 (dd, 1H, J3a,3e=15.4 Hz, J3a,4=2.2 Hz, H-3a
II), 2.27 (dd, 
1H, J3a,3e=12.6 Hz, J3e,4=4.4 Hz, H-3e
I), 2.95 (dd, 1H, J3a,3e=15.4 Hz, J3e,4=3.6 Hz, 
H-3eII), 3.43 (s, 3H, OMeI), 3.47 (s, 3H, OMeII), 3.73 (brs, 1H, J4,5=2.0 Hz, J5,6=1.8 
Hz, H-5I), 3.93 (dddd, 1H, J=1.6, 1.6, 4.8, 13.0 Hz, OCH2-), 3.97 (dddd, 1H, J=1.4, 
1.6, 5.4, 13.0 Hz, OCH2-), 4.12 (dd, 1H, J5,6=1.8 Hz, J6,7=10.0 Hz, H-6
I), 4.22 (dd, 
1H, J4,5=10.0 Hz, J5,6=8.0 Hz, H-5
III), 4.23 (dd, 1H, J6,7a=2.4 Hz, J7a,7b=12.0 Hz, 
H-7a
III), 4.26 (dd, 1H, J6,7b=4.0 Hz, J7a,7b=12.0 Hz, H-7b
III), 4.28 (dd, 1H, J5,6=2.0 Hz, 
J6,7=7.4 Hz, H-6
II), 4.37 (dd, 1H, J4,5=8.0 Hz, J5,6=2.0 Hz, H-5
II), 4.52 (ddd, 1H, 
J3a,4=2.2 Hz, J3e,4=3.6 Hz, J4,5=8.0 Hz, H-4
II), 4.60 (dd, 1H, J7,8a=5.0 Hz, J8a,8b=12.6 
Hz, H-8a
II), 4.65 (ddd, 1H, J3a,4=12.0 Hz, J3e,4=4.4 Hz, J4,5=2.0 Hz, H-4
I), 4.69 (dd, 1H, 
J7, 8a=3.6 Hz, J8a, 8b=12.6 Hz, H-8a
I), 4.88 (dd, 1H, J7, 8b=2.6 Hz, J8a, 8b=12.6 Hz, H-8b
I), 
4.93 (dddd, 1H, J=1.4, 1.6, 3.0, 10.6 Hz, =CH2), 5.01 (dddd, 1H, J=1.6, 1.6, 3.2, 17.2 
Hz, =CH2), 5.04 (d, 1H, J1,2=2.0 Hz, H-1
III), 5.24 (dd, 1H, J1,2=2.0 Hz, J2,3=3.2 Hz, 
H-2III), 5.28 (dd, 1H, J7,8b=2.4 Hz, J8a,8b=12.6 Hz, H-8b
II), 5.32 (dd, 1H, J3,4=10.2 Hz, 
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J4,5=10.0 Hz, H-4
III), 5.37 (ddd, 1H, J5,6=8.0 Hz, J6,7a=2.4 Hz, J6,7b=4.0 Hz, H-6
III), 
5.51 (dd, 1H, J2,3=3.2 Hz, J3,4=10.2 Hz, H-3
III), 5.62-5.68 (m, 1H, -CH=), 5.65 (ddd, 
1H, J6,7=7.4 Hz, J7,8a=5.0 Hz, J7,8b=2.4 Hz, H-7
I), 5.69 (ddd, 1H, J6,7=10.0 Hz, 
J7,8a=3.6 Hz, J7,8b=2.6 Hz, H-7
I), 7.37–7.45 (m, 8H, ArI, ArII), 7.51–7.56 (m, 4H, ArI, 
ArII), 7.93–8.01 (m, 8H, ArI, ArII). 13C NMR (150 MHz, CDCl3): 20.7, 20.74, 20.8 
and 21.1 (Ac-CH3), 24.7 and 25.1 (Isop-Me), 31.9 (C-3
II), 34.4 (C-3I), 52.25 (OMeI), 
52.28 (OMeII), 62.4 (C-8I), 62.5 (C-8II), 63.7 (C-7III), 64.7 (OCH2-), 65.2 (C-4
III), 67.4 
(C-6III), 67.6 (C-4I), 68.7 (C-3III), 69.2 (C-7I), 69.2 (C-5III), 70.0 (C-4II), 70.3 (C-2III), 
70.4 (C-6II), 70.5 (C-6I), 70.7 (C-7II), 72.3 (C-5I), 74.0 (C-5II), 97.0 (C-2II), 98.7 (C-2I), 
99.0 (C-1III), 109.7 (Cisop), 116.2 (=CH2), 128.3, 128.4, 128.5, 129.3, 129.6, 129.85, 
129.9, 130.2, 132.8, 133.1 (ArI and ArII), 133.4 (-CH=), 165.1, 165.2, 165.8, 167.4 
(Bz: C=O), 167.4 (C-1I), 169.2 (C-1II), 169.6, 169.7, 169.8, 170.4 and 170.7 (Ac: 
C=O). IR: 1745, 1725, 1278, 1248, 1218 cm-1. Anal. Calcd for C69H76O30: C, 59.82; H, 
5.53. Found C, 59.65; H, 5.67. Ortho ester 12: Mp 99.0 ˚C, []25D = +7.5 (c 1.0, 
CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.21 (s, 3H, Me), 1.40 (s, 3H, Me), 1.65 (s, 
3H, ester-Me), 1.91 (dd, 1H, J3a,3e=15.4 Hz, J3a,4=2.2 Hz, H-3a
II), 1.97, 2.03, 2.04, 
2.07 (s, 3H x 4, Ac), 2.31 (dd, 1H, J3a,3e=12.6 Hz, J3a,4=12.4 Hz, H-3a
I), 2.47 (dd, 1H, 
J3a,3e=12.6 Hz, J3e,4=4.0 Hz, H-3e
I), 2.86 (dd, 1H, J3a,3e=15.4 Hz, J3e,4=3.6 Hz, H-3e
II), 
3.38 (dd, 1H, J4,5=9.6 Hz, J5,6=2.0 Hz, H-5
III), 3.43 (s, 3H, OMeI), 3.81 (s, 3H, OMeII), 
3.86 (dddd, 1H, J=1.6, 1.6, 3.4, 13.4 Hz, OCH2-), 3.97 (dddd, 1H, J=1.6, 1.6, 3.2, 
13.4 Hz, OCH2-), 4.05 (dd, 1H, J5,6=nd Hz, J6,7=8.6 Hz, H-6
I), 4.09 (dd, 1H, J6,7a=7.8 
Hz, J7a,7b=11.6 Hz, H-7a
III), 4.11 (brs, 1H, J4,5=2.4 Hz, J5,6=nd Hz, H-5
I), 4.15 (dd, 
1H, J6,7b=4.8 Hz, J7a,7b=11.6 Hz, H-7b
III), 4.21 (dd, 1H, J5,6=1.8 Hz, J6,7=7.0 Hz, 
H-6II), 4.31 (dd, 1H, J4,5=7.6 Hz, J5,6=1.8 Hz, H-5
II), 4.33 (ddd, 1H, J3a,4=12.4 Hz, 
J3e,4=4.0 Hz, J4,5=2.4 Hz, H-4
I), 4.47 (ddd, 1H, J3a,4=2.2 Hz, J3e,4=3.6 Hz, J4,5=7.6 Hz, 
H-4II), 4.50 (dd, 1H, J1,2=2.2 Hz, J2,3=3.8 Hz, H-2
III), 4.60 (dd, 1H, J7,8a=4.6 Hz, 
J8a,8b=12.4 Hz, H-8a
II), 4.64 (dd, 1H, J7, 8a=3.4 Hz, J8a, 8b=12.6 Hz, H-8a
I), 4.65 (d, 1H, 
J1,2=2.2 Hz, H-1
III), 4.94 (dddd, 1H, J=1.4, 1.4, 3.0, 10.6 Hz, =CH2), 5.00 (dd, 1H, J7, 
8b=2.4 Hz, J8a, 8b= 12.6 Hz, H-8b
I), 5.02 (dd, 1H, J2,3=3.8 Hz, J3,4=10.0 Hz, H-3
III), 
5.05 (dddd, 1H, J=1.6, 1.6, 3.4, 17.2 Hz, =CH2), 5.11 (dd, 1H, J3,4=10.0 Hz, J4,5=9.6 
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Hz, H-4III), 5.14 (ddd, 1H, J5,6=2.0 Hz, J6,7a=7.8 Hz, J6,7b=4.8 Hz, H-6
III), 5.24 (dd, 1H, 
J7,8b=2.4 Hz, J8a,8b =12.4 Hz, H-8b
II), 5.38 (ddd, 1H, J6,7=8.6 Hz, J7,8a=3.4 Hz, 
J7,8b=2.4 Hz, H-7
I), 5.59–5.64 (m, 1H, -CH=), 5.65 (ddd, 1H, J6,7=7.0 Hz, J7,8a=4.6 Hz, 
J7,8b=2.4 Hz, H-7
II), 7.39-7.47 (m, 8H, ArI, ArII), 7.54-7.55 (m, 4H, ArI, ArII), 
7.95–8.01 (m, 8H, ArI, ArII). 13C NMR (150 MHz, CDCl3):  20.6, 20.6, 20.7 
(Ac-CH3), 24.7 and 25.3 (Isop-Me), 26.3 (ester-Me), 32.6 (C-3
II), 34.3 (C-3I), 52.2 
(OMeI), 52.5 (OMeII), 62.2 (C-8II), 62.4 (C-8I), 62.5 (C-7III), 64.2 (OCH2-), 64.6 
(C-4III), 66.8 (C-6III), 67.5 (C-5I), 69.2 (C-4I), 69.8 (C-4II), 70.2 (C-6II), 70.3 (C-3III), 
70.4 (C-7I), 70.96 (C-7II), 70.96 (C-6I), 71.1 (C-5III), 72.1 (C-5II), 76.2 (C-2II), 97.2 
(C-1III), 98.5 (C-2I), 98.8 (C-2II), 109.7 (Cisop), 115.6 (=CH2), 124.8 (eater-C), 128.40, 
128.43, 128.5, 129.5, 129.7, 129.8, 129.9, 130.0, 130.4, 133.0, 133.07, 133.14 (ArI 
and ArII), 133.7 (-CH=), 165.1, 165.3, 165.9, 166.2 (Bz: C=O), 167.5 (C-1I) , 169.4 
(C-1II), 170.1, 170.17, 170.24 and 170.6 (Ac: C=O). IR: 1746, 1724, 1279, 1248, 
1219 cm-1. ESI-HRMS for C69H76O30: 1407.4319 [M+Na]
+. Found 1407.4302. 
6.5 (2,3,4,6-Tetra-O-acetyl--D-mannopyranosyl)-(1-5)-[methyl O-[methyl (7,8-
di-O-benzoyl-4,5-O-isopropylidene-3-deoxy--D-manno-2-octulopyranosyl)onate]]
-(2-4)-(allyl 7,8-di-O-benzoyl-3-deoxy--D-manno-2-octulopyranosid)onate (13)  
A reaction mixture of imidate 9 (75.2 mg, 152.6 mol), 6 (50.0 mg, 51.0 mol) 
and MS-AW 300 (57.8 mg) was suspended in dichloromethane (1.4 mL). The reaction 
was stirred for 1 h under argon, and then cooled to 0 °C. 0.01 M TMSOTf (200.0 L, 
2.00 mol) in dichloromethane was added dropwise to the reaction mixture. After 
stirring for 2 h, the reaction was neutralized by the addition of triethylamine and 
saturated sodium hydrogen carbonate. The reaction solution was diluted with 
dichloromethane and then filtered through Celite. The filtrate was extracted twice 
with dichloromethane. The combined organic layer was dried over Na2SO4, filtrated 
and concentrated. The residue was purified by BioRad S-X3 (toluene/ethyl acetate, 
1:1) to give 13 (60.9 mg, 91%) as colorless powder. Mp 85.5 ˚C, []25D = +37.5 (c 1.0, 
CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.21 (s, 3H, Me), 1.38 (s, 3H, Me), 1.85 (dd, 
1H, J3a,3e=15.4 Hz, J3a,4=2.2 Hz, H-3a
II), 2.00, 2.02, 2.05, 2.16 (s, 3H x 4, Ac), 2.23 
(dd, 1H, J3a,3e=12.6 Hz, J3a,4=12.2 Hz, H-3a
I), 2.28 (dd, 1H, J3a,3e=12.6 Hz, J3e,4=4.8 
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Hz, H-3eI), 2.95 (dd, 1H, J3a,3e=15.4 Hz, J3e,4=3.6 Hz, H-3e
II), 3.42 (s, 3H, OMeI), 
3.56 (s, 3H, OMeII), 3.78 (brs, 1H, J4,5=2.2 Hz, J5,6=1.6 Hz, H-5
I), 3.92 (dddd, 1H, 
J=1.6, 1.6, 5.0, 13.0 Hz, OCH2-), 3.97 (dddd, 1H, J=1.4, 1.4, 5.4, 13.0 Hz, OCH2-), 
4.09 (dd, 1H, J5,6a=2.0 Hz, J6a,6b=12.2 Hz, H-6a
III), 4.11 (dd, 1H, J5,6=1.6 Hz, J6,7=9.4 
Hz, H-6I), 4.18 (dd, 1H, J5,6=1.8 Hz, J6,7=7.2 Hz, H-6
II), 4.32 (ddd, 1H, J4,5=10.0 Hz, 
J5,6a=2.0 Hz, J5,6b=3.2 Hz, H-5
III), 4.35 (dd, 1H, J4,5=7.8 Hz, J5,6=1.8 Hz, H-5
II), 4.39 
(dd, 1H, J5,6b=3.2 Hz, J6a,6b=12.2 Hz, H-6b
III), 4.52 (ddd, 1H, J3a,4=2.2 Hz, J3e,4=3.6 
Hz, J4,5=7.8 Hz, H-4
II), 4.63 (dd, 1H, J7,8a=5.2 Hz, J8a,8b =12.6 Hz, H-8a
II), 4.63 (dd, 
1H, J7, 8a=3.8 Hz, J8a, 8b=12.6 Hz, H-8a
I), 4.73 (ddd, 1H, J3a,4=11.8 Hz, J3e,4=4.8 Hz, 
J4,5=2.2 Hz, H-4
I), 4.82 (d, 1H, J1,2=2.2 Hz, H-1
III), 4.82 (dd, 1H, J7, 8b=2.4 Hz, J8a, 
8b=12.6 Hz, H-8b
I), 4.92 (dddd, 1H, J=1.4, 1.6, 2.8, 10.6 Hz, =CH2), 5.01 (dddd, 1H, 
J=1.4, 1.6, 3.2, 17.2 Hz, =CH2), 5.30 (dd, 1H, J7,8b=2.4 Hz, J8a,8b =12.6 Hz, H-8b
II), 
5.34 (dd, 1H, J3,4=3.4 Hz, J4,5=10.0 Hz, H-4
III), 5.40 (dd, 1H, J2,3=11.0 Hz, J3,4=3.4 
Hz, H-3III), 5.42 (dd, 1H, J1,2=3.4 Hz, J2,3=11.0 Hz, H-2
III), 5.46 (ddd, 1H, J6,7=9.4 Hz, 
J7,8a=3.8 Hz, J7,8b=2.4 Hz, H-7
I), 5.67 (ddd, 1H, J6,7=7.2 Hz, J7,8a=5.2 Hz, J7,8b=2.4 Hz, 
H-7II), 5.63–570 (m, 1H, -CH=), 7.37–7.44 (m, 8H, ArI, ArII), 7.52–7.57 (m, 4H, ArI, 
ArII), 7.94–7.99 (m, 8H, ArI, ArII). 13C NMR (150 MHz, CDCl3): 20.7, 20.76, 20.78 
and 20.9 (Ac-CH3), 24.6 and 25.1 (Me), 24.6 (C-3
II), 25.1 (C-3I), 52.2 (OMeI), 52.4 
(OMeII), 61.8 (C-6III), 62.2 (C-8II), 62.3 (C-8I), 64.8 (OCH2-), 66.0 (C-4
III), 67.5 
(C-4I), 68.7 (C-5III), 68.9 (C-7I), 69.2 (C-2III), 69.6 (C-4II), 69.8 (C-3III), 70.5 (C-6I), 
70.6 (C-6II), 70.8 (C-7II), 72.2 (C-5II), 72.5 (C-5I), 96.7 (C-2II), 98.5 (C-1III), 98.7 
(C-2I), 109.8 (Cisop), 116.3 (=CH2), 128.36, 128.41, 128.46, 128.50, 129.0, 129.62, 
129.64, 129.7, 129.8, 130.17 and 133.15 (ArI and ArII), 133.47 (-CH=), 164.8, 165.3, 
165.8, 166.2 (Bz: C=O), 167.3 (C-1I), 168.7 (C-1II), 169.56, 169.61, 169.8 and 170.8 
(Ac: C=O). IR (neat): 1746, 1724, 1278, 1249, 1217 cm-1. ESI-HRMS calcd for 
C66H72O28: 1335.4108 [M+Na]
+. Found 1335.4097. 
6.6 (3,4,6-Tri-O-acetyl-2-azido-2-deoxy--D-galactopyranosyl)-(1-5)-[methyl O-
[methyl (7,8-di-O-benzoyl-4,5-O-isopropylidene-3-deoxy--D-manno-2-octulopyr
-anosyl)onate]]-(2-4)-(allyl 7,8-di-O-benzoyl-3-deoxy--D-manno-2-octulopyrano
-sid)onate (14)   
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A reaction mixture of 6 (50.0 mg, 51.0 mol), imidate 10 (72.6 mg, 152.6 
mol) and MS-AW 300 (57.8 mg) in dichloromethane (1.4 mL) was stirred for 1 h 
under argon and cooled to 0 °C. Then 0.01 M TMSOTf (200 L, 2.00 mol) in 
dichloromethane was added dropwise to the reaction mixture and stirred for 4 h. The 
solution was neutralized by the addition of triethylamine and saturated NaHCO3 and 
diluted with dichloromethane. The reaction mixture was filtered through Celite and 
the filtrate was extracted with dichloromethane. The organic phase was dried over 
Na2SO4, filtered and concentrated. Purification of the residue by BioRad S-X3 
(toluene/ethyl acetate, 1:1) obtained compound 14 (38.0 mg, 58%) as colorless 
powder. Mp 96.0 ˚C, []25D = +51.0 (c 1.0, CHCl3), 1H-NMR (600 MHz, CDCl3): 
1.21 (s, 3H, Me), 1.39 (s, 3H, Me), 1.92 (dd, 1H, J3a,3e=15.4 Hz, J3a,4=2.2 Hz, 
H-3aII), 1.96, 2.06, 2.11 (s, 3H x 3, Ac), 2.21 (dd, 1H, J3a,3e=12.6 Hz, J3a,4=12.4 Hz, 
H-3aI), 2.27 (dd, 1H, J3a,3e=12.6 Hz, J3e,4=4.6 Hz, H-3e
I), 3.01 (dd, 1H, J3a,3e=15.6 Hz, 
J3e,4=3.6 Hz, H-3e
II), 3.32 (s, 3H, OMeI), 3.59 (s, 3H, OMeII), 3.74 (dd, 1H, J1,2=3.4 
Hz, J2,3=11.0 Hz, H-2
III), 3.83 (brs, 1H, J4,5=2.0 Hz, J5,6=nd Hz, H-5
I), 3.95 (dddd, 1H, 
J=5.4 and 13.0 Hz, OCH2-), 3.97 (dddd, 1H, J=5.0 and 13.0 Hz, OCH2-), 4.08 (dd, 1H, 
J5,6a=5.5 Hz, J6a,6b=10.8 Hz, H-6a
III), 4.14 (dd, 1H, J5,6=nd Hz, J6,7=9.6 Hz, H-6
I), 
4.15 (dd, 1H, J5,6b=9.0 Hz, J6a,6b=10.8 Hz, H-6b
III), 4.21 (dd, 1H, J5,6=1.6 Hz, J6,7=7.6 
Hz, H-6II), 4.36 (dd, 1H, J4,5=7.8 Hz, J5,6=1.6 Hz, H-5
II), 4.52 (ddd, 1H, J3a,4=2.2 Hz, 
J3e,4=3.6 Hz, J4,5=7.8 Hz, H-4
II), 4.54 (ddd, 1H, J4,5=0.8 Hz, J5,6a=5.5 Hz, J5,6b=9.0 Hz, 
H-5III), 4.62 (dd, 1H, J7,8a=4.2 Hz, J8a,8b=12.6 Hz, H-8a
II), 4.64 (dd, 1H, J7, 8a=3.0 Hz, 
J8a, 8b=12.0 Hz, H-8a
I), 4.79 (ddd, 1H, J3a,4=12.4 Hz, J3e,4=4.6 Hz, J4,5=2.0 Hz, H-4
I), 
4.91 (dddd, 1H, J=10.0 and 1.4 Hz, =CH2), 4.99 (dddd, 1H, J=10.0 and nd Hz, =CH2), 
5.00 (dd, 1H, J7, 8b=2.6 Hz, J8a, 8b=12.0 Hz, H-8b
I), 5.05 (d, 1H, J1,2=3.4 Hz, H-1
III), 
5.32 (dd, 1H, J2,3=11.0 Hz, J3,4=3.2 Hz, H-3
III), 5.33 (dd, 1H, J7,8b=2.5 Hz, J8a,8b=12.6 
Hz, H-8b
II), 5.48 (dd, 1H, J3,4=3.2 Hz, J4,5=0.8 Hz, H-4
III), 5.63-5.67 (m, 1H, -CH=), 
5.67 (ddd, 1H, J6,7=7.6 Hz, J7,8a=4.2 Hz, J7,8b=2.5 Hz, H-7
II), 5.70(ddd, 1H, J6,7=9.6 
Hz, J7,8a=3.0 Hz, J7,8b=2.6 Hz, H-7
I), 7.36–7.39 (m, 2H, ArI, ArII), 7.42–7.45 (m, 3H, 
ArI, ArII), 7.51–7.58 (m, 4H, ArI, ArII), 7.94–8.03 (m, 8H, ArI, ArII). 13C NMR (150 
MHz, CDCl3):  20.6 and 20.7 (Ac-CH3), 24.6 and 25.1 (Me), 31.9 (C-3II), 34.4 (C-3I), 
52.1 (OMeII), 52.2 (OMeI), 58.2 (C-2III), 60.4 (C-6III), 62.0 (C-8II), 62.2 (C-8I), 64.8 
(OCH2-), 66.6 (C-5
III), 67.1 (C-4III), 67.7 (C-4I), 68.8 (C-3III), 69.4 (C-7I), 69.9 (C-4II), 
70.4 (C-6I, C-6II), 70.7 (C-7II), 72.0 (C-5I), 72.2 (C-5II), 96.6 (C-2II), 97.9 (C-1III), 98.2 
(C-2I), 109.8 (Cisop), 116.4 (=CH2), 128.4, 128.47, 128.52, 129.5, 129.65, 129.72, 
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129.8, 130.2, 132.9, 133.1 and 133.5 (ArI and ArII), 133.15 (-CH=), 165.2, 165.8, 
166.2 (Bz: C=O), 167.1 (C-1I), 169.0 (C-1II), 169.7, 170.1 and 170.2 (Ac: C=O). IR 
(neat): 2112, 1748, 1723, 1278, 1251, 1218 cm-1. ESI-HRMS for C64H69N3O26: 
1318.4067 [M+Na]. Found 1318.4072.  
6.7 (3,4,6-Tri-O-acetyl-2-acetamido-2-deoxy--D-galactopyranosyl)-(1-5)-[methy
-l O-[methyl (7,8-di-O-benzoyl-4,5-O-isopropylidene-3-deoxy--D-manno-2-octu
-lopyranosyl)onate]]-(2-4)-(allyl 7,8-di-O-benzoyl-3-deoxy--D-manno-2-octulop-
yranosid)onate (16)   
Triphenylphosphine (6.2 mg, 23.7 mol) was added to a solution of 14 (23.7 
mg, 18.3 mol) dissolved in a mixed solvent (THF/H2O, 19:1, 0.36 mL). After 
stirring for 16 h, the reaction mixture was diluted with toluene and concentrated by 
evaporation to give a residue 15. Without purification, the residue was directly 
acetylated with pyridine/Ac2O (1/0.04, v/v, 190.0 L) in the presence of a catalytic 
amount of DMAP over 18 h. After removing the solvent, the residue was purified by 
TLC (CH2Cl2/EtOAc/hexane, 3:3:1) to give compound 16 (15.4 mg, 64%) as 
colorless powder. Mp 99.0 ˚C, []25D = +62.1 (c 1.2, CHCl3), 1H-NMR (600 MHz, 
CDCl3):  1.20 (s, 3H, Me), 1.37 (s, 3H, Me), 1.88 (dd, 1H, J3a,3e=15.6 Hz, J3a,4=2.0 
Hz, H-3aII), 1.97, 2.00, 2.14 (s, 3H x 3, Ac), 2.02 (s, 3H, NHAc), 2.18 (dd, 1H, 
J3a,4=11.8 Hz, J3a,3e=13.0 Hz, H-3a
I), 2.23 (dd, 1H, J3e,4=5.6 Hz, J3a,3e=13.0 Hz, H-3e
I), 
3.02 (dd, 1H, J3a,3e=15.6 Hz, J3e,4=3.4 Hz, H-3e
II), 3.35 (s, 3H, OMeI), 3.43 (s, 3H, 
OMeII), 3.74 (brs, 1H, J4,5=2.0 Hz, J5,6=1.6 Hz, H-5
I), 3.83 (dddd, 1H, J=1.4, 1.6, 4.8 
and 11.0 Hz, OCH2-), 3.90 (dddd, 1H, J=1.6, 1.6, 6.0 and 12.4 Hz, OCH2-), 4.06 (dd, 
1H, J5,6a=5.0 Hz, J6a,6b=10.8 Hz, H-6a
III), 4.11 (dd, 1H, J5,6=1.6 Hz, J6,7=9.8 Hz, H-6
I), 
4.14 (dd, 1H, J5,6b=9.4 Hz, J6a,6b=10.8 Hz, H-6b
III), 4.19 (dd, 1H, J5,6=1.6 Hz, J6,7=8.0 
Hz, H-6II), 4.36 (dd, 1H, J4,5=7.8 Hz, J5,6=1.6 Hz, H-5
II), 4.53 (ddd, 1H, J3a,4=2.0 Hz, 
J3e,4=3.4 Hz, J4,5=7.8 Hz, H-4
II), 4.53 (ddd, 1H, J4,5=2.2 Hz, J5,6a=5.0 Hz, J5,6b=9.4 Hz, 
H-5III), 4.53 (dd, 1H, J7,8a=4.0 Hz, J8a,8b =12.4 Hz, H-8a
I), 4.60 (dd, 1H, J7, 8a=4.0 Hz, 
J8a, 8b=12.6 Hz, H-8a
II), 4.71 (dd, 1H, J1,2=3.4 Hz, J2,3=11.4 Hz, JNH, 2=10.0 Hz, H-2
III), 
4.75 (ddd, 1H, J3a,4=11.4 Hz, J3e,4=5.6 Hz, J4,5=2.0 Hz, H-4
I), 4.85 (dd, 1H, J7,8b=2.6 
Hz, J8a,8b=12.4 Hz, H-8b
I), 4.94 (dddd, 1H, J=1.2, 17.6 Hz, =CH2), 4.96 (dddd, 1H, 
J=1.8, 10.6 Hz, =CH2), 5.03 (d, 1H, J1,2=3.4 Hz, H-1
III), 5.34 (dd, 1H, J2,3=11.4 Hz, 
J3,4=3.2 Hz, H-3
III), 5.34 (dd, 1H, J7, 8b=2.4 Hz, J8a, 8b=12.6 Hz, H-8b
II), 5.40 (dd, 1H, 
J3,4=3.2 Hz, J4,5=2.2 Hz, H-4
III), 5.53 (ddd, 1H, J6,7=9.8 Hz, J7,8a=4.0 Hz, J7,8b=2.6 Hz, 
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H-7I), 5.66 (ddd, 1H, J6,7=8.0 Hz, J7,8a=4.0 Hz, J7,8b=2.4 Hz, H-7
II), 5.70 (m, 1H, 
-CH=), 6.43 (d, 1H, JNH,2=10.0Hz. NHAc), 7.37–7.38 (m, 2H, ArI, ArII), 7.40–7.46 (m, 
6H, ArI, ArII), 7.51–7.59 (m, 4H, ArI, ArII), 7.93–8.07 (m, 8H, ArI, ArII). 13C NMR 
(150 MHz, CDCl3):  20.6, 20.75, 20.84 (Ac-CH3), 23.0 (NHAc-CH3), 25.0 and 25.1 
(Me), 31.7 (C-3II), 34.9 (C-3I), 47.6 (C-2III), 52.1 (OMeII), 52.4 (OMeI), 60.4 (C-6III), 
61.9 (C-8II), 62.4 (C-8I), 65.43 (OCH2-), 66.45 (C-5
III), 66.8 (C-4III), 67.4 (C-4I), 68.5 
(C-3III), 68.6 (C-7I), 69.9 (C-4II), 70.2 (C-6II), 70.5 (C-7II), 70.6 (C-5I), 70.7 (C-6I), 
72.1 (C-5II), 96.2 (C-2II), 97.9 (C-1III), 99.2 (C-2I), 109.9 (Cisop), 117.0 (=CH2), 128.39, 
128.42, 128.5, 128.6, 128.8, 129.3, 129.6, 129.70, 129.73, 129.8, 129.9 and 130.1 (ArI 
and ArII), 133.0 (-CH=), 164.9, 165.1, 165.7, 166.2 (Bz: C=O), 168.3 (C-1I), 168.6 
(C-1II), 170.1, 107.3, 170.5 (Ac: C=O), 170.9 (NHAc-C=O). IR(neat): 1746, 1723, 
1278, 1249, 1217 cm-1. ESI-HRMS for C66H73NO27: 1334.4268 [M+Na]. Found 
1334.4253.  
6.8 (L-Glycero--D-manno-heptopyranosyl)-(1-5)-[O-(sodium 3-deoxy--D-mann
-o-2-octulopyranosylonate)]-(2-4)-sodium (allyl 3-deoxy--D-manno-2-octulopyr
-anosid)onate (17)   
Aqueous 80% trifluoroacetic acid (TFA, 220 L) was added to a solution of 11 
(21.0 mg, 15.2 mol) in dichloromethane (2.2 mL) at room temperature. After stirring 
for 1 h, the solvent was removed by evaporation under an argon stream to give a crude 
compound that was not subjected to further purification. The crude compound was 
dissolved in methanol (3.0 mL), and then 0.1 M sodium hydroxide (2.4 mL, 0.24 
mmol) was added at room temperature. After stirring for 24 h, the mixture was 
concentrated by evaporation. The residue was purified by gel filtration 
chromatography (Biogel P-2) to give compound 17 as colorless powder in 87% yield.  
[]25D = +30.2 (c 0.5, H2O), 1H-NMR (600 MHz, D2O):1.62 (dd, 1H, J3a,3e=13.0 Hz, 
J3a,4=12.6 Hz, H-3a
II), 1.82 (dd, 1H, J3a,3e=12.4 Hz, J3a,4=12.8 Hz, H-3a
I), 1.91 (dd, 
1H, J3a,3e=12.8 Hz, J3e,4=4.2 Hz, H-3e
I), 2.06 (dd, 1H, J3a,3e=13.0 Hz, J3e,4=4.8 Hz, 
H-3eII), 3.44 (dd, 1H, J5,6=2.4 Hz, J6,7=8.8 Hz, H-6
I), 3.46 (dd, 1H, J7,8a=6.2 Hz, 
J8a,8b=11.6 Hz, H-8a
II), 3.54 (dd, 1H, J5,6=0.6 Hz, J6,7=8.0 Hz, H-6
II), 3.59-3.83 (m, 
12H, H-8aI, H-8bI, H-7I, H-8bII, H-7II, H-7aIII, H-7bIII, H-5III, H-4III, H-3III, OCH2), 
3.87-3.90 (m, 3H, H-6III, H-5II, H-2III), 3.96 (ddd, 1H, J=3.0, 5.0, 12.2 Hz, H-4II), 4.07 
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(brs, 1H, H-5I), 4.11 (ddd, 1H, J=2.0, 4.2, 12.4 Hz, H-4I), 5.06 (ddd, 1H, J=10.4 Hz, 
=CH2), 5.17 (d, 1H, J=1.8 Hz, H-1
III), 5.19 (dddd, 1H, J=1.4, 3.2, 17.2 Hz, =CH2), 
5.78-5.85 (m, 1H, -CH=). 13C NMR (150 MHz, D2O):  34.3 (C-3I), 34.5 (C-3II), 62.9 
(C-8I), 63.2 (C-8II), 63.9 (C-7III), 64.0 (OCH2), 66.1 (C-4
II), 66.2 (C-5II), 66.3 (C-4III), 
69.0 (C-7I), 69.2 (C-6III), 69.5 (C-4I), 70.0 (C-2III), 70.2 (C-7II), 70.4 (C-3III), 71.9 
(C-6I), 72.0 (C-6II), 72.6 (C-5III), 72.8 (C-5I), 100.0 (C-2I, C-2II), 101.1 (C-1III), 117.1 
(=CH2), 134.0 (-CH=), 174.87 (C-1
I), 174.93 (C-1II). IR (neat): 3346, 3333, 1678, 
1623 cm-1. ESI-HRMS for C26H41O21: 689.2149 [M-2Na+H]. Found 689.2140. 
6.9 (-D-Mannopyranosyl)-(1-5)-[O-(sodium 3-deoxy--D-manno-2-octulopyran
-osylonate]]-(2-4)-sodium (allyl 3-deoxy--D-manno-2-octulopyranosid)onate (1
8) 
The procedure was similar to that described for compound 17. The reaction was 
performed with 51.3 mg of 13, 80% trifluoro acetic acid (1.7 mL), and 0.1 M sodium 
hydroxide (5.0 mL) to afford 26.1 mg (93%) of compound 18. []25D = +80.4 (c 0.8, 
H2O), 
1H-NMR (600 MHz, D2O):  1.70 (dd, 1H, J3a,3e=12.8 Hz, J3a,4=12.0 Hz, 
H-3aII), 1.90 (dd, 1H, J3a,3e=12.2 Hz, J3a,4=12.2 Hz, H-3a
I), 2.01 (dd, 1H, J3a,3e=12.2 
Hz, J3e,4=4.4 Hz, H-3e
I), 2.05 (dd, 1H, J3a,3e=12.8 Hz, J3e,4=4.6 Hz, H-3e
II), 3.49 (dd, 
1H, H-6I), 3.51 (dd, 1H, H-8aII), 3.62–3.72 (m, 5H, H-8aI, H-6II, H-7I, OCH2, H-6aIII), 
3.77–3.95 (m, 10H, H-4III, H-5II, OCH2, H-8bII, H-8bI, H-3III, H-7II, H-6bIII, H-4II, 
H-5III,) 4.01 (ddd, 1H, H-4I), 4.02 (d, 1H, H-2III), 4.15 (brs, 1H, H-5I), 5.10 (dddd, 1H, 
=CH2), 5.13 (d, 1H, J1,2=1.6 Hz, H-1
III), 5.22 (dddd, 1H, -CH=), 5.82–5.88 (m, 1H, 
-CH=). 13C NMR (150 MHz, D2O):  34.4 (C-3I), 34.6 (C-3II), 60.5 (C-4III), 62.7 
(C-8I), 63.3 (C-8II), 64.0 (OCH2), 65.9 (C-6
III), 66.1 (C-4II), 66.7 (C-5II), 69.2 (C-7I), 
70.1 (C-2III), 70.3 (C-3III), 70.5 (C-7II), 70.7 (C-4I), 71.7 (C-6II), 72.2 (C-6I), 72.7 
(C-5III), 73.2 (C-5I), 100.00 (C-2I), 100.6 (C-1III), 101.5 (C-2II), 117.0 (=CH2), 134.0 
(-CH=), 175.0 (C-1I), 175.1 (C-1II). IR (neat): 3381, 3274, 1604, 1568 cm-1. 
ESI-HRMS for C25H39O20: 659.2035 [M-2Na+H]. Found 659.2061.  
6.10 (2-Acetamido-2-deoxy--D-galactopyranosyl)-(1-5)-[O-(sodium 3-deoxy--
D-manno-2-octulopyranosylonate]]-(2-4)-sodium (allyl 3-deoxy--D-manno-2-oct
-ulopyranosid)onate (19)  
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The procedure was similar to that described for compound 17. The reaction was 
performed with 27.4 mg of 16, 80% trifluoro acetic acid (0.9 mL), and 0.1 M sodium 
hydroxide (2.5 mL) to afford compound 19 (15.6 mg) in quantitative yield. []25D = 
+116.5 (c 0.3, H2O), 
1H-NMR (600 MHz, D2O):  1.73 (dd, 1H, J3a,4=12.6 Hz, 
J3a,3b=13.0 Hz, H-3a
II), 1.94–2.04 (m, 2H, H-3aI, H-3bI), 2.02 (s, 3H, Ac), 2.10 (d, 1H, 
J3b,4=4.4 Hz, J3a,3b=13.0 Hz, H-3b
II), 3.52 (H-6I), 3.54 (dd, 1H, H-8aII), 3.65–3.77 (m, 
6H, H-6II, H-8aI, H-7I, OCH2, H-6a
III, H-6bIII), 3.81–3.86 (m, 3H, H-8bII, H-8bI, 
OCH2), 3.88–3.91 (m, 1H, H-7II), 3.94–3.99 (m, 4H, H-5II, H-3III, H-4II, H-4III), 4.26 
(ddd, 1H, J=2.0, 5.4, 11.2 Hz, H-4I), 4.16 (dd, 1H, J1,2=3.4 Hz, H-2
III), 4.17 (brs, 1H, 
H-5I), 4.26 (d, 1H, J=6.4 Hz, H-5III), 5.14 (dddd, 1H, =CH2), 5.19 (d, 1H, J1,2=3.4 Hz, 
H-1III), 5.26 (dddd, 1H, =CH2), 5.86-5.92 (m, 1H, -CH=). 
13C NMR (150 MHz, D2O): 
22.0 (CH3), 34.5 (C-3I), 34.6 (C-3II), 50.3 (C-2III), 60.4 (C-6III), 62.8 (C-8I), 63.3 
(C-8II), 64.1 (OCH2), 66.0 (C-4
II), 66.6 (C-5II), 67.6 (C-3III), 68.4 (C-4III), 69.2 (C-7II), 
70.3 (C-7I), 70.5 (C-5III), 70.9 (C-4I), 71.9 (C-6II), 72.60 (C-6I), 72.63 (C-5I), 97.7 
(C-1III), 100.4 (C-2II), 101.2 (C-2I), 117.0 (=CH2), 134.1 (-CH=), 174.7, 175.0, 175.2 
(3C, C-1I, C-1II, C=O). IR (neat): 3295, 1680, 1614 cm-1. ESI-HRMS for C27H42NO20: 
700.2300 [M-2Na+H]. Found 700.2294.  
6.11 Methyl 3,4,6,7-tetra-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyran
-oside (23)  
A catalytic amount of N,N-dimethyl-4-aminopyridine (DMAP) was added to a 
solution of methyl 6,7-di-O-acetyl-2-O-benzyl-L-glycero-D-manno-heptopyranoside 
(20; 1.9 g, 4.8 mmol) in acetic anhydride (4.5 mL)/pyridine (9.7 mL) at 0 °C. After 
stirring for 2 h at room temperature, the mixture was concentrated and purified by 
silica gel chromatography (ethyl acetate/hexane, 4:5) to give 23 (2.2 g, 94%).  
[]25D= -19.2 (c 3.1, CHCl3), 1H-NMR (600 MHz, CDCl3):  1.96, 2.01, 2.05, 2.13 (s, 
3H x 4, Ac), 3.35 (s, 3H, OCH3), 3.82 (dd, 1H, J1,2=1.4 Hz, J2,3=3.2 Hz, H-2), 3.99 
(dd, 1H, J4,5=10.2 Hz, J5,6=2.0 Hz, H-5), 4.25 (dd, 1H, J6,7a=7.6 Hz, J7a,7b=11.2 Hz, 
H-7a), 3.34 (dd, 1H, J6,7b=5.8 Hz, J7a,7b=11.2 Hz, H-7b), 4.63 (d, 1H, J=12.4 Hz, 
OCH2Ph), 4.69 (d, 1H, J=12.4 Hz, OCH2Ph), 4.78 (d, 1H, J1,2=1.4 Hz, H-1), 5.19 (dd, 
1H, J2,3=3.2 Hz, J3,4=10.2 Hz, H-3), 5.27 (ddd, 1H, J5,6=2.0 Hz, J6,7a=7.6 Hz, J6,7b=5.8 
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Hz, H-6), 5.44 (dd, 1H, J3,4=10.2 Hz, J4,5=10.2 Hz, H-4), 7.29–7.37 (m, 5H, Ph). 13C 
NMR (150 MHz, CDCl3):  20.6, 20.7, 20.8, 20.84 (Ac-CH3), 55.3 (OCH3) 62.0 
(C-7), 65.2 (C-4), 67.1 (C-6), 68.5 (C-5), 71.5 (C-3), 73.2 (OCH2Ph), 74.9 (C-2), 99.4 
(C-1), 128.0, 128.4, 129.9, 137.6 (Ph), 169.6, 170.2, 170.5, 170.51 (Ac: C=O). 
ESI-HRMS for C23H30O11: 505.1686 [M+Na]
+. Found 505.1644. 
6.12 3,4,6,7-Tetra-O-acetyl-2-O-benzyl-L-glycero-D-manno-heptopyranose (24)  
A mixture of H2SO4/AcOH/Ac2O (9.0 mL, 2:50:25) was added to a solution of 
methyl 3,4,6,7-tetra-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyranoside (23; 
2.2 g, 4.5 mmol) in acetic acid and acetic anhydride (1:2, 10.0 mL). After stirring for 
2 h at room temperature, the reaction mixture was neutralized by the addition of 
sodium acetate (3.5 g), poured into saturated sodium hydrogen carbonate, and 
extracted with dichloromethane. The combined organic layer was washed with brine, 
dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was 
purified by silica gel chromatography (ethyl acetate/hexane, 4:5) to give a syrup (2.2 g, 
95%). The syrup was treated with hydrazine acetate (0.5 g, 5.6 mmol) in DMF (30.0 
mL) for 2 h at room temperature. The reaction mixture was diluted with ethyl acetate, 
washed with water and brine, dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by silica gel chromatography (ethyl 
acetate/hexane, 1:1) to give 24 (1.6 g, 80%). 1H-NMR (600 MHz, CDCl3):1.98, 
2.02, 2.06, 2.14 (s, 3H x 4, Ac), 3.86 (dd, 1H, J1,2=1.8 Hz, J2,3=3.2 Hz, H-2), 4.14 (dd, 
1H, J6,7a=7.0 Hz, J7a,7b=11.4 Hz, H-7a), 4.18 (dd, 1H, J4,5=10.0 Hz, J5,6=2.0 Hz, H-5), 
4.40 (dd, 1H, J6,7b=5.4 Hz, J7a,7b=11.4 Hz, H-7b), 4.64 (d, 1H, J=12.4 Hz, OCH2Ph), 
4.67 (d, 1H, J=12.4 Hz, OCH2Ph), 5.23 (ddd, 1H, J5,6=2.0 Hz, J6,7a=7.0 Hz, J6,7b=5.4 
Hz, H-6), 5.27 (dd, 1H, J2,3=3.2 Hz, J3,4=10.2 Hz, H-3), 5.29 (d, 1H, J1,2=1.8 Hz, H-1), 
5.44 (dd, 1H, J3,4=10.2 Hz, J4,5=10.0 Hz, H-4), 7.30–7.37 (m, 5H, Ph). 13C NMR (150 
MHz, CDCl3): 20.7, 20.8, 20.85 (Ac-CH3), 62.8 (C-7), 65.5 (C-4), 67.2 (C-6), 68.7 
(C-5), 71.4 (C-3), 73.2 (OCH2Ph), 75.6 (C-2), 93.0 (C-1), 127.9, 128.0, 128.4, 137.7 
(Ph), 169.8, 170.3, 170.6, 171.3 (Ac: C=O). ESI-HRMS for C22H28O11: 491.1529 
[M+Na]+. Found 491.1514.  
6.13 3,4,6,7-Tetra-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyranosyl tri
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-chloroacetimidate (25)  
Compound 24 (1.5 g, 3.2 mmol) was dissolved in dry dichloromethane (3.0 mL).  
Potassium carbonate (2.2 g, 16.0 mmol) was added followed by trichloroacetonitrile 
(3.2 mL, 32.0 mmol) and the mixture was stirring for 22 h at room temperature. The 
reaction mixture was filtered through Celite. The solution was concentrated and 
purified by silica gel column chromatography (ethyl acetate/hexane, 2:3+1% Et3N) to 
give 25 (1.9 g, 96%). []25D= -13.4 (c 3.7, CHCl3), 1H-NMR (600 MHz, CDCl3):  
1.96, 2.01, 2.02, 2.13 (s, 3H x 4, Ac), 4.06 (dd, 1 H, J1,2=1.8 Hz, J2,3=3.4 Hz, H-2), 
4.18 (dd, 1H, J6,7a=7.6 Hz, J7a,7b=11.4 Hz, H-7a), 4.20 (dd, 1H, J4,5=9.2 Hz, J5,6=2.0 
Hz, H-5), 4.28 (dd, 1H, J6,7b=5.6 Hz, J7a,7b=11.4 Hz, H-7b), 4.65 (d, 1H, J=12.2 Hz, 
OCH2Ph), 4.78 (d, 1H, J=12.2 Hz, OCH2Ph), 5.23 (dd, 1H, J2,3=3.4 Hz, J3,4=10.2 Hz, 
H-3), 5.27 (ddd, 1H, J5,6=2.0 Hz, J6,7a=7.6 Hz, J6,7b=5.6 Hz, H-6), 5.54 (dd, 1H, 
J3,4=10.2 Hz, J4,5=9.2 Hz, H-4), 6.35 (d, 1H, J1,2=1.8 Hz, H-1), 7.27–7.40 (m, 5H, Ph), 
8.68 (s, 1H, OC(NH)CCl3). 
13C NMR (150 MHz, CDCl3): 20.7, 20.8, 20.86 
(Ac-CH3), 62.0 (C-7), 64.6 (C-4), 66.8 (C-6), 71.0 (C-5), 71.3 (C-3), 73.1 (OCH2Ph), 
73.3 (C-2), 90.6 (OCNHCCl3), 95.3 (C-1), 128.1, 128.4, 137.2 (Ph), 160.0 
(OCNHCCl3), 169.5, 170.4, 170.5 (Ac: C=O). ESI-HRMS for C24H28Cl3NO11: 
634.0626 [M+Na]+. Found 634.0639. 
6.14 Methyl (2,3,4,6-tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acet
-yl--D-glucopyranosyl)-(1-4)-6,7-di-O-acetyl-2-O-benzyl-3-O-tert-butyldimethyl-
silyl-L-glycero--D-manno-heptopyranoside (27)  
A mixture of 21 (1.5 g, 2.9 mmol), 
(2,3,4,6-tetra-O-acetyl--D-galactopyranosyl)-(1-4)-2,3,6-tri-O-acetyl--D-glucopyran
osyl trichloroacetimidate (26; 5.6 g, 7.2 mmol), and MS-AW 300 molecular sieves 
(7.0 g) in dry dichloromethane (50.0 mL) was stirred for 1 h under argon, then cooled 
to 0 °C. TMSOTf (106.0 L, 0.6 mmol) in dry dichloromethane (0.5 mL) was added 
dropwise to the reaction mixture and the mixture was stirred for 3 h. The solution was 
neutralized by the addition of triethylamine and saturated sodium hydrogen carbonate, 
and diluted with dichloromethane. The mixture was filtered through Celite and the 
filtrate was extracted with dichloromethane. The organic phase was dried over 
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anhydrous sodium sulfate, filtered, and concentrated. Purification of the residue by 
BioRad S-X1 size exclusion beads (toluene/ethyl acetate, 1:1) and flash column 
chromatography (toluene/acetone, 5:1) afforded 27 (2.6 g, 79%). []25D= +1.0 (c 1.0, 
CHCl3), 
1H-NMR (600 MHz, CDCl3):  0.08, 0.09 [s, 3H x 2, Si(CH3)2C(CH3)3], 0.90 
[s, 9H, Si(CH3)2C(CH3)3], 1.96, 1.98, 2.04, 2.05, 2.05, 2.06, 2.09, 2.13, 2.15 (s, 3H x 
8, Ac), 3.33 (s, 3H, OCH3), 3.55 (ddd, 1H, J4,5=10.0 Hz, J5,6a=5.2 Hz, J5,6b=2.0 Hz, 
H-5II), 3.56 (brs, 1H, J1,2=3.4 Hz, J2,3=nd Hz, H-2
I), 3.64 (dd, 1H, J4,5=8.8 Hz, J5,6=nd 
Hz, H-5I), 3.76 (dd, 1H, J3,4=9.2 Hz, J4,5=10.0 Hz, H-4
II), 3.80 (m, 1H, J3,4=nd Hz, 
J4,5=8.8 Hz, H-4
I), 3.86 (ddd, 1H, J4,5=0.8 Hz, J5,6a=7.4 Hz, J5,6b=6.2 Hz, H-5
III), 4.06 
(m, 1H, J2,3=nd Hz, J3,4=nd Hz, H-3
I), 4.07 (dd, 1H, J5,6a=7.4 Hz, J6a,6b=11.2 Hz, 
H-6aIII), 4.09 (dd, 1H, J5,6a=5.2 Hz, J6a,6b=10.2 Hz, H-6a
II), 4.15 (dd, 1H, J5,6b=6.2 Hz, 
J6a,6b=11.2 Hz, H-6b
III), 4.21 (dd, 1H, J6,7a=7.4 Hz, J7a,7b=11.2 Hz, H-7a
I), 4.33 (dd, 
1H, J6,7b=5.6 Hz, J7a,7b=11.2 Hz, H-7b
I), 4.38 (dd, 1H, J5,6b=2.0 Hz, J6a,6b=10.2 Hz, 
H-6bII), 4.48 (d, 1H, J1,2=8.0 Hz, H-1
III), 4.55 (d, 1H, J1,2=8.0 Hz, H-1
II), 4.63 (d, 1H, 
J=11.8 Hz, OCH2Ph), 4.72 (d, 1H, J1,2=3.4 Hz, H-1
I), 4.77 (d, 1H, J=11.8 Hz, 
OCH2Ph), 4.87 (dd, 1H, J1,2=8.0 Hz, J2,3=9.4 Hz, H-2
II), 4.93 (dd, 1H, J2,3=10.4 Hz, 
J3,4=3.4 Hz, H-3
III), 5.10 (dd, 1H, J1,2=8.0 Hz, J2,3=10.4 Hz, H-2
III), 5.18 (dd, 1H, 
J2,3=9.4 Hz, J3,4=9.2 Hz, H-3
II), 5.34 (dd, 1H, J3,4=3.4 Hz, J4,5=0.8 Hz, H-4
III), 5.35 (m, 
1H, J5,6=nd Hz, J6,7a=7.4 Hz, J6,7b=5.6 Hz, H-6
I), 7.24–7.36 (m, 5H, Ph). 13C NMR 
(150 MHz, CDCl3):  -4.8, -4.6 (Si(CH3)2C(CH3)3), 18.1 (Si(CH3)2C(CH3)3), 20.5, 
20.6, 20.67, 20.7, 20.85, 20.9, 25.9, 29.7 (Ac-CH3), 25.8 (Si(CH3)2C(CH3)3), 55.2 
(OCH3), 60.6 (C-6
III), 62.3 (C-6II), 62.5 (C-7I), 66.5 (C-4III), 68.7 (C-6I), 69.1 (C-2III), 
70.2 (C-5I), 70.6 (C-5III), 70.9 (C-3III), 71.0 (C-3I), 71.9 (C-2II), 72.4 (C-5II), 72.9 
(C-3II, CH2Ph), 76.5 (C-4
II), 77.4 (C-4I), 78.3 (C-2I), 100.3 (C-1I, C-1II), 100.9 (C-1III), 
127.3, 127.37, 128.1, 138.5 (Ph), 169.0, 169.5, 169.7, 170.0, 170.1, 170.2, 170.23, 
170.3, 170.36 (Ac: C=O). Anal. Calcd for C51H74O26Si: C, 54.15; H, 6.59. Found: C, 
53.94; H, 6.48.  
6.15 Methyl (2,3,4,6-tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acet
-yl--D-glucopyranosyl)-(1-4)-6,7-di-O-acetyl-2-O-benzyl-L-glycero--D-manno-h-
eptopyranoside (28)  
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Compound 27 (486.0 mg, 429.7 mol) was dissolved in a mixture of 
trifluoroacetic acid and water (9:1, v/v, 10.0 mL) at room temperature. After stirring 
for 5 min, the mixture was diluted with toluene and concentrated. The residue was 
purified by flash column chromatography (dichloromethane/acetone, 9:1) to give 28 
(424.0 mg, 97%). []25D= +8.0 (c 1.0, CHCl3). 1H NMR (600 MHz, CDCl3):  1.97, 
2.04, 2.04, 2.05, 2.06, 2.09, 2.12, 2.13, 2.16 (s, 3H x 9, Ac), 3.30 (s, 3H, OCH3), 3.64 
(m, 1H, J4,5=9.5 Hz, H-5
I), 3.66 (dd, 1H, J3,4=9.5 Hz, J4,5=9.5 Hz, H-4
I), 3.73 (ddd, 
1H, J5,6a=6.5 Hz, J5,6b=2.0 Hz, H-5
II), 3.76 (dd, 1H, J3,4=9.5 Hz, H-4
II), 3.77 (dd, 1H, 
J1,2=2.0 Hz, J2,3=3.3 Hz, H-2
I), 3.88 (ddd, 1H, J4,5=1.5 Hz, J5,6a=7.5 Hz, J5,6b=6.5 Hz, 
H-5III), 3.92 (dd, 1H, J2,3=3.3 Hz, J3,4=9.5 Hz, H-3
I), 3.98 (d, 1H, J3-OH,H-3=2.5 Hz, 
3-OH), 4.04 (dd, 1H, J5,6a=6.5 Hz, J6a,6b=12.0 Hz, H-6a
II), 4.08 (dd, 1H, J5,6a=7.5 Hz, 
J6a,6b=11.0 Hz, H-6a
III), 4.13 (dd, 1H, J5,6b=6.5 Hz, J6a,6b=11.0 Hz, H-6b
III), 4.27 (dd, 
1H, J6,7a=6.5 Hz, J7a,7b=11.0 Hz, H-7a
I), 4.30 (dd, 1H, J6,7b=7.0 Hz, J7a,7b=11.0 Hz, 
H-7bI), 4.49 (d, 1H, J1,2=8.0 Hz, H-1
III), 4.54 (d, 1H, J1,2=8.0 Hz, H-1
II), 4.59 (dd, 1H, 
J5,6b=2.0 Hz, J6a,6b=12.0 Hz, H-6b
II), 4.70 (d, 1H, J=12.0 Hz, OCH2Ph), 4.75 (d, 1H, 
J1,2=2.0 Hz, H-1
I), 4.84 (d, 1H, J=12.0 Hz, OCH2Ph), 4.94 (dd, 1H, J1,2=8.0 Hz, 
J2,3=9.5 Hz, H-2
II), 4.97 (dd, 1H, J2,3=10.8 Hz, J3,4=3.5 Hz, H-3
III), 5.19 (dd, 1H, 
J1,2=8.0 Hz, J2,3=10.8 Hz, H-2
III), 5.22 (dd, 1H, J2,3=9.5 Hz, J3,4=9.5 Hz, H-3
II), 5.25 
(ddd, 1H, J6,7a=6.5 Hz, J6,7b=7.0 Hz, H-6
I), 5.35 (dd, 1H, J3,4=3.5 Hz, J4,5=1.5 Hz, 
H-4III), 7.38–7.25 (m, 5H, Ph). 13C NMR (150 MHz, CDCl3):  20.3, 20.34, 20.4, 20.5, 
20.6, 20.7 (Ac-CH3), 55.0 (OCH3), 60.7 (C-6
III), 61.8 (C-6II), 62.0 (C-7I), 66.5 (C-4III), 
68.0 (C-6I), 68.4 (C-5I), 69.0 (C-2III), 69.8 (C-3I), 70.6 (C-5III), 70.8 (C-3III), 71.3 
(C-2II), 72.55 (C-5II), 72.6 (C-3II), 73.0 (OCH2Ph), 76.0 (C-2
I), 76.2 (C-4II), 79.6 
(C-4I), 99.0 (C-1I), 100.4 (C-1II), 100.9 (C-1III), 127.3, 127.34, 128.1, 138.4 (Ph), 
168.9, 169.3, 169.87, 169.9, 170.0, 170.1, 170.2, 170.23 (Ac: C=O). ESI-HRMS for 
C45H60O26: 1039.3271 [M+Na]
+. Found: 1039.3303. 
6.16 Methyl (2,3,4,6-tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acet
-yl--D-glucopyranosyl)-(1-4)-3,6,7-tri-O-acetyl-2-O-benzyl-L-glycero--D-manno
-heptopyranoside (29)  
Compound 28 (280.3 mg, 275.8 mol) was acetylated with pyridine/Ac2O (1:1, 
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v/v, 1.6 mL) in the presence of a catalytic amount of N,N-dimethyl-4-aminopyridine 
(DMAP) over 2 h. After removing the solvent, the residue was purified by flash 
column chromatography (dichloromethane/ethyl acetate, 5:2) to give 29 (180.9 mg, 
73%). []25D= +6.1 (c 0.8, CHCl3), 1H-NMR (600 MHz, CDCl3):  1.96, 1.97, 2.04, 
2.05, 2.06, 2.08, 2.09, 2.15, 2.16 (s, 3H x 10, Ac), 3.34 (s, 3H, OCH3), 3.61 (ddd, 1H, 
J4,5=10.0 Hz, J5,6a=4.8 Hz, J5,6b=1.8 Hz, H-5
II), 3.76 (dd, 1H, J1,2=2.4 Hz, J2,3=3.4 Hz, 
H-2I), 3.80 (dd, 1H, J4,5=9.6 Hz, J5,6=1.0 Hz, H-5
I), 3.84 (dd, 1H, J3,4=8.6 Hz, 
J4,5=10.0 Hz, H-4
II), 3.86 (ddd, 1H, J4,5=0.8 Hz, J5,6a=7.6 Hz, J5,6b=6.6 Hz, H-5
III), 
3.88 (dd, 1H, J3,4=8.4 Hz, J4,5=9.6 Hz, H-4
I), 4.07 (dd, 1H, J5,6a=7.6 Hz, J6a,6b=11.4 
Hz, H-6aIII), 4.10 (dd, 1H, J5,6a=5.4 Hz, J6a,6b=12.0 Hz, H-6a
II), 4.12 (dd, 1H, J5,6b=6.6 
Hz, J6a,6b=11.4 Hz, H-6b
III), 4.25 (dd, 1H, J6,7a=7.4 Hz, J7a,7b=11.2 Hz, H-7a
I), 4.32 
(dd, 1H, J6,7b=6.0 Hz, J7a,7b=11.2 Hz, H-7b
I), 4.38 (dd, 1H, J5,6b=1.8 Hz, J6a,6b=12.0 
Hz, H-6bII), 4.47 (d, 1H, J1,2=8.0 Hz, H-1
III), 4.55 (d, 1H, J=12.2 Hz, OCH2Ph), 4.57 
(d, 1H, J1,2=7.2 Hz, H-1
II), 4.64 (d, 1H, J=12.2 Hz, OCH2Ph), 4.77 (d, 1H, J1,2=2.4 Hz, 
H-1I), 4.82 (dd, 1H, J1,2=7.2 Hz, J2,3=8.2 Hz, H-2
II), 4.93 (dd, 1H, J2,3=10.4 Hz, 
J3,4=3.4 Hz, H-3
III), 5.10 (dd, 1H, J1,2=8.0 Hz, J2,3=10.4 Hz, H-2
III), 5.15 (dd, 1H, 
J2,3=8.2 Hz, J3,4=8.6 Hz, H-3
II), 5.27 (dd, 1H, J2,3=3.4 Hz, J3,4=8.4 Hz, H-3
I), 5.34 (dd, 
1H, J3,4=3.4 Hz, J4,5=0.8 Hz, H-4
III), 5.39 (ddd, 1H, J5,6=1.0 Hz, J6,7a=7.2 Hz, J6,7b=6.0 
Hz, H-6I), 7.26–7.33 (m, 5H, Ph). 13C NMR (150 MHz, CDCl3):  20.5, 20.6, 20.68, 
20.7, 20.74, 20.8, 20.9 (Ac-CH3), 55.3 (OCH3), 60.7 (C-6
III), 62.2 (C-6II), 62.4 (C-7I), 
66.6 (C-4III), 68.1 (C-6I), 69.0 (C-2III), 69.3 (C-3I), 70.6 (C-5III), 70.7 (C-5I), 71.0 
(C-3III), 71.9 (C-2II), 72.1 (C-5II), 72.7 (OCH2Ph), 73.3 (C-3
II), 73.9 (C-4I), 75.2 (C-2I), 
76.2 (C-4II), 99.1 (C-1I), 99.9 (C-1II), 101.1 (C-1III), 127.8, 127.9, 128.4, 137.7 (Ph), 
169.1, 169.7, 169.9, 170.2, 170.3, 170.4, (Ac: C=O). ESI-HRMS for C47H62O27: 
1067.3376 [M+Na]+. Found 1081.3368. 
6.17 (2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acetyl--D-g
-lucopyranosyl)-(1-4)-3,6,7-tri-O-acetyl-2-O-benzyl-L-glycero-D-manno-heptopyr-
anose (30)  
A solution of 29 (195.0 mg, 184.1 mol) in a mixture of H2SO4/AcOH/Ac2O 
(0.1:6:14, 4.0 mL) was stirred for 3 h at room temperature. The reaction mixture was 
 59 
neutralized by the addition of sodium acetate, poured into saturated sodium hydrogen 
carbonate, and extracted with dichloromethane. The combined organic layer was 
washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue was purified by flash column chromatography (ethyl acetate/hexane, 2:1) 
to give a syrup (124.5 mg, 64%). The syrup was treated with hydrazine acetate (13.0 
mg, 120.4 mol) in DMF (1.0 mL) for 8 h at 0 °C. The reaction mixture was diluted 
with ethyl acetate, washed with water and brine, dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by silica gel column 
chromatography (ethyl acetate/hexane, 2:1) to give 30 (89.1 mg, 77%). 1H-NMR (600 
MHz, CDCl3):  1.96, 1.98, 2.04, 2.06, 2.06, 2.07, 2.15, 2.15 (s, 3H x 10, Ac), 3.37 
(brs, 1H, OH), 3.61 (ddd, 1H, J4,5=10.0 Hz, J5,6a=4.6 Hz, J5,6b=2.0 Hz, H-5
II), 3.79 (dd, 
1H, J1,2=2.8 Hz, J2,3=3.2 Hz, H-2
I), 3.85 (dd, 1H, J3,4=9.0 Hz, J4,5=10.0 Hz, H-4
II), 
3.86 (ddd, 1H, J4,5=1.2 Hz, J5,6a=7.6 Hz, J5,6b=6.2 Hz, H-5
III), 3.89 (dd, 1H, J3,4=8.6 
Hz, J4,5=9.8 Hz, H-4
I), 3.98 (dd, 1H, J4,5=9.8 Hz, J5,6=nd Hz, H-5
I), 4.07 (dd, 1H, 
J5,6a=7.6 Hz, J6a,6b=11.0 Hz, H-6a
III), 4.09 (dd, 1H, J5,6a=4.6 Hz, J6a,6b=12.0 Hz, 
H-6aII), 4.15 (dd, 1H, J5,6b=6.2 Hz, J6a,6b=11.0 Hz, H-6b
III), 4.15 (dd, 1H, J6,7a=7.0 Hz, 
J7a,7b=11.0 Hz, H-7a
I), 4.38 (dd, 1H, J6,7b=6.2 Hz, J7a,7b=11.0 Hz, H-7b
I), 4.39 (dd, 1H, 
J5,6b=2.0 Hz, J6a,6b=12.0 Hz, H-6b
II), 4.48 (d, 1H, J1,2=8.0 Hz, H-1
III), 4.56 (d, 1H, 
J=12.2 Hz, OCH2Ph), 4.57 (d, 1H, J1,2=7.2 Hz, H-1
II), 4.63 (d, 1H, J=12.2 Hz, 
OCH2Ph), 4.82 (dd, 1H, J1,2=7.2 Hz, J2,3=8.4 Hz, H-2
II), 4.93 (dd, 1H, J2,3=10.4 Hz, 
J3,4=3.4 Hz, H-3
III), 5.10 (dd, 1H, J1,2=8.0 Hz, J2,3=10.4 Hz, H-2
III), 5.15 (dd, 1H, 
J2,3=8.4 Hz, J3,4=9.0 Hz, H-3
II), 5.27 (d, 1H, J1,2=2.8 Hz, H-1
I), 5.33 (dd, 1H, J3,4=3.4 
Hz, J4,5=1.2 Hz, H-4
III), 5.33 (dd, 1H, J2,3=3.2 Hz, J3,4=8.6 Hz, H-3
I), 5.37 (ddd, 1H, 
J5,6=nd Hz, J6,7a=7.0 Hz, J6,7b=6.2 Hz, H-6
I), 7.27–7.33 (m, 5H, Ph). 13C NMR (150 
MHz, CDCl3):  20.5, 20.6, 20.65, 20.66, 20.7, 20.79, 20.8, 20.9 (Ac-CH3), 60.7 
(C-6III), 62.4 (C-6II), 62.6 (C-7I), 66.6 (C-4III), 68.1 (C-6I), 69.0 (C-2III), 69.3 (C-3I), 
70.5 (C-5III), 70.6 (C-5I), 71.0 (C-3III), 71.9 (C-2II), 72.0 (C-5II), 72.7 (OCH2Ph), 73.2 
(C-3II), 74.0 (C-4I), 75.7 (C-2I), 76.2 (C-4II), 92.4 (C-1I), 99.8 (C-1II), 101.1 (C-1III), 
127.7, 127.8, 128.4, 137.7 (Ph), 169.2, 169.66, 169.7, 170.0, 170.15, 170.2, 170.24, 
170.4, 170.9 (Ac: C=O). ESI-HRMS for C46H60O27: 1067.3220 [M+Na]
+. Found 
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1067.3226. 
6.18 (2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acetyl--D-g
-lucopyranosyl)-(1-4)-3,6,7-tri-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptop-
yranosyl trichloroacetimidate (31) 
 Trichloroacetonitrile (85.0 L, 842.1 mol) was added to a solution of 30 
(88.0 mg, 84.2 mol) in dry dichloromethane (0.8 mL) under argon. Potassium 
carbonate (58.0 mg, 421.0 mol) was added to the reaction mixture. After stirring for 
13 h at room temperature, the mixture was filtered through Celite. The solution was 
concentrated and purified by silica gel column chromatography (ethyl acetate/hexane, 
2:1) to give 31 (96.0 mg, 100%). []25D= -5.7 (c 1.3, CHCl3), 1H-NMR (600 MHz, 
CDCl3):  1.96, 1.99, 2.00, 2.06, 2.04, 2.04, 2.04, 2.05, 2.06, 2.07, 2.15, 2.15 (s, 3H x 
10, Ac), 3.65 (ddd, 1H, J4,5=10.0 Hz, J5,6a=4.6 Hz, J5,6b=2.0 Hz, H-5
II), 3.84 (dd, 1H, 
J3,4=9.2 Hz, J4,5=10.0 Hz, H-4
II), 3.87 (ddd, 1H, J4,5=nd Hz, J5,6a=7.6 Hz, J5,6b=6.2 Hz, 
H-5III), 3.88 (dd, 1H, J3,4=5.6 Hz, J4,5=9.4 Hz, H-4
I), 3.94 (dd, 1H, J4,5=9.4 Hz, 
J5,6=0.8 Hz, H-5
I), 4.04 (dd, 1H, J1,2=3.6 Hz, J2,3=2.8 Hz, H-2
I), 4.07 (dd, 1H, 
J5,6a=7.6 Hz, J6a,6b=11.2 Hz, H-6a
III), 4.09 (dd, 1H, J5,6a=4.8 Hz, J6a,6b=12.0 Hz, 
H-6aII), 4.14 (dd, 1H, J5,6b=6.2 Hz, J6a,6b=11.2 Hz, H-6b
III), 4.16 (dd, 1H, J6,7a=7.2 Hz, 
J7a,7b=11.4 Hz, H-7a
I), 4.22 (dd, 1H, J6,7b=5.8 Hz, J7a,7b=11.4 Hz, H-7b
I), 4.47 (dd, 1H, 
J5,6b=1.6 Hz, J6a,6b=12.0 Hz, H-6b
II), 4.49 (d, 1H, J1,2=8.0 Hz, H-1
III), 4.61 (d, 1H, 
J1,2=7.6 Hz, H-1
II), 4.63 (d, 1H, J=12.0 Hz, OCH2Ph), 4.68 (d, 1H, J=12.0 Hz, 
OCH2Ph), 4.85 (dd, 1H, J1,2=7.6 Hz, J2,3=8.6 Hz, H-2
II), 4.94 (dd, 1H, J2,3=10.6 Hz, 
J3,4=3.6 Hz, H-3
III), 5.10 (dd, 1H, J1,2=8.0 Hz, J2,3=10.4 Hz, H-2
III), 5.16 (dd, 1H, 
J2,3=8.6 Hz, J3,4=9.2 Hz, H-3
II), 5.29 (ddd, 1H, J5,6=0.8 Hz, J6,7a=7.2 Hz, J6,7b=6.2 Hz, 
H-6I), 5.33 (dd, 1H, J3,4=3.4 Hz, J4,5=nd Hz, H-4
III), 5.48 (dd, 1H, J2,3=2.8 Hz, J3,4=5.6 
Hz, H-3I), 6.31 (d, 1H, J1,2=3.6 Hz, H-1
I), 7.26–7.34 (m, 5H, Ph), 8.68 (NH). 13C 
NMR (150 MHz, CDCl3):  20.5, 20.54, 20.7, 20.74, 20.76, 20.79, 20.8, 20.9, 21.0 
(Ac-CH3), 60.7 (C-6
III), 62.1 (C-7I and C-6II), 66.6 (C-4III), 67.9 (C-6I), 69.3 (C-2III), 
69.9 (C-3I), 70.6 (C-5III), 71.0 (C-3III), 71.5 (C-2II), 71.6 (C-5II), 72.4 (-OCH2Ph and 
C-5I), 73.0 (C-3II), 74.0 (C-4I), 74.9 (C-2I), 76.0 (C-4II), 90.8 (OCNHCCl3), 96.0 
(C-1I), 99.2 (C-1II), 101.1 (C-1III), 127.9, 128.0, 128.4, 137.2 (Ph), 160.5 
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(OCNHCCl3), 169.0, 169.6, 169.8, 169.9, 170.1, 170.13, 170.16, 170.2, 170.24, 170.4 
(Ac: C=O). ESI-HRMS for C48H60Cl3NO27: 1210.2316 [M+Na]
+. Found 1210.2294. 
6.19 Methyl (2,3,4,6-tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acet
-yl--D-glucopyranosyl)-(1-4)-6,7-di-O-acetyl-L-glycero--D-manno-heptopyranos
-ide (32)  
Compound 28 (227.0 mg, 0.2 mmol) was hydrogenated in the presence of 10% 
Pd/C (100.0 mg) in ethyl acetate (15.0 mL) under atmospheric pressure of hydrogen. 
After stirring for 3.5 h at room temperature, the reaction mixture was filtered through 
Celite and concentrated. The residue was purified by flash column chromatography 
(dichloromethane/acetone, 3:1) to give 32 (198.0 mg, 97%). []25D= +26.0 (c 1.0, 
CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.97, 2.04, 2.04, 2.05, 2.07, 2.12, 2.14, 2.16, 
2.17 (s, 3H x 9, Ac), 2.55 (d, 1H, J2-OH,H-2=1.5 Hz, 2-OH), 3.35 (s, 3H, OCH3), 3.55 
(dd, 1H, J3,4=8.0 Hz, J4,5=9.8 Hz, H-4
I), 3.71 (dd, 1H, J4,5=9.8 Hz, J5,6=1.0 Hz, H-5
I), 
3.72 (ddd, 1H, J4,5=10.0 Hz, J5,6a=5.5 Hz, J5,6b=2.0 Hz, H-5
II), 3.78 (dd, 1H, J3,4=9.0 
Hz, J4,5=10.0 Hz, H-4
II), 3.81 (dd, 1H, J2,3=3.5 Hz, J3,4=8.0 Hz, H-3
I), 3.96 (dd, 1H, 
J1,2=1.0 Hz, J2,3=3.5 Hz, H-2
I), 3.88 (ddd, 1H, J4,5=1.0 Hz, J5,6a=7.5 Hz, J5,6b=6.5 Hz, 
H-5III), 4.03 (dd, 1H, J5,6a=5.5 Hz, J6a,6b=12.0 Hz, H-6a
II), 4.08 (dd, 1H, J5,6a=7.5 Hz, 
J6a,6b=11.3 Hz, H-6a
III), 4.14 (dd, 1H, J5,6b=6.5 Hz, J6a,6b=11.3 Hz, H-6b
III), 4.22 (m, 
1H, J5,6=1.0 Hz, H-6
I), 4.29 (m, 2H, H-7aI, H-7bI), 4.30 (d, 1H, J3-OH,H-3=1.0 Hz, 
3-OH), 4.46 (d, 1H, J1,2=8.0 Hz, H-1
II), 4.51 (d, 1H, J1,2=8.5 Hz, H-1
III), 4.65 (dd, 1H, 
J5,6b=2.0 Hz, J6a,6b=12.0 Hz, H-6b
II), 4.80 (d, 1H, J1,2=1.0 Hz, H-1
I), 4.93 (dd, 1H, 
J1,2=8.0 Hz, J2,3=9.5 Hz, H-2
II), 4.97 (dd, 1H, J2,3=10.5 Hz, J3,4=3.5 Hz, H-3
III), 5.11 
(dd, 1H, J1,2=8.5 Hz, J2,3=10.5 Hz, H-2
III), 5.22 (dd, 1H, J2,3=9.5 Hz, J3,4=9.0 Hz, 
H-3II), 5.35 (dd, 1H, J3,4=3.5 Hz, J4,5=1.0 Hz, H-4
III). 13C NMR (150 MHz, CDCl3):  
20.4, 20.42, 20.5, 20.54, 20.6, 20.64, 20.9 (Ac-CH3), 55.2 (OCH3), 60.7 (C-6
III), 61.6 
(C-6II), 62.0 (C-7I), 66.5 (C-4III), 67.7 (C-5I), 67.9 (C-6I), 69.0 (C-2III), 69.5 (C-3I), 
69.5 (C-2I), 70.8 (C-3III), 71.0 (C-5III), 71.2 (C-2II), 72.5 (C-3II), 72.8 (C-5II), 76.0 
(C-4II), 79.0 (C-4I), 100.1 (C-1I), 100.6 (C-1II), 100.9 (C-1III), 169.0, 169.3, 170.0, 
170.04, 170.16, 170.2, 170.26, 170.3 (Ac: C=O). ESI-HRMS for C38H54O26: 949.2801 
[M+Na]+. Found 949.2766.  
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6.20 (2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acetyl--D-g
-lucopyranosyl)-(1-4)-1,2,3,6,7-penta-O-acetyl-L-glycero--D-manno-heptopyrano
-se (33) 
Compound 32 (342.0 mg, 0.4 mmol) was treated with acetic anhydride (1.0 mL) 
and pyridine (2.0 mL) at room temperature. The reaction mixture was stirred 
overnight and concentrated. The residue was purified by silica gel column 
chromatography (dichloromethane/acetone, 4:1) to give a syrup. The syrup was 
dissolved in a mixture of H2SO4/AcOH/Ac2O (8.0 mL, 0.1:6:14) at room temperature. 
After stirring for 15 h, the reaction mixture was neutralized by the addition of sodium 
acetate (0.2 g), poured into saturated sodium hydrogen carbonate, and extracted with 
chloroform. Combined organic phase was washed with brine, dried over anhydrous 
sodium sulfate, filtered, and concentrated. The residue was purified by silica gel 
column chromatography (dichloromethane/acetone, 4:1) to give 33 (257.0 mg, 67%).  
[]25D= +29.0 (c 1.0, CHCl3), 1H-NMR (600 MHz, CDCl3):  1.97, 1.99, 2.03, 2.05, 
2.06, 2.07, 2.08, 2.13, 2.14, 2.15, 2.16, 2.18 (s, 3H x 12, Ac), 3.61 (ddd, 1H, J4,5=9.5 
Hz, J5,6a=7.0 Hz, J5,6b=5.5 Hz, H-5
II), 3.82 (dd, 1H, J3,4=8.5 Hz, J4,5=9.5 Hz, H-4
II), 
3.85–3.88 (m, 2H, H-5III, H-4I), 3.91 (dd, 1H, J4,5=9.5 Hz, J5,6=1.2 Hz, H-5I), 
4.05–4.09 (m, 2H, H-6aIII, H-7aI), 4.13 (dd, 1H, J5,6b=6.2 Hz, J6a,6b=11.0 Hz, H-6bIII), 
4.19 (dd, 1H, J5,6a=7.0 Hz, J6a,6b=11.5 Hz, H-6a
II), 4.24 (dd, 1H, J5,6b=5.5 Hz, 
J6a,,6b=11.5 Hz, H-6b
II), 4.40 (dd, 1H, J6,7b=2.0 Hz, J7a,7b=12.0 Hz, H-7b
I), 4.49 (d, 1H, 
J1,2=8.0 Hz, H-1
III), 4.61 (d, 1H, J1,2=7.5 Hz, H-1
II), 4.82 (dd, 1H, J1,2=7.5 Hz, J2,3=8.0 
Hz, H-2II), 4.95 (dd, 1H, J2,3=10.5 Hz, J3,4=3.4 Hz, H-3
III), 5.11 (dd, 1H, J1,2=8.0 Hz, 
J2,3=10.5 Hz, H-2
III), 5.16 (dd, 1H, J2,3=8.0 Hz, J3,4=8.5 Hz, H-3
II), 5.22 (dd, 1H, 
J1,2=2.5 Hz, J2,3=9.0 Hz, H-2
I), 5.32–5.36 (m, 3H, H-6I, H-4III, H-3I), 6.06 (d, 1H, 
J1,2=2.5 Hz, H-1
I).  13C NMR (150 MHz, CDCl3):  20.5, 20.51, 20.6, 20.65, 20.7, 
20.8, 20.81, 20.9, 21.1 (Ac-CH3), 60.7 (C-6
III), 62.2 (C-6II), 62.3 (C-7I), 66.6 (C-4III), 
67.9 (C-3I), 68.4 (C-6I), 68.9 (C-2III), 69.1 (C-2I), 70.6 (C-5III), 71.0 (C-3III), 71.4 
(C-5I), 71.9 (C-2II), 72.2 (C-5II), 73.1 (C-3II), 73.2 (C-4I), 76.0 (C-4II), 90.4 (C-1I), 
99.8 (C-1II), 101.2 (C-1III), 168.3, 169.1, 169.5, 169.53, 169.6, 169.8, 170.1, 170.14, 
170.2, 170.3, 170.4 (Ac: C=O). ESI-HRMS for C43H58O29: 1061.2961 [M+Na]
+. 
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Found 1061.2981. 
6.21 (2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acetyl--D-g
-lucopyranosyl)-(1-4)-2,3,6,7-tetra-O-acetyl-L-glycero-D-manno-heptopyranose (3
4) 
Compound 33 (256.6 mg, 247.0 mol) was treated with hydrazine acetate (45.5 
mg, 494.0 mol) in DMF (3.0 mL) for 8 h at 0 °C. The reaction mixture was diluted 
with ethyl acetate, washed with water and brine, dried over anhydrous sodium sulfate, 
filtered, and concentrated. The residue was purified by silica gel column 
chromatography (acetone/dichloromethane, 1:4) to give 34 (223.4 mg, 90%). 
1H-NMR (600 MHz, CDCl3):  1.96, 1.98, 2.04, 2.06, 2.07, 2.08, 2.13, 2.16, 2.19 (s, 
3H x 11, Ac), 3.27 (brs, 1H, OH), 3.62 (ddd, 1H, J4,5=10.0 Hz, J5,6a=4.6 Hz, J5,6b=1.6 
Hz, H-5II), 3.81 (dd, 1H, J3,4=9.4 Hz, J4,5=10.0 Hz, H-4
II), 3.87 (ddd, 1H, J5,6a=7.8 Hz, 
J5,6b=6.2 Hz, H-5
III), 3.88 (dd, 1H, J4,5=9.8 Hz, H-4
I), 4.06 (dd, 1H, J5,6a=4.6 Hz, 
J6a,6b=12.0 Hz, H-6a
II), 4.07 (dd, 1H, J5,6a=7.8 Hz, J6a,6b=11.2 Hz, H-6a
III), 4.09 (dd, 
1H, J4,5=9.8 Hz, H-5
I), 4.12 (dd, 1H, J5,6b=6.2 Hz, J6a,6b=11.2 Hz, H-6b
III), 4.16 (dd, 
1H, J6,7a=6.8 Hz, J7a,7b=11.4 Hz, H-7a
I), 4.38 (dd, 1H, J5,6b=1.6 Hz, J6a,6b=12.0 Hz, 
H-6bII), 4.39 (dd, 1H, J6,7b=5.8 Hz, J7a,7b=11.4 Hz, H-7b
I), 4.49 (d, 1H, J1,2=8.0 Hz, 
H-1III), 4.60 (d, 1H, J1,2=6.8 Hz, H-1
II), 4.80 (dd, 1H, J1,2=6.8 Hz, J2,3=8.2 Hz, H-2
II), 
4.94 (dd, 1H, J2,3=10.4 Hz, J3,4=3.4 Hz, H-3
III), 5.11 (dd, 1H, J1,2=8.0 Hz, J2,3=10.4 
Hz, H-2III), 5.15 (dd, 1H, J2,3=8.2 Hz, J3,4=9.4 Hz, H-3
II), 5.22–5.23 (m, 2H, H-6I, 
H-4III), 5.34 (d, 1H, J1,2=3.2 Hz, H-1
I), 5.40 (dd, 1H, H-3I), 5.41 (dd, 1H, J1,2=3.2 Hz, 
H-2I). 13C NMR (150 MHz, CDCl3):  20.5, 20.6, 20.8, 20.9, 20.92 (Ac-CH3), 60.7 
(C-6III), 62.5 (C-6II), 62.8 (C-7I), 66.6 (C-4III), 68.3 (C-6I), 68.96 (C-3I), 69.0 (C-2III), 
69.1 (C-2I), 70.4 (C-5I), 70.6 (C-5III), 71.0 (C-3III), 71.9 (C-2II), 71.92 (C-5II), 73.1 
(C-3II), 73.3 (C-4I), 76.0 (C-4II), 92.0 (C-1I), 99.1 (C-1II), 101.1 (C-1III), 169.2, 169.7, 
169.8, 170.0, 170.1, 170.2, 170.4, 170.5 (Ac: C=O). ESI-HRMS for C41H56O28: 
1019.2856 [M+Na]+. Found 1019.2848.   
6.22 (2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acetyl--D-g
-lucopyranosyl)-(1-4)-2,3,6,7-tetra-O-acetyl-L-glycero--D-manno-heptopyranosyl
trichloroacetimidate (35)  
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Trichloroacetonitrile (57.0 L, 565.6 mol) was added to a solution of 34 (57.1 
mg, 57.3 mol) in dry dichloromethane (1.0 mL) under argon. Potassium carbonate 
(39.3 mg, 284.4 mol) was added to the reaction mixture. After stirring for 24 h at 
room temperature, the mixture was filtered through Celite. The solution was 
concentrated and purified by silica gel column chromatography (ethyl acetate/hexane, 
2:1) to give 35 (60.2 mg, 92%). []25D= +2.4 (c 1.0, CHCl3), 1H-NMR (600 MHz, 
CDCl3):  1.97, 2.00, 2.00, 2.04, 2.07, 2.12, 2.15, 2.19 (s, 3H x 11, Ac), 3.63 (ddd, 1H, 
J4,5=10.0 Hz, J5,6a=4.0 Hz, J5,6b=2.0 Hz, H-5
II), 3.84–3.89 (m, 3H, H-4II, H-5III, H-4I), 
4.01 (dd, 1H, J4,5=9.8 Hz, J5,6=1.4 Hz, H-5
I), 4.06 (dd, 1H, J5,6a=7.2 Hz, J6a,6b=11.2 
Hz, H-6aIII), 4.09 (dd, 1H, J5,6a=4.0 Hz, J6a,6b=12.2 Hz, H-6a
II), 4.14 (dd, 1H, J5,6b=6.2 
Hz, J6a,6b=11.2 Hz, H-6b
III), 4.17 (dd, 1H, J6,7a=7.2 Hz, J7a,7b=11.4 Hz, H-7a
I), 4.21 
(dd, 1H, J6,7b=6.0 Hz, J7a,7b=11.4 Hz, H-7b
I), 4.47 (dd, 1H, J5,6b=2.0 Hz, J6a,6b=12.2 
Hz, H-6bII), 4.53 (d, 1H, J1,2=8.0 Hz, H-1
III), 4.61 (d, 1H, J1,2=7.0 Hz, H-1
II), 4.83 (dd, 
1H, J1,2=7.0 Hz, J2,3=7.8 Hz, H-2
II), 4.95 (dd, 1H, J2,3=10.6 Hz, J3,4=3.4 Hz, H-3
III), 
5.10 (dd, 1H, J1,2=8.0 Hz, J2,3=10.6 Hz, H-2
III), 5.16 (dd, 1H, J2,3=7.8 Hz, J3,4=10.4 
Hz, H-3II), 5.34 (dd, 1H, J4,5=0.8 Hz, J3,4=3.4 Hz, H-4
III), 5.37 (ddd, 1H, J5,6=1.4 Hz, 
J6,7a=7.2 Hz, J6,7b=6.0 Hz, H-6
I), 5.43 (dd, 1H, J1,2=2.2 Hz, J2,3=3.4 Hz, H-2
I), 5.44 
(dd, 1H, J2,3=3.4 Hz, H-3
I), 6.23 (d, 1H, J1,2=2.2 Hz, H-1
I), 8.74 (NH). 13C NMR (150 
MHz, CDCl3):  20.5, 20.57, 20.6, 20.7, 20.74, 20.8 (Ac-CH3), 60.7 (C-6III), 62.0 
(C-6II), 62.1 (C-7I), 66.6 (C-4III), 67.8 (C-2I), 67.9 (C-6I), 69.0 (C-3I and C-2III), 70.6 
(C-5III), 71.0 (C-3III), 71.6 (C-2II), 71.7 (C-5II), 72.1 (C-5I), 73.1 (C-3II), 73.3 (C-4I), 
75.8 (C-4II), 90.5 (OCNHCCl3), 94.6 (C-1
I), 99.9 (C-1II), 101.1 (C-1III), 160.0 
(OCNHCCl3), 169.1, 169.4, 169.42, 169.67, 169.7, 170.0, 170.1, 170.2, 170.3, 170.4 
(Ac: C=O). ESI-HRMS for C43H56Cl3NO28: 1162.1952 [M+Na]
+. Found 1162.1940. 
6.23 Methyl (3,4,6,7-tetra-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyra-
nosyl)-(1-3)-4,6,7-tri-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyranoside
(36)  
A mixture of 25 (188.0 mg, 308.0 mol), and 22 (135.0 mg, 308.0 mol), and 4 
Å molecular sieves (135.0 mg) was suspended in dry dichloromethane (0.9 mL). The 
reaction mixture was stirred for 1 h under argon, and then cooled to -78 °C.  
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TMSOTf (2.2 μL, 12.3 mol) in dichloromethane was added dropwise to the reaction 
mixture. The reaction was warmed to room temperature and stirred for 2 h. The 
reaction was neutralized by the addition of a few drops of triethylamine and aqueous 
saturated sodium hydrogen carbonate. The reaction mixture was diluted with 
dichloromethane and filtered through Celite. The filtrate was extracted twice with 
dichloromethane. The combined organic phase was dried over anhydrous sodium 
sulfate, filtered, and concentrated. The residue was purified by BioRad S-X3 size 
exclusion beads (toluene/ethyl acetate, 1:1) to give 36 (136.6 mg, 50%). []25D= 
+41.2 (c 1.0, CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.77, 1.94, 1.96, 2.04, 2.05, 
2.09, 2.13 (s, 3H x 7, Ac), 3.31 (s, 3H, OCH3), 3.66 (dd, 1H, J1,2=1.6 Hz, J2,3=3.0 Hz, 
H-2I), 3.76 (dd, 1H, J4,5=10.0 Hz, J5,6=1.8 Hz, H-5
II), 3.81 (dd, 1H, J1,2=1.6 Hz, 
J2,3=3.0 Hz, H-2
II), 3.87 (dd, 1H, J4,5=10.0 Hz, J5,6=2.0 Hz, H-5
I), 4.02 (dd, 1H, 
J6,7a=6.4 Hz, J7a,7b=11.2 Hz, H-7a
II), 4.07 (dd, 1H, J2,3=3.0 Hz, J3,4=9.8 Hz, H-3
I), 
4.11 (dd, 1H, J6,7b=6.8 Hz, J7a,7b=11.2 Hz, H-7b
II), 4.23 (dd, 1H, J6,7a=7.6 Hz, 
J7a,7b=11.2 Hz, H-7a
I), 4.32 (dd, 1H, J6,7b=5.6 Hz, J7a,7b=11.2 Hz, H-7b
I), 4.59, 4.64 (d, 
2H, J=12.2 Hz, OCH2Ph), 4.76 (d, 1H, J1,2=1.6 Hz, H-1
I), 4.82, 4.84 (d, 2H, J=12.8 
Hz, OCH2Ph), 5.03 (d, 1H, J1,2=1.6 Hz, H-1
II), 5.05 (ddd, 1H, J5,6=1.8 Hz, J6,7a=6.4 
Hz, J6,7b=6.8 Hz, H-6
II), 5.21 (ddd, 1H, J5,6=2.0 Hz, J6,7a=7.6 Hz, J6,7b=5.6 Hz, H-6
I), 
5.31 (dd, 1H, J2,3=3.0 Hz, J3,4=10.0 Hz, H-3
II), 5.40 (dd, 1H, J3,4=9.8 Hz, J4,5=10.0 Hz, 
H-4II), 5.47 (dd, 1H, J3,4=9.8 Hz, J4,5=10.0 Hz, H-4
I), 7.28–7.45 (m, 10H, Ph). 13C 
NMR (150 MHz, CDCl3):  20.4, 20.66, 20.69, 20.7, 20.8, 20.83 (Ac-CH3), 55.1 
(OCH3), 61.5 (C-7
II), 62.0 (C-7I), 65.5 (C-4II), 66.9 (C-6I), 67.1 (C-6II), 67.8 (C-4I), 
68.8 (C-5I), 69.2 (C-5II), 70.8 (C-3II), 72.6 (OCH2Ph), 73.4 (OCH2Ph), 74.4 (C-3
I), 
75.1 (C-2I), 75.5 (C-2II), 99.2 (C-1II), 99.4 (C-1I), 128.0, 128.1, 128.2, 128.4, 128.7, 
129.0, 137.4, 137.6 (Ph), 169.3, 169.4, 169.7, 170.1, 170.3, 170.5, 170.6 (Ac: O=C).  
ESI-HRMS for C43H54O20: 913.3106 [M+Na]
+. Found 913.3093. 
6.24 (3,4,6,7-Tetra-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyranosyl)-
(1-3)-4,6,7-tri-O-acetyl-2-O-benzyl-L-glycero-D-manno-heptopyranose (37)  
Compound 36 (158.5 mg, 178.0 mol) was dissolved in a mixture of 
H2SO4/AcOH/Ac2O (4.0 mL, 0.1:6:14) and stirred for 2 h at room temperature. The 
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reaction mixture was neutralized by the addition of sodium acetate (1.2 g), poured into 
saturated sodium hydrogen carbonate and extracted with dichloromethane. The 
combined organic layer was washed with brine, dried over anhydrous sodium sulfate, 
filtered, and concentrated to a syrup (156.5 mg). The crude syrup was treated with 
hydrazine acetate (20.4 mg, 221.0 mol) in DMF (1.2 mL) for 7 h at 0 °C. The 
reaction mixture was diluted with ethyl acetate, washed with water and brine, dried 
over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified 
by silica gel column chromatography (ethyl acetate/hexane, 1:1) to give 37 (122.4 mg, 
78%). 1H-NMR (600 MHz, CDCl3):  1.82, 1.95, 1.96, 2.05, 2.06, 2.10, 2.15 (s, 3H x 
7, Ac), 3.03 (s, 1H, OH), 3.70 (dd, 1H, J1,2=2.0 Hz, J2,3=2.6 Hz, H-2
I), 3.72 (dd, 1H, 
J4,5=10.0 Hz, J5,6=1.8 Hz, H-5
II), 3.81 (dd, 1H, J1,2=1.6 Hz, J2,3=3.0 Hz, H-2
II), 4.07 
(dd, 1H, J4,5=10.2 Hz, J5,6=2.0 Hz, H-5
I), 4.10 (dd, 1H, J6,7a=5.2 Hz, J7a,7b=11.4 Hz, 
H-7aII), 4.14 (dd, 1H, J6,7b=nd Hz, J7a,7b=11.4 Hz, H-7b
II), 4.14 (dd, 1H, J6,7a=nd Hz, 
J7a,7b=11.4 Hz, H-7a
I), 4.16 (dd, 1H, J2,3=2.6 Hz, J3,4=7.0 Hz, H-3
I), 4.38 (dd, 1H, 
J6,7b=5.4 Hz, J7a,7b=11.4 Hz, H-7b
I), 4.59, 4.64 (d, 2H, J=12.2 Hz, OCH2Ph), 4.82, 
4.85 (d, 2H, J=12.8 Hz, OCH2Ph), 5.04 (ddd, 1H, J5,6=1.8 Hz, J6,7a=5.2 Hz, J6,7b=nd 
Hz, H-6II), 5.06 (d, 1H, J1,2=1.6 Hz, H-1
II), 5.18 (ddd, 1H, J5,6=2.0 Hz, J6,7a=nd Hz, 
J6,7b=5.4 Hz, H-6
I), 5.30 (d, 1H, J1,2=2.0 Hz, H-1
I), 5.31 (dd, 1H, J2,3=3.0 Hz, 
J3,4=10.2 Hz, H-3
II), 5.40 (dd, 1H, J3,4=10.2 Hz, J4,5=10.0 Hz, H-4
II), 5.47 (dd, 1H, 
J3,4=7.0 Hz, J4,5=10.2 Hz, H-4
I), 7.30–7.46 (m, 10H, Ph). 13C NMR (150 MHz, 
CDCl3):  20.6, 20.7, 20.75, 20.9, 21.5 (Ac-CH3), 61.7 (C-7II), 62.6 (C-7I), 65.5 
(C-4II), 67.1 (C-6I), 67.16 (C-6II), 68.0 (C-4I), 68.9 (C-5I), 69.3 (C-5II), 70.7 (C-3II), 
72.6 (OCH2Ph), 73.4 (OCH2Ph), 74.2 (C-3
I), 75.4 (C-2I), 75.5 (C-2II), 92.9 (C-1I), 
99.4 (C-1II), 128.0, 128.2, 128.25, 128.5, 128.7, 129.1, 137.4, 137.6 (Ph), 169.4, 169.5, 
169.8, 170.4, 170.7, 171.1 (Ac: O=C). ESI-HRMS for C42H52O20: 899.2950 [M+Na]
+. 
Found 899.2930. 
6.25 (3,4,6,7-Tetra-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyranosyl)-
(1-3)-4,6,7-tri-O-acetyl-2-O-benzyl-L-glycero-D-manno-heptopyranosyl trichloro-
acetimidate (38)  
Trichloroacetonitrile (192.0 L, 1.9 mmol) was added to a solution of 37 (139.9 
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mg, 160.0 mol) in dry dichloromethane (1.6 mL) under argon. Potassium carbonate 
(113.0 mg, 0.8 mmol) was added to the reaction. After stirring for 21 h at room 
temperature, the mixture was filtered through Celite. The solution was concentrated 
and purified by flash column chromatography (ethyl acetate/hexane, 1:1) to give 38 as 
a mixture of anomers (129.5 mg, 80%, =6:1). -isomer: []25D= +18.6 (c 1.5, 
CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.90, 1.94, 1.97, 2.01, 2.05, 2.06, 2.13 (s, 3H 
x 7, Ac), 3.40 (dd, 1H, J4,5=10.0 Hz, J5,6=2.0 Hz, H-5
II), 3.75 (dd, 1H, J1,2=1.4 Hz, 
J2,3=3.0 Hz, H-2
II), 3.89 (dd, 1H, J6,7a=4.0 Hz, J7a,7b=11.6 Hz, H-7a
II), 3.94 (dd, 1H, 
J1,2=1.6 Hz, J2,3=3.2 Hz, H-2
I), 4.05 (dd, 1H, J2,3=3.2 Hz, J3,4=6.6 Hz, H-3
I), 4.08 (dd, 
1H, J4,5=10.0 Hz, J5,6=2.0 Hz, H-5
I), 4.11 (dd, 1H, J6,7b=7.2 Hz, J7a,7b=11.6 Hz, 
H-7bII), 4.16 (dd, 1H, J6,7a=7.6 Hz, J7a,7b=11.4 Hz, H-7a
I), 4.27 (dd, 1H, J6,7b=5.4 Hz, 
J7a,7b=11.4 Hz, H-7b
I), 4.60, 4.62 (d, 2H, J=12.2 Hz, OCH2Ph), 4.73, 4.91 (d, 2H, 
J=12.4 Hz, OCH2Ph), 4.98 (ddd, 1H, J5,6=2.0 Hz, J6,7a=4.0 Hz, J6,7b=8.6 Hz, H-6
II), 
5.02 (d, 1H, J1,2=1.4 Hz, H-1
II), 5.20 (dd, 1H, J2,3=3.0 Hz, J3,4=10.2 Hz, H-3
II), 5.21 
(ddd, 1H, J5,6=2.0 Hz, J6,7a=7.6 Hz, J6,7b=5.4 Hz, H-6
I), 5.31 (dd, J3,4=10.2 Hz, 
J4,5=10.0 Hz, H-4
II), 5.52 (dd, J3,4=6.6 Hz, J4,5=10.0 Hz, H-4
I), 6.40 (d, 1H, J1,2=1.6 
Hz, H-1I), 7.27–7.50 (m, 10H, Ph), 8.80 (s, 1H, NH). 13C NMR (150 MHz, CDCl3):  
20.6, 20.7, 20.76, 20.8 (Ac-CH3), 62.1 (C-7
I), 62.6 (C-7II), 65.3 (C-4II), 66.7 (C-6I), 
66.9 (C-4I), 67.2 (C-6II), 69.8 (C-5II), 70.8 (C-3II), 71.5 (C-5I), 72.2 (OCH2Ph), 73.5 
(OCH2Ph), 73.7 (C-2
I), 75.3 (C-3I), 75.8 (C-2II), 90.6 (OCNHCCl3), 95.0 (C-1
I), 100.2 
(C-1II), 127.8, 128.0, 128.2, 128.5, 128.6, 128.9, 136.9, 137.4 (Ph), 159.5 
(OCNHCCl3), 169.4, 169.7, 170.2, 170.5 (Ac: O=C). ESI-HRMS for C44H52Cl3NO20: 
1042.2046 [M+Na]+. Found 1042.2051. -isomer: []25D= -12.6 (c 0.3, CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.75, 1.88, 1.90, 1.97, 1.98, 2.02, 2.05 (s, 3H x 7, Ac), 
3.52 (dd, 1H, J4,5=9.8 Hz, J5,6=2.0 Hz, H-5
II), 3.64 (dd, 1H, J4,5=10.0 Hz, J5,6=2.6 Hz, 
H-5I), 3.74 (dd, 1H, J1,2=2.0 Hz, J2,3=3.0 Hz, H-2
II), 3.78 (dd, 1H, J2,3=2.8 Hz, 
J3,4=9.6 Hz, H-3
I), 3.89 (dd, 1H, J1,2=nd Hz, J2,3=2.8 Hz, H-2
I), 4.00 (dd, 1H, J6,7a=7.8 
Hz, J7a,7b=11.6 Hz, H-7a
I), 4.03 (dd, 1H, J6,7a=6.6 Hz, J7a,7b=11.2 Hz, H-7a
II), 4.11 (dd, 
1H, J6,7b=6.4 Hz, J7a,7b=11.2 Hz, H-7b
II), 4.38 (dd, 1H, J6,7b=5.0 Hz, J7a,7b=11.6 Hz, 
H-7bI), 4.53, 4.55 (d, 2H, J=12.8 Hz, OCH2Ph), 4.98 (ddd, 1H, J5,6=2.0 Hz, J6,7a=6.6 
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Hz, J6,7b=6.4 Hz, H-6
II), 4.93, 4.98 (d, 2H, J=12.6 Hz, OCH2Ph), 4.97 (d, 1H, J1,2=2.0 
Hz, H-1II), 5.20 (ddd, 1H, J5,6=2.0 Hz, J6,7a=7.8 Hz, J6,7b=5.0 Hz, H-6
I), 5.25 (dd, 1H, 
J2,3=3.0 Hz, J3,4=10.2 Hz, H-3
II), 5.32 (dd, 1H, J3,4=10.2 Hz, J4,5=9.8 Hz, H-4
II), 5.46 
(dd, 1H, J3,4=9.6 Hz, J4,5=10.0 Hz, H-4
I), 5.72 (d, 1H, J1,2=nd Hz, H-1
I), 7.19–7.48 (m, 
10H, Ph), 8.69 (s, 1H, NH). 13C NMR (150 MHz, CDCl3):  19.5, 19.7, 19.71, 19.8, 
19.83, 19.9 (Ac-CH3), 60.0 (C-7
I), 61.3 (C-7II), 64.4 (C-4II), 65.6 (C-6I), 66.0 (C-4I), 
66.5 (C-6II), 68.1 (C-5II), 69.5 (C-3II), 72.4 (C-5I), 72.5 (OCH2Ph), 72.53 (OCH2Ph), 
73.1 (C-2I), 74.5 (C-3I), 75.9 (C-2II), 89.4 (OCNHCCl3), 96.0 (C-1
I), 98.4 (C-1II), 
126.8, 127.0, 127.0, 127.4, 127.6, 136.3, 136.4 (Ph), 159.7 (OCNHCCl3), 168.2, 
168.4, 168.7, 169.1, 169.2, 169.6,169.8 (Ac: O=C). ESI-HRMS for C44H52Cl3NO20: 
1042.2046 [M+Na]+. Found 1042.2012. 
6.26 (2,3,4,6-Tetra-O-benzyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-benzyl--D
-glucopyranosyl)-(1-5)-[methyl O-[methyl (7,8-di-O-benzoyl-4,5-O-isopropylide-
ne-3-deoxy--D-manno-2-octulopyranosyl)onate]]-(2-4)-(allyl 7,8-di-O-benzoyl-3
-deoxy--D-manno-2-octulopyranosid)onate (41)  
A mixture of 6 (10.0 mg, 10.2 mol), and 40 (34.1 mg, 30.5 mol), and 
MS-AW 300 molecular sieves (10.0 mg) was suspended in diethyl ether and 
dichloromethane (3:1, 0.4 mL). The reaction mixture was stirred for 1 h under argon, 
and cooled to 0 °C. Then, 0.01 M TMSOTf (60.0 L, 0.6 mol) in dichloromethane 
was added dropwise to the reaction mixture. After stirring for 1 h, the reaction was 
warmed to room temperature and stirred for 1 h. The reaction solution was neutralized 
by the addition of a few drops of triethylamine and aqueous saturated sodium 
hydrogen carbonate. The reaction mixture was diluted with dichloromethane and was 
filtered through Celite. The filtrate was extracted twice with dichloromethane. The 
combined organic phase was dried over anhydrous sodium sulfate, filtered, and 
concentrated. The residue was purified by BioRad S-X1 size exclusion beads 
(toluene/ethyl acetate, 1:1) and TLC chromatography(ethyl acetate/hexane, 1:3) to 
give 41 (4.0 mg, 20%). []25D= +41.0 (c 0.5, CHCl3), 1H-NMR (600 MHz, CDCl3):  
0.98 (dd, 1H, J3a,3b=15.4 Hz, J3a,4=2.4 Hz, H-3a
II), 1.18 (s, 3H, Me), 1.34 (s, 3H, Me), 
2.23 (dd, 1H, J3a,3b=12.4 Hz, J3a,4=5.0 Hz, H-3a
I), 2.26 (dd, 1H, J3a,3b=12.4 Hz, 
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J3b,4=11.8 Hz, H-3b
I), 2.59 (dd, 1H, J3a,3b=15.4 Hz, J3b,4=3.4 Hz, H-3b
II), 3.31 (ddd, 
1H, J4,5=nd Hz, J5,6a=5.0 Hz, J5,6b=nd Hz, H-5
IV), 3.32 (dd, 1H, J2,3=9.8 Hz, J3,4=2.8 
Hz, H-3IV), 3.38 (dd, 1H, J5,6a=5.0 Hz, J6a,6b=8.8 Hz, H-6a
IV), 3.38 (s, 3H, OMeI), 3.48 
(s, 3H, OMeII), 3.51 (dd, 1H, J1,2=3.4 Hz, J2,3=9.8 Hz, H-2
III), 3.56 (dd, 1H, J5,6b=nd 
Hz, J6a,6b=8.8 Hz, H-6b
IV), 3.64 (dd, 1H, J5,6a=1.6 Hz, J6a,6b=9.2 Hz, H-6a
III), 3.69 (dd, 
1H, J4,5=3.0 Hz, J5,6=1.2 Hz, H-5
I), 3.74 (dd, 1H, J1,2=7.8 Hz, J2,3=9.8 Hz, H-2
IV), 
3.86 (dd, 1H, J5,6=1.6 Hz, J6,7=7.6 Hz, H-6
II), 3.86 (dddd, 1H, J=1.4, 3.2, 4.8, 13.0 Hz, 
OCH2-), 3.90 (dd, 1H, J3,4=2.8 Hz, J4,5=nd Hz, H-4
IV), 3.90 (dd, 1H, J2,3=9.8 Hz, 
J3,4=nd Hz, H-3
III), 3.94 (dd, 1H, J5,6b=nd Hz, J6a,6b=9.2 Hz, H-6b
III), 3.94 (ddd, 1H, 
J3a,4=2.4 Hz, J3b,4=3.4 Hz, J4,5=nd Hz, H-4
II), 3.95 (dddd, 1H, J=nd Hz, OCH2-), 4.03 
(dd, 1H, J5,6=1.2 Hz, J6,7=9.4 Hz, H-6
I), 4.04 (dd, 1H, J4,5=nd Hz, J5,6=1.6 Hz, H-5
II), 
4.05 (dd, 1H, J3,4=nd Hz, J4,5=10.0 Hz, H-4
III), 4.11 (ddd, 1H, J4,5=10.0 Hz, J5,6a=1.6 
Hz, J5,6b=nd Hz, H-5
III), 4.25, 4.37 (d, 2H, J=11.8 Hz, CH2Ph), 4.28 (dd, 1H, J7,8a=3.4 
Hz, J8a,8b=12.6 Hz, H-8a
I), 4.35 (d, 1H, J1,2=7.8 Hz, H-1
IV), 4.36, 4.60 (d, 2H, J=12.0 
Hz, CH2Ph), 4.46 (dd, 1H, J7,8b=2.6 Hz, J8a,8b=12.6 Hz, H-8b
I), 4.55, 4.97 (d, 2H, 
J=11.2 Hz, CH2Ph), 4.58 (dd, 1H, J7,8a=4.6 Hz, J8a,8b=12.8 Hz, H-8a
II), 4.62, 4.66 (d, 
2H, J=12.0 Hz, CH2Ph), 4.70 (ddd, 1H, J3a,4=5.0 Hz, J3b,4=11.8 Hz, J4,5=3.0 Hz, H-4
I), 
4.70, 5.01 (d, 2H, J=10.4 Hz, CH2Ph), 4.77, 5.00 (d, 2H, J=12.4 Hz, CH2Ph), 4.86, 
4.87 (d, 2H, J=nd Hz, CH2Ph), 4.86 (dddd, 1H, J=nd Hz, =CH2), 4.88 (d, 1H, J1,2=3.4 
Hz, H-1III), 4.93 (dddd, 1H, J=1.6, 1.6, 3.2, 17.2 Hz, =CH2), 5.30 (dd, 1H, J7,8b=2.6 
Hz, J8a,8b=12.8 Hz, H-8b
II), 5.58-5.64 (m,1H, -CH=), 5.59 (ddd, 1H, J6,7=7.6 Hz, 
J7,8a=4.6 Hz, J7,8b=2.6 Hz, H-7
II), 5.75 (ddd, 1H, J6,7=9.4 Hz, J7,8a=3.4 Hz, J7,8b=2.6 
Hz, H-7I), 7.03–7.56 (m, 47H, Ar), 7.84–8.00 (m, 8H, Ar). 13C NMR (150 MHz, 
CDCl3):  24.6 and 25.1 (Isop-Me), 31.4 (C-3II), 34.4 (C-3I), 52.0 (OMeI), 52.1 
(OMeII), 62.1 (C-8I), 62.1 (C-8II), 64.7 (OCH2-), 67.7 (C-4
I), 67.9 (C-6III), 68.1 
(C-6IV), 69.3 (C-7I), 69.8 (C-4II), 69.9 (C-6II), 70.66 (C-7II), 70.7 (C-6I), 71.0 (C-5III), 
72.03 (C-5I), 72.06 (C-5II), 72.3, 72.6, 73.0, 73.4, 74.4, 74.7, 75.3 (OCH2Ph), 72.9 
(C-5IV), 73.7 (C-4IV), 76.2 (C-4III), 78.9 (C-2III), 80.2 (C-2IV), 80.3 (C-3III), 82.3 
(C-3IV), 96.2 (C-2II), 98.3 (C-1III), 98.8 (C-2I), 102.7 (C-1IV), 109.6 (Cisop), 116.2 
(=CH2), 126.3, 126.7, 126.9, 127.3, 127.4, 127.5, 127.7, 127.8, 127.9, 128.0, 128.1, 
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128.14, 128.2, 128.3, 128.31, 128.4, 128.40, 128.45, 128.6, 129.6, 129.65, 129.7, 
129.75, 129.8, 130.0, 130.3, 132.9, 133.0, 133.1, 133.4 (Ar), 133.6 (-CH=), 138.14, 
138.2, 138.5, 139.0, 139.1, 139.3, 139.9 (Ar), 164.8, 1651, 165.8, 166.1 (Bz: C=O), 
167.7 (C-1I), 168.7 (C-1II). MALDI-TOF MS for C113H116O29: 1959.750 [M+Na]
+. 
Found 1959.300. 
6.27 (2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(1-4)-(2,3,6-tri-O-acetyl--D-g
-lucopyranosyl)-(1-4)-(3,6,7-tri-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptop
-yranosyl)-(1-5)-[methyl O-[methyl (7,8-di-O-benzoyl-4,5-O-isopropylidene-3-de
o-xy--D-manno-2-octulopyranosyl)onate]]-(2-4)-(allyl 7,8-di-O-benzoyl-3-deoxy
--D-manno-2-octulopyranosid)onate (43)  
A mixture of 6 (42.0 mg, 42.7 mol), 31 (96.0 mg, 84.1 mol), and MS-AW 
300 molecular sieves (43.0 mg) was suspended in dry dichloromethane (1.6 mL). The 
reaction mixture was stirred for 1 h under argon, and then 0.01 M TMSOTf (260.0 L, 
2.5 mol) in dichloromethane was added dropwise to the reaction mixture. After 
stirring for 2 h, the reaction was neutralized by the addition of a few drops of 
triethylamine and aqueous saturated sodium hydrogen carbonate. The reaction 
mixture was diluted with dichloromethane and filtered through Celite. The filtrate was 
extracted twice with dichloromethane. The combined organic phase was dried over 
anhydrous sodium sulfate, filtered and concentrated. The residue was purified by 
BioRad S-X1 size exclusion beads (toluene/ethyl acetate, 1:1) and TLC 
chromatography (ethyl acetate/hexane, 2:1) to give 43 (22.8 mg, 26%). []25D= +2.9 
(c 1.9, CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.22 (s, 3H, Me), 1.41 (s, 3H, Me), 
1.90, 1.91, 1.95, 1.99, 2.01, 2.02, 2.03, 2.03, 2.05, 2.14 (s, 3H x 10, Ac), 2.02 (dd, 1H, 
J3a,3b=15.6 Hz, J3a,4=2.2 Hz, H-3a
II), 2.18 (dd, 1H, J3a,3b=12.6 Hz, J3a,4=12.4 Hz, 
H-3aI), 2.38 (dd, 1H, J3a,3b=12.6 Hz, J3b,4=4.4 Hz, H-3b
I), 2.91 (dd, 1H, J3a,3b=15.6 Hz, 
J3b,4=3.4 Hz, H-3b
II), 3.49 (s, 3H, OMeI), 3.55 (s, 3H, OMeII), 3.54 (ddd, 1H, J4,5=9.6 
Hz, J5,6a=5.0 Hz, J5,6b=1.6 Hz, H-5
IV), 3.79 (dd, 1H, J4,5=nd Hz, J5,6=nd Hz, H-5
I), 
3.79 (dd, 1H, J3,4=9.0 Hz, J4,5=9.6 Hz, H-4
IV), 3.82 (ddd, 1H, J4,5=0.6 Hz, J5,6a=7.2 Hz, 
J5,6b=6.2 Hz, H-5
V), 3.82 (dd, 1H, J1,2=1.6 Hz, J2,3=2.8 Hz, H-2
III), 3.85 (dd, 1H, 
J3,4=9.4 Hz, J4,5=10.2 Hz, H-4
III), 3.91 (dd, 1H, J=nd Hz, OCH2-), 3.92 (dd, 1H, 
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J6,7a=7.8 Hz, J7a,7b=11.4 Hz, H-7a
I), 3.95 (dd, 1H, J4,5=10.2 Hz, J5,6=nd Hz, H-5
III), 
3.97 (dd, 1H, J=nd Hz, OCH2-), 4.07 (dd, 1H, J5,6a=7.2 Hz, J6a,6b=11.2 Hz, H-6a
V), 
4.08 (dd, 1H, J5,6=nd Hz, J6,7=9.4 Hz, H-6
I), 4.08 (dd, 1H, J5,6a=5.0 Hz, J6a,6b=12.0 Hz, 
H-6aIV), 4.11 (dd, 1H, J5,6b=6.2 Hz, J6a,6b=11.2 Hz, H-6b
V), 4.22 (dd, 1H, J6,7b=5.2 Hz, 
J7a,7b=11.4 Hz, H-7b
I), 4.30 (dd, 1H, J5,6=1.6 Hz, J6,7=6.0 Hz, H-6
II), 4.38 (dd, 1H, 
J4,5=7.8 Hz, J5,6=1.6 Hz, H-5
II), 4.47 (d, 1H, J1,2=7.8 Hz, H-1
IV), 4.35 (dd, 1H, 
J5,6b=1.6 Hz, J6a,6b=12.0 Hz, H-6b
IV), 4.43 (d, 1H, J1,2=8.0 Hz, H-1
V), 4.45, 4.54 (d, 
2H, J=12.0 Hz, CH2Ph), 4.46 (ddd, 1H, J3a,4=12.4 Hz, J3b,4=4.4 Hz, J4,5=nd Hz, H-4
I), 
4.55 (ddd, 1H, J3a,4=2.2 Hz, J3b,4=3.4 Hz, J4,5=7.8 Hz, H-4
II), 4.62 (dd, 1H, J7,8a=6.2 
Hz, J8a,8b=12.4 Hz, H-8a
II), 4.63 (dd, 1H, J7,8a=3.8 Hz, J8a,8b=12.4 Hz, H-8a
I), 4.79 (dd, 
1H, J1,2=7.8 Hz, J2,3=8.8 Hz, H-2
IV), 4.88 (dd, 1H, J7,8b=2.4 Hz, J8a,8b=12.4 Hz, H-8b
I), 
4.91 (dd, 1H, J2,3=10.4 Hz, J3,4=3.4 Hz, H-3
V), 4.93 (dd, 1H, J=1.4, nd Hz, =CH2), 
5.01 (d, 1H, J1,2=1.6 Hz, H-1
III), 5.05 (dd, 1H, J=1.6, 1.6, 3.2, 17.2 Hz, =CH2), 5.08 
(dd, 1H, J1,2=8.0 Hz, J2,3=10.4 Hz, H-2
V), 5.12 (dd, 1H, J2,3=8.8 Hz, J3,4=9.0 Hz, 
H-3IV), 5.18 (dd, 1H, J7,8b=2.2 Hz, J8a,8b=12.4 Hz, H-8b
II), 5.30 (ddd, 1H, J5,6=nd Hz, 
J6,7a=7.8 Hz, J6,7b=5.2 Hz, H-6
III), 5.33 (dd, 1H, J3,4=3.4 Hz, J4,5=0.6 Hz, H-4
III), 5.34 
(dd, 1H, J2,3=2.8 Hz, J3,4=9.4 Hz, H-3
III), 5.58 (ddd, 1H, J6,7=9.4 Hz, J7,8a=3.8 Hz, 
J7,8b=2.4 Hz, H-7
I), 5.63-5.69 (m,1H, -CH=), 5.75 (ddd, 1H, J6,7=6.0 Hz, J7,8a=6.2 Hz, 
J7,8b=2.2 Hz, H-7
II), 7.27–7.57 (m, 17H, Ar), 7.94–8.00 (m, 8H, Ar). 13C NMR (150 
MHz, CDCl3):  20.5, 20.54, 20.7, 20.8, 20.84, 20.9, 23.0, 23.8 (Ac-CH3), 24.6 and 
25.1 (Isop-Me), 32.0 (C-3II), 34.7 (C-3I), 52.2 (OMeII), 52.3 (OMeI), 64.5 (OCH2-), 
60.7 (C-6V), 62.3 (C-6IV), 62.4 (C-8I), 63.2 (C-8II), 63.5 (C-7III), 66.6 (C-4V), 68.2 
(C-6III), 68.22 (C-4I), 69.0 (C-2V), 69.67 (C-7I), 69.7 (C-3III), 70.0 (C-4II), 70.5 (C-6I), 
70.6 (C-5V), 70.91 (C-7II), 70.9 (C-5III), 71.0 (C-3V), 71.0 (C-6II), 71.4 (C-5I), 71.8 
(C-2IV), 72.1 (C-5IV), 72.3 (OCH2Ph), 72.5 (C-5
II), 73.3 (C-3IV), 73.9 (C-4III), 76.9 
(C-2III), 76.3 (C-4IV), 97.88 (C-2II), 97.9 (C-1III), 98.7 (C-2I), 100.2 (C-1IV), 101.1 
(C-1V), 109.5 (Cisop), 116.0 (=CH2), 127.4, 127.6, 128.2, 128.3, 128.4, 128.5, 128.6, 
128.8, 129.4, 129.7, 129.8, 130.1, 130.2, 130.9, 132.8, 133.0, 133.2, 133.5 (Ar), 
133.53 (-CH=), 138.4 (Ar), 165.2, 165.3, 166.0, 166.2 (Bz: C=O), 167.6 (C-1I), 169.1 
(C-1II), 169.6, 169.6, 169.7, 170.1, 170.2, 170.3, 170.4, 170.4 (Ac: C=O). 
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MALDI-TOF MS for C98H112O45: 2031.638 [M+Na]
+. Found 2030.629.  
6.28 (3,4,6,7-Tetra-O-acetyl-2-O-benzyl-L-glycero--D-manno-heptopyranosyl)-
(1-3)-(2-O-benzyl-4,6,7-tri-O-acetyl-L-glycero--D-manno-heptopyranosyl)-(1-5)-
[methyl O-[methyl (7,8-di-O-benzoyl-4,5-O-isopropylidene-3-deoxy--D-manno-
2-octulopyranosyl)onate]]-(2-4)-(allyl 7,8-di-O-benzoyl-3-deoxy--D-manno-2-oct
-ulopyranosid)onate (44)  
A mixture of 6 (62.3 mg, 63.4 mol), 38 (129.5 mg, 126.8 mol, /=6:1), and 
MS-AW 300 molecular sieves (62 mg) was suspended in dichloromethane (2.7 mL). 
The reaction mixture was stirred for 1 h under argon, and then 0.01 M TMSOTf 
(380.0 μL, 3.8 mol) in dichloromethane was added dropwise to the reaction mixture. 
After stirring for 1 h, the reaction was neutralized by the addition of a few drops of 
triethylamine and aqueous saturated sodium hydrogen carbonate. The reaction 
mixture was diluted with dichloromethane and filtered through Celite. The filtrate was 
extracted twice with dichloromethane. The combined organic phase was dried over 
anhydrous sodium sulfate, filtered and concentrated. The residue was purified by 
BioRad S-X1 size exclusion beads (toluene/ethyl acetate, 1:1) and TLC 
chromatography (ethyl acetate/hexane, 3:2) to give 44 (66.9 mg, 57%). []25D= -7.0 (c 
1.0, CHCl3), 
1H-NMR (600 MHz, CDCl3):  1.19 (s, 3H, Me), 1.36 (s, 3H, Me), 1.88, 
1.93, 1.94, 1.97, 1.99, 2.01, 2.11 (s, 3H x 7, Ac), 2.02 (dd, 1H, J3a,3b=15.6 Hz, 
J3a,4=2.6 Hz, H-3a
II), 2.08 (dd, 1H, J3a,3b=12.4 Hz, J3a,4=12.2 Hz, H-3a
I), 2.25 (dd, 1H, 
J3a,3b=12.4 Hz, J3b,4=4.0 Hz, H-3b
I), 2.96 (dd, 1H, J3a,3b=15.6 Hz, J3b,4=3.6 Hz, H-3b
II), 
3.38 (s, 3H, OMeI), 3.43 (s, 3H, OMeII), 3.69 (dd, 1H, J4,5=2.2 Hz, J5,6=nd Hz, H-5
I), 
3.80 (dd, 1H, J1,2=1.8 Hz, J2,3=3.0 Hz, H-2
IV), 3.89 (dd, 1H, J=1.6, 3.0, 4.8, 13.0 Hz, 
OCH2-), 3.94 (dd, 1H, J=1.4, 2.8, 5.6, nd Hz, OCH2-), 3.95 (dd, 1H, J4,5=9.8 Hz, 
J5,6=8.2 Hz, H-5
IV), 3.95 (dd, 1H, J1,2=1.6 Hz, J2,3=2.4 Hz, H-2
III), 4.06 (dd, 1H, 
J2,3=2.4 Hz, J3,4=10.0 Hz, H-3
III), 4.09 (dd, 1H, J5,6=nd Hz, J6,7=9.6 Hz, H-6
I), 4.10 
(dd, 1H, J4,5=9.8 Hz, J5,6=8.6 Hz, H-5
III), 4.21 (dd, 1H, J6,7a=6.0 Hz, J7a,7b=nd Hz, 
H-7aIV), 4.21 (dd, 1H, J6,7b=2.0 Hz, J7a,7b=nd Hz, H-7b
IV), 4.24 (dd, 1H, J6,7a=5.8 Hz, 
J7a,7b=11.8 Hz, H-7a
III), 4.26 (dd, 1H, J5,6=1.8 Hz, J6,7=7.2 Hz, H-6
II), 4.32 (dd, 1H, 
J6,7b=3.4 Hz, J7a,7b=11.8 Hz, H-7b
III), 4.35 (dd, 1H, J4,5=7.8 Hz, J5,6=1.8 Hz, H-5
II), 
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4.49 (ddd, 1H, J3a,4=2.6 Hz, J3b,4=3.6 Hz, J4,5=7.8 Hz, H-4
II), 4.59 (dd, 1H, J7,8a=3.8 
Hz, J8a,8b=12.4 Hz, H-8a
I), 4.61 (dd, 1H, J7,8a=4.2 Hz, J8a,8b=12.4 Hz, H-8a
II), 4.61, 
4.68 (d, 2H, J=nd Hz, CH2Ph), 4.62, 4.70 (d, 2H, J=nd Hz, CH2Ph), 4.67 (ddd, 1H, 
J3a,4=12.2 Hz, J3b,4=4.0 Hz, J4,5=2.2 Hz, H-4
I), 4.80 (dd, 1H, J7,8b=2.6 Hz, J8a,8b=12.4 
Hz, H-8bI), 4.93 (dd, 1H, J=1.2, 1.6, 2.8, 10.6 Hz, =CH2), 4.98 (dd, 1H, J=1.6, 1.6, 
3.2, 17.2 Hz, =CH2), 5.07 (d, 1H, J1,2=1.6 Hz, H-1
III), 5.15 (dd, 1H, J2,3=3.0 Hz, 
J3,4=10.0 Hz, H-3
IV), 5.20 (ddd, 1H, J5,6=8.2 Hz, J6,7a=6.0 Hz, J6,7b=2.0 Hz, H-6
IV), 
5.21 (d, 1H, J1,2=1.8 Hz, H-1
IV), 5.27 (dd, 1H, J7,8b=2.4 Hz, J8a,8b=12.4 Hz, H-8b
II), 
5.31 (ddd, 1H, J5,6=8.6 Hz, J6,7a=5.8 Hz, J6,7b=3.4 Hz, H-6
III), 5.41 (dd, J3,4=10.0 Hz, 
J4,5=9.8 Hz, H-4
IV), 5.52 (dd, J3,4=10.0 Hz, J4,5=9.8 Hz, H-4
III), 5.57 (ddd, 1H, 
J6,7=9.6 Hz, J7,8a=3.8 Hz, J7,8b=2.6 Hz, H-7
I), 5.63–5.69 (m,1H, -CH=), 5.68 (ddd, 1H, 
J6,7=7.2 Hz, J7,8a=4.2 Hz, J7,8b=2.4 Hz, H-7
II), 7.21–7.60 (m, 22H, Ar), 7.94–8.04 (m, 
8H, Ar). 13C NMR (150 MHz, CDCl3):  20.6, 20.8, 20.83 and 20.87, 20.9 (Ac-CH3), 
24.6 and 25.1 (Isop-Me), 32.0 (C-3II), 34.5 (C-3I), 52.1 (OMeII), 52.2 (OMeI), 62.4 
(C-8II), 62.6 (C-8I), 63.5 (C-7IV), 64.1 (C-7III), 64.8 (OCH2-), 65.3 (C-4
IV), 66.9 
(C-4III), 67.6 (C-4I), 67.7 (C-6III), 68.0 (C-6IV), 69.0 (C-7I), 69.9 (C-4II), 70.0 (C-5IV), 
70.1 (C-3III), 70.3 (C-6I), 70.3 (C-5III), 70.3 (C-6II), 70.6 (C-7II), 71.2 (C-3IV), 72.1, 
72.9 (OCH2Ph), 72.2 (C-5
II), 74.1 (C-5I), 75.5 (C-2IV), 77.2 (C-2III), 97.0 (C-2II), 98.8 
(C-2I), 99.0 (C-1IV), 99.2 (C-1III), 109.6 (Cisop), 116.4 (=CH2), 127.3, 127.4, 127.7, 
127.8, 128.3, 128.32, 128.4, 128.6, 128.8, 128.9, 129.5, 129.6, 129.7, 129.75, 129.9, 
130.1, 132.9, 133.0, 133.3 (Ar), 133.4 (-CH=), 133.8, 137.8, 138.3 (Ar), 165.2, 165.4, 
165.8, 166.2 (Bz: C=O), 167.4 (C-1I), 169.4 (C-1II), 169.6, 169.7, 169.8, 170.4, 170.5, 
170.7, 170.8 (Ac: C=O). MALDI-TOF MS for C94H104O38: 1863.611 [M+Na]
+. Found 
1862.589. 
6.29 (L-Glycero--D-manno-heptopyranosyl)-(1-3)-(L-glycero--D-manno-heptop-
yranosyl)-(1-5)-[O-(sodium 3-deoxy--D-manno-2-octulopyranosylonate)]-(2-4)-s
-odium (propyl 3-deoxy--D-manno-2-octulopyranosid)onate (45)  
Compound 44 (10.0 mg, 5.4 mol) in dry methanol (0.3 mL) was added to a 
suspension of Pd(OH)2-C (20%, 0.3 mg) in dry methanol (0.2 mL), under a H2 
atmosphere with stirring at room temperature. After stirring for 3 days, insoluble 
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materials were removed by filtration through Celite and the filtrate was evaporated. 
The residue was dissolved in dichloromethane (0.7 mL) and aqueous 80% 
trifluoroacetic acid (80.0 L) was added at room temperature. After stirring for 1 h, 
the solvent was removed by evaporation under an argon stream to give a crude 
compound that was not subjected to further purification. The crude compound was 
dissolved in methanol (1.0 mL), and then 0.1 M sodium hydroxide (1.3 mL, 0.13 
mmol) was added at room temperature. After stirring for 24 h, the mixture was 
concentrated by evaporation. The residue was purified by gel filtration 
chromatography (Biogel P-2) and a Sep-Pak C18 column (H2O) to give 45 (4.5 mg, 
90%) as a colorless powder. []25D=+127.6 (c 0.5, H2O), 1H-NMR (600 MHz, D2O): 
 0.92 (t, 3H, J=7.4 Hz, CH3), 1.54–1.61 (m, 2H, CH2), 1.76 (dd, 1H, J3a,3b=13.2 Hz, 
J3a,4=12.6 Hz, H-3a
II), 1.93 (dd, 1H, J3a,3b=12.6 Hz, J3a,4=12.4 Hz, H-3a
I), 2.06 (dd, 
1H, J3a,3b=12.6 Hz, J3b,4=4.2 Hz, H-3b
I), 2.20 (dd, 1H, J3a,3b=13.2 Hz, J3b,4=4.8 Hz, 
H-3bII), 3.21–3.24 (m, 1H, OCH2), 3.28–3.32 (m, 1H, OCH2), 3.57 (dd, 1H, J6,7=9.4 
Hz, H-6I), 3.61 (dd, 1H, J7,8a=6.2 Hz, J8a,8b=11.8 Hz, H-8a
II), 3.66 (dd, 1H, J6,7=8.2 Hz, 
H-6II), 3.68 (dd, 1H, J6,7a=5.7 Hz, J7a,7b=10.8 Hz, H-7a
III), 3.73–3.77 (m, 4H, H-7bIII, 
H-7aIV, H-7bIV, H-5III), 3.81 (dd, 1H, J7,8a=6.4 Hz, J8a,8b=11.6 Hz, H-8a
I), 3.84–3.98 
(m, 8H, H-7I, H-3III, H-4III, H-7II, H-8bII, H-4IV, H-5IV, H-8bI), 4.01–4.06 (m, 4H, 
H-5II, H-3IV, H-6III, H-6IV), 4.07 (dd, 1H, J1,2=1.2 Hz, J2,3=3.2 Hz, H-2
III), 4.09 (ddd, 
1H, J3a,4=12.6 Hz, J3b,4=4.8 Hz, J4,5=3.0 Hz, H-4
II), 4.13 (dd, 1H, J1,2=1.6 Hz, J2,3=3.0 
Hz, H-2IV), 4.22 (brs, 1H, J4,5=2.2 Hz, H-5
I), 4.26 (ddd, 1H, J3a,4=12.4 Hz, J3b,4=4.2 
Hz, J4,5=2.2 Hz, H-4
I), 5.17 (d, 1H, J1,2=1.2 Hz, H-1
III), 5.29 (d, 1H, J1,2=1.6 Hz, 
H-1IV). 13C NMR (150 MHz, D2O):  10.9 (CH3), 23.9 (CH2), 35.2 (C-3I, C-3II), 63.5 
(C-7IV, C-8I), 64.0 (C-8II), 64.6 (C-7III), 65.4 (OCH2,), 66.4 (C-4
III), 66.8 (C-4II), 66.81 
(C-5II), 67.0 (C-4IV), 69.4 (C-6III), 69.7 (C-7I), 70.0 (C-6IV), 70.1 (C-4I), 70.6 (C-2III), 
70.8 (C-2IV), 70.83 (C-7II), 71.1 (C-3IV), 72.4 (C-5III), 72.6 (C-6I), 72.62 (C-6II), 73.3 
(C-5IV and C-5I), 79.2 (C-3III), 100.5, 100.7 (C-2I, C-2II), 101.3 (C-1III), 103.0 (C-1IV), 
175.6, 175.9 (C-1I, C-1II). ESI-HRMS for C33H55O27: 883.2931 [M-2Na+H]
-. Found 
883.2929. 
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6.30-D-Galactopyranosyl-(1-4)--D-glucopyranosyl)-(1-4)-L-glycero--D-manno
-heptopyranosyl-(1-5)-[O-(sodium 3-deoxy--D-manno-2-octulopyranosylonate)]
-(2-4)-sodium (propyl 3-deoxy--D-manno-2-octulopyranosid)onate (46)  
Compound 43 (9.0 mg, 4.5 mol) was hydrogenated in the presence of 
Pd(OH)2-C (20%, 0.2 mg) in dry methanol (0.5 mL) under atmospheric pressure of 
hydrogen for 2 days at room temperature. The reaction mixture was filtered through 
Celite and concentrated. The residue was dissolved in dichloromethane (0.6 mL) and 
aqueous 80% trifluoroacetic acid (70.0 L) was added at room temperature. After 
stirring for 1 h, the solvent was removed by evaporation under an argon stream to give 
a crude compound that was not subjected to further purification. The crude compound 
was dissolved in methanol (1.0 mL), and then 0.1 M sodium hydroxide (1.4 mL, 0.14 
mmol) was added at room temperature. After stirring for 24 h, the mixture was 
concentrated by evaporation. The residue was passed through a Bio-Gel P-2 column 
(2.5 x 100 cm, H2O) and a Sep-Pak C18 column (H2O) to give 46 (2.5 mg, 53%) as a 
colorless powder. []25D = +17.4 (c 0.3, H2O), 1H-NMR (600 MHz, D2O):  0.91 (t, 
3H, J=7.4 Hz, CH3), 1.55–1.62 (m, 2H, CH2), 1.77 (dd, 1H, J3a,3b=12.8 Hz, J3a,4=12.6 
Hz, H-3aII), 1.92 (dd, 1H, J3a,3b=12.8 Hz, J3a,4=12.0 Hz, H-3a
I), 2.07 (dd, 1H, 
J3a,3b=12.8 Hz, J3b,4=4.4 Hz, H-3b
I), 2.18 (dd, 1H, J3a,3b=12.8 Hz, J3b,4=4.6 Hz, H-3b
II), 
3.19–3.24 (m, 1H, OCH2), 3.26–3.30 (m, 1H, OCH2), 3.39 (dd, 1H, J1,2=8.0 Hz, 
J2,3=8.8 Hz, H-2
IV), 3.54 (dd, 1H, J1,2=7.8 Hz, J2,3=10.0 Hz, H-2
V), 3.58 (dd, 1H, 
J6,7=8.4 Hz, H-6
I), 3.59 (dd, 1H, J7,8a=6.2 Hz, J8a,8b=11.6 Hz, H-8a
II), 3.64–3.84 (m, 
14H, H-3V, H-6II, H-3IV, H-6aIV, H-6bIV, H-5V, H-4IV, H-6aV, H-6bV, H-7aIII, H-5III, 
H-7bIII, H-8aI, H-7I), 3.89 (dd, 1H, J7,8b=2.6 Hz, J8a,8b=11.6 Hz, H-8b
II), 3.91–3.99 (m, 
4H, H-4V, H-7II, H-5IV, H-8bI), 4.00–4.07 (m, 3H, H-4III, H-3III, H-5II), 4.09 (brs, 1H, 
J1,2=1.6 Hz, H-2
III), 4.10 (ddd, 1H, J3a,4=12.6 Hz, J3b,4=4.6 Hz, J4,5=3.0 Hz, H-4
II), 
4.14 (ddd, 1H, J6,7a=7.8 Hz, J6,7b=4.8 Hz, H-6
III), 4.21 (brs, 1H, J4,5=2.2 Hz, H-5
I), 
4.24 (ddd, 1H, J3a,4=12.0 Hz, J3b,4=4.4 Hz, J4,5=2.2 Hz, H-4
I), 4.44 (d, 1H, J1,2=7.8 Hz, 
H-1V), 4.58 (d, 1H, J1,2=8.0 Hz, H-1
IV), 5.32 (d, 1H, J1,2=1.6 Hz, H-1
III). 13C NMR 
(150 MHz, D2O): 10.8 (CH3), 23.8 (CH2), 35.0, 35.3 (C-3I, C-3II), 60.6 (C-6IV), 61.6 
(C-6V), 63.5 (C-8I), 64.0 (C-8II), 64.6 (C-7III), 65.4 (OCH2), 66.9 (C-4
II), 67.0 (C-5II), 
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69.2 (C-6III), 69.7 (C-7I), 69.9 (C-4V), 70.2 (C-4I), 70.3 (C3III), 70.5 (C-2III), 70.7 
(C-7II), 71.6 (C-5III), 72.0 (C-2V), 72.3 (C-5IV), 72.6 (C-6I), 72.7 (C-6II), 73.1 (C-4III), 
73.4 (C-5I), 74.6 (C-3IV), 75.5 (C-2IV), 76.0 (C-3V), 76.5 (C-5V), 78.8 (C-4IV), 100.5, 
100.8 (C-2I, C-2II), 101.0 (C-1III), 103.0 (C-1IV), 103.6 (C-1V), 175.5, 175.9 (C-1I, 
C-1II). ESI-HRMS for C38H63O31: 1015.3353 [M-2Na+H]
-. Found 1015.3370. 
6.31 (-D-Galactopyranosyl-(1-4)--D-glucopyranosyl)-(1-5)-[O-(sodium 3-deox-
y--D-manno-2-octulopyranosylonate)]-(2-4)-sodium (propyl 3-deoxy--D-mann
-o-2-octulopyranosid)onate (47)  
Compound 41 (5.3 mg, 2.7 mol) was hydrogenated in the presence of 
Pd(OH)2-C (20%, 1.5 mg) in dry methanol (0.4 mL) under atmospheric pressure of 
hydrogen for 1 day at room temperature. The reaction mixture was filtered through 
Celite and concentrated. The residue was treated with aqueous 80% trifluoroacetic 
acid (40.0 L) at room temperature. After stirring for 5 min, the solvent was removed 
by evaporation under an argon stream to give a crude compound that was not 
subjected to further purification. The crude compound was dissolved in methanol (0.8 
mL), and then 0.1 M sodium hydroxide (0.5 mL, 0.05 mmol) was added at room 
temperature. After stirring for 24 h, the mixture was concentrated by evaporation.  
The residue was purified by a Bio-Gel P-2 column (2.5 x 100 cm, H2O) anda Sep-Pak 
C18 column (H2O) to give 47 (1.4 mg, 60%) as a colorless powder. []25D = +20.1 (c 
0.1, H2O), 
1H-NMR (600 MHz, D2O):  0.90 (t, 3H, J=7.4 Hz, CH3), 1.53–1.60 (m, 
2H, CH2), 1.80 (dd, 1H, J3a,3b=12.8 Hz, J3a,4=12.6 Hz, H-3a
II), 2.02 (dd, 1H, 
J3a,3b=12.6 Hz, H-3a
I), 2.06–2.08 (m, 2H, H-3bI, H-3bII), 3.21–3.30 (m, 2H, OCH2), 
3.55 (dd, 1H, J1,2=7.8 Hz, J2,3=10.2 Hz, H-2
IV), 3.56–3.60 (m, 3H, H-2III, H-6I, H-8aII), 
3.66 (dd, 1H, J2,3=10.2 Hz, J3,4=3.4 Hz, H-3
IV), 3.72–3.82 (m, 6H, H-6II, H-4III, 
H-6aIV, H-6bIV, H-5IV, H-8aI), 3.89–4.01 (m, 9H, H-8bI, H-7II, H-4IV, H-6aIII, H-6bIII, 
H-3III, H-8bII, H-5II, H-4I), 4.06 (ddd, 1H, J6,7=9.0 Hz, J7,8a=3.0 Hz, J7, 8b=2.4 Hz, 
H-7I), 4.09–4.12 (m, 1H, J3a,4=12.6 Hz, J3b,4=4.8 Hz, J4,5=2.2 Hz, H-4II), 4.23 (brs, 1H, 
H-5I), 4.23–4.26 (m, 1H, H-5III), 4.47 (d, 1H, J1,2=7.8 Hz, H-1IV), 5.28 (dd, 1H, 
J1,2=3.6 Hz, H-1
III).  13C NMR (150 MHz, D2O):  10.8 (CH3), 22.8 (CH2), 35.2 
(C-3I, C-3II), 60.2 (C-6III), 61.7 (C-6IV), 63.3 (C-8I), 64.0 (C-8II), 65.3 (OCH2), 66.7 
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(C-4II), 67.5 (C-5II), 69.2 (C-7I), 69.3 (C-4IV), 70.1, 71.3, 71.6, 71.8, 72.0, 72.3, 72.4, 
73.0, 73.2 (C-4I, C-7II, C-2IV, C-5III, C-6II, C-6I, C-2III, C-3III, C-5I), 74.0 (C-3IV), 75.9 
(C-5IV), 78.5 (C-4III), 99.6, 100.5 (C-2I, C-2II), 102.3 (C-1III), 103.5 (C-1IV), 175.9 and 
176.1 (C-1I, C-1II). ESI-HRMS for C31H51O25: 823.2719 [M-2Na+H]
-. Found 
823.2732. 
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Summary 
Lipopolysaccharides (LPSs) and lipooligosaccharides (LOSs) are the major 
glycolipds expressed in the outer membrane of gram-negative bacteria and play an 
important role in the pathogenesis of bacterial infections. LPS is composed of 
O-specific polysaccharide, a core oligosaccharide (core OS), and lipid A, whereas 
LOS lacks an O-antigen. The core OS, which is a significant target for vaccine 
development and diagnostics of pathogenic bacteria, can be further subdivided into 
the inner core and outer core. The inner core OS is composed of a 4,5-branched 
3-deoxy-D-manno-2-octulosonic acid (Kdo) structures. However, there are few reports 
about the synthesis of this branch Kdo structure. To synthesize this branch Kdo 
structure and extend our previous research, a new synthetic approach was developed.  
In this study, chapter 2 described the synthesis of linked Kdo disaccharide; 
chapter 3 showed a new synthetic approach to synthesize 4,5-branched Kdo 
trisaccharides using Kdo disaccharide as an acceptor; in chapter 4 more complex 
4,5-branched Kdo structures were synthesized by using the same Kdo disaccharide as 
the acceptor; chapter 5 showed the conclusions. 
In chapter 2, 2-4 linked Kdo disaccharide was obtained by glycosidation of Kdo 
donor with 4,5-diol acceptor. To optimize the condition of this reaction, several types 
of Kdo donors with different leaving groups were prepared from the common Kdo 
intermediate and were glycosylated with 4,5-diol acceptor. The results showed that all 
donors produced the -glycoside as the main product and the stereoselectivity was not 
influenced by the type of leaving group. Moreover, the -fluoride donor with 
BF3·OEt2 as the activator provided the best yield and -selectivity of product. 
In chapter 3, Kdo(2-4)Kdo as an acceptor was glycosylated with 
L-glycero-D-manno-heptosyl (Hep), mannosyl (Man), and 2-azido-2-deoxy-galactosyl 
imidates (GalN3), respectively, and three corresponding 4,5-branched trisaccharides, 
Hep(1-5)[Kdo(2-4)]Kdo, Man(1-5)[Kdo(2-4)]Kdo and 
GalN3(1-5)[Kdo(2-4)]Kdo, were successfully synthesized in good yield and high 
-selectivity. These results confirmed that glycosylation at the 4-OH position of the 
Kdo acceptor followed by a second glycosylation at 5-OH position could produce the 
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target 4,5-branched Kdo structures and this new synthetic strategy is different from 
Paulsen’s method. 
In chapter 4, to extend the utility of the new synthetic strategy, more complex 
4,5-branched Kdo structures were synthesized by using the same Kdo disaccharide as 
the acceptor. To do it, firstly the L-glycero-D-manno-heptopyranose (Hep) units, 
Gal(1-4)Glc(1-4)Hep and Hep(1-3)Hep, for the branched core oligosaccharide 
were prepared from the corresponding Hep building blocks. Then, the Hep units were 
glycosylated with the common acceptor Kdo(2-4)Kdo to afford 4,5-branched core 
oligosaccharide structures. Three complex 4,5-branched Kdo structures, 
Gal(1-4)Glc(1-5)[Kdo(2-4)]Kdo and Hep(1-3)Hep(1-5)[Kdo(2-4)]Kdo, 
Gal(1-4)Glc(1-4)Hep(1-5)[Kdo(2-4)]Kdo, were successfully obtained.  
In all, the new synthetic approach using Kdo(2-4)Kdo as an intermediate is 
useful for the synthesis of 4,5-branched core OS structures including Kdo 
trisaccharides, Kdo tetrasaccharides and Kdo pentasaccharide. 
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グラム陰性菌が産生するリポ多糖およびリポオリゴ糖の内部コア糖鎖の合成
研究：4,5 で分岐した 3-デオキシ-D-マンノオクト-2-ウロン酸の構築 
要旨 
リポ多糖(LPS)やリポオリゴ糖(LOS)はグラム陰性細菌が細胞外膜に産生
する複合糖脂質であり、細菌感染において重要な役割を持っている。LPS は O
抗原多糖、コアオリゴ糖(コア OS)、そして Lipid A からなり、これに対して
LOS は O 抗原を欠損した構造をしている。コア OS は内部コアと外部コアに分
けられる。コア OSは細菌の属によって特に糖鎖構造が保存された領域であり、
病原性細菌の診断ツールや感染予防のためのワクチン開発の抗原となる標的
分子として注目されている。多くの LPS/LOSの内部コア OSには 4,5-分岐した
3-デオキシ-D-マンノオクト-2-ウロン酸(Kdo)構造が存在している。このよう
な分岐構造を有する Kdo 構造を含んだ分岐糖鎖の化学合成法についてはわず
かな報告しか存在しない。本論文では、この分岐構造を合成するために、新し
い化学合成法を達成した。 
本論文では、第 2 章に 2-4 結合を有する Kdo2 糖の合成について述べてい
る。第 3章ではこの 2糖を糖受容体として用いた 4,5分岐構造を有する３糖の
新しい合成経路での合成について述べている。第 4 章では 4,5-分岐 Kdo 構造
を含むより大きな糖鎖の合成法について述べられ、第 5章でこれらについての
総括が述べられている。 
第 2章では、4,5-ジオール Kdo受容体と様々な Kdo供与体とのグリコシル
化反応について述べている。この反応の反応条件を最適化するために、数種類
の脱離基を持った Kdo 誘導体を共通の中間体から調製した。そして 4,5-ジオ
ール受容体とのグリコシルを検討した。その結果すべての供与体においてα-
グリコシドを主生成物として得られること、そして BF3OEt2を活性化剤に用い
たα体のフッ化糖供与体を用いた反応では最も良い収率とα選択性を与える
ことが明らかになった。 
第 3 章では第 2 章で合成を達成した Kdoα(2-4)Kdo を糖受容体として用
い、L-グリセロ-D-マンノヘプトース(Hep)、マンノース (Man)および 2-アジ
ド-2-デオキシガラクトースのイミデート誘導体による 5 位水酸基へのグリコ
シル化反応の検討を行った。そしてα選択的に良好な収率で合成することに成
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功した。この結果は Kdo の 4,5-ジオール誘導体に対してまず 4 位水酸基にへ
のグリコシル化続く 5 位水酸基へのグリコシル化反応は目的とする 4,5-分岐
構造を持つ Kdoの合成が可能であることを示した。この方法はこれまでに唯一
報告されている Paulsenらの方法とは異なる方法であり、このような糖鎖の合
成における新しい合成の方法論を提供するものである。 
第 4 章では 3 章で達成した新しい 4,5-分岐 Kdo 糖鎖合成法の有用性を拡
大するために、より複雑な糖鎖の合成を試みた結果について述べた。はじめに
Hepを含む供与体ユニット Galβ(1-4)Glcβ(1-4)Hepと Hepα(1-3)Hepの合成
を対応する Hepビルディングブロックから調製した。その後共通の受容体であ
る Kdoα(2-4)Kdoを用いたグリコシル化による 4,5分岐 Kdo糖鎖の合成を行っ
た。その結果 3 種類の 4,5 分岐 Kdo 糖鎖である Galβ(1-4)Glcα(1-5)[Kdoα
(2-4)]Kdo、 Hepα(1-3)Hepα(1-5)[Kdoα(2-4)]Kdo そして Galβ(1-4)Glcβ
(1-4)Hepα(1-5)[Kdoα(2-4)]Kdoの合成を達成した。 
Kdoα(2-4)Kdoを中間体として用いる 4,5分岐 Kdoの新しい合成法はこの
構造を有する LPS/LOSの内部コア糖鎖の合成に有用であることを示した。 
 
 
 
 
 
 86 
Acknowledge 
This work was supported by JSPS KAKENHI Grant Number 23580474 and 
15K01822.  We thank Professors Jun-ichi Tamura and Toshiki Nokami for helpful 
discussions and are also grateful to Ms. Maki Taniguchi for technical assistance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 87 
List of publications 
1. Ruiqin Yi, Atsushi Ogaki, Mayumi Fukunaga, Hiromitsu Nakajima, Tsuyoshi 
Ichiyanagi. Synthesis of 4,5-disubstituted-3-deoxy-D-manno-octulosonic acid (Kdo) 
derivatives. Tetrahedron 70: 3675-3682. 2014.06 (The corresponding content is in 
chapter 2 and chapter 3)      
2. Ruiqin Yi, Hirofumi Narimoto, Miku Nozoe, Tsuyoshi Ichiyanagi. Convergent 
synthesis of 4,5-branched inner-core oligosaccharides of lipopoly- and 
lipooligosaccharide. Bioscience, Biotechnology, and Biochemistry. Accepted at June 
13th, 2015 (The corresponding content is in chapter 4) 
 
